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List of abbreviations 
ANOVA  Analysis of Variance    
BMI  body mass index 
CHD  congenital heart defect  
CI  confidence interval 
CLP  cleft lip with or without cleft palate 
CV  coefficient of variation 
CX43  connexin 43 
DNA  deoxyribonucleic acid 
DRI  dietary reference intake 
en%  percentage of total energy intake 
et al.  and others 
FFQ  food frequency questionnaire 
GATA4  GATA binding protein 4 
H  hour 
L  litre  
mg  milligram 
min  minute 
mL  millilitre 
MS  methionine synthase 
MTHFR  5,10-methylenetetrahydrofolate reductase  
MTRR  methionine synthase reductase 
n  number 
NA  not available 
NKX2.5  NK2 transcription factor 2.5 
nmol  nanomol 
NTD  neural tube defect 
OFC  orofacial clefting 
OR  odds ratio 
P  probability 
PCR  polymerase chain reaction 
pmol  picomol 
RBC  red blood cell 
RDA  recommended dietary allowance 
RFLP  restriction fragment length polymorphism 
SEM  standard error of the mean 
TBX1  T-Box 1 
TBX5  T-Box 5 
TC  transcobalamin 
TDT  transmission disequilibrium test 
tHcy  plasma total homocysteine 
THF  tetrahydrofolate 
μg  microgram 
μmol  micromol 
oC  degrees Celsius 
24HR  24-hour recall 
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Congenital heart defects (CHDs) originate from abnormal organogenesis during the embryonic period. 
They belong to the most common group of major congenital malformations in newborns. Cardiac 
outflow tract defects are the most prevalent CHDs, such as membranous ventricular septal defects, 
pulmonary valve stenosis, tetralogy of Fallot and transposition of the great arteries.1 CHDs are 
associated with other anomalies or occur as part of a syndrome, but are generally present as an 
isolated malformation. Worldwide, one million children per year are born with a CHD.2 In the 
Netherlands about six per 1,000 live births are affected with a CHD and these malformations occur in 
approximately nine per 1,000 live births in the United States of America.3, 4 The reported rate of CHDs 
increased nearly two-fold since the early 1970s.4 The increase is assumed to result partially from 
improved case ascertainment and reporting. In addition, it might be caused by changes in the 
distribution of risk factors in the population.5 At present, birth defects are the leading cause of infant 
mortality6 with CHDs accounting for one in every three birth defect-related infant deaths.7 Over the 
last decades the overall CHD related mortality declined as well as the mortality for most specific 
CHDs.8  From 1979 through 1998 the decline of CHD mortality was 38.3% in the United States, but it 
did not decrease as rapidly as the overall infant mortality decrease of 44.9%.9  
The increasing number of children with a CHD that now survive into adolescence and adulthood 
stresses the need for the health-care community to prepare for the challenging and often complex 
needs and life-long surveillance of adults with a CHD.4 A substantial part of these surviving children 
has to undergo surgery and complex medical treatments and they often suffer from serious physical 
and psychological problems. Moreover, parental distress and financial problems contribute to a 
reduced quality of life in families of CHD children.10 In addition, the estimated average lifetime cost 
was $344,500 per new case of the most clinically important CHDs in 1992 in the United States of 
America.11 Therefore, prevention of CHDs can substantially reduce the paediatric morbidity and 
mortality, and related health care costs as well. However, knowledge about cardiovascular 
development and pathogenesis is necessary for primary prevention of CHDs. 
Embryonic cardiovascular development in human occurs between the third and eighth weeks after 
conception.12 Thus, heart development is essentially completed when most women enter antenatal 
care. Therefore, detailed information about embryonic cardiovascular development generally 
originates from animal models. The heart primordia are derived from the cardiogenic mesenchyme 
where angioblasts aggregate and develop into angioblastic cords. These cords form a pair of lateral 
endocardial tubes, which are brought together by folding of the embryo during the early fourth week 
and fuse into the single primitive heart tube (Figure 1, panel A). Between weeks five and eight of 
development, the primitive heart tube undergoes processes of looping, remodelling, and septation, 
starting at the inflow end and progresses towards the outflow end of the heart (Figure 1, panel A-
D).13 
During cardiac looping localized parts of the endocardial epithelium will undergo epithelial-to-
mesenchymal transformation, thereby giving rise to mesenchymal cells that migrate into the 
endocardial cushions.14 These cushions are named according to the region in which they develop: the 
outflow tract cushions and the atrioventricular cushions. The formation of the atrial septum and 
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ventricular septum together with rearrangement of the inflow and outflow tract separates the heart 
into four different chambers. The definitive structures that separate the atrial and ventricular cavities 
are almost entirely muscular tissue. The small part of the septum that is not muscular, i.e., the 
membranous septum, is partly formed from the atrioventricular cushions, and in part from the 
proximal end of the fused outflow cushions.15  
The common outflow lumen is separated into a pulmonary trunk and an aorta by outflow tract 
septation. This process involves the cardiac neural crest cell population that contributes to the 
condensed mesenchyme of the aorticopulmonary septum.16, 17 Precise control of processes such as 
neural crest cell migration, differentiation, proliferation, apoptosis and intracellular signalling are 
essential for correct formation and modelling of the heart and vascular system. The outflow tract 
cushions are remodelled into arterial valves.18 Finally, the aorta with its aortic valves is continuous 
with the left ventricle, and the pulmonary trunk with its pulmonary valves originates from the right 
ventricle.13 
Figure 1. Embryonic car-
diovascular development 
in the chicken. The heart 
primordia develop into 
angioblastic cords, which 
form a pair of lateral 
endocardial tubes. The 
single primitive heart tube is 
formed by folding of the 
embryo and fusion of the 
endocardial tubes (panel A). 
Thereafter, the primitive 
heart tube undergoes 
processes of looping and 
remodelling (panel B-D). 
Reproduced with permission 
from B. Hogers and R.E. 
Poelmann. Dept. Anatomy, 
LUMC, the Netherlands. 
 
With regard to aetiology, only approximately 15% of the CHDs can be attributed to a known cause, 
even when including genetic and chromosomal conditions with environmental exposures. The 
strongest genetic contributors to CHDs are the chromosomal abnormalities, e.g., trisomy 21, 18, 13, 
and the 22q11 deletion.4 Genetic causes related to human CHDs comprise of mutations in NKX2.5, 
CX43, GATA4, JAGGED-1, TBX1 and TBX5 genes.19, 20 Known maternal environmental risk factors are 
diabetes mellitus, use of medications, pesticides and solvents, obesity, and febrile illnesses.1 Most 
A B 
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CHDs, however, are considered as complex diseases with a multifactorial aetiology, which are thought 
to result from interactions between both genetic and environmental factors.21 
The first studies showing that B-vitamins might be involved in the pathogenesis of congenital 
anomalies originate from the 1950s. Multiple congenital malformations including cardiovascular 
defects were observed in rats when a folic acid deficient diet was given to female rats in early 
pregnancy.22, 23 Some decades later, the role of B-vitamins in vascular pregnancy complications was 
reported. Mothers of a child with a congenital malformation and women with placental abruption 
showed a folate deficiency.24, 25 Interestingly, Raymond et al. demonstrated an association between 
placental abruption and congenital anomalies, particularly CHDs.26 These data support the hypothesis 
that vascular disruptions in early pregnancy may lead to abnormal placental development and birth 
defects.21 Thereafter, several epidemiological studies reported that the use of folic acid containing 
supplements in the periconceptional period reduces the risk of having a child with a CHD.27-30 
Natural folates occur in foods and differ chemically from the synthetic form, i.e., folic acid, that is used 
in supplements and fortified foods. Food folate has a 50% lower bioavailability compared with that of 
synthetic folic acid. The term folate represents the many derivatives of this B-vitamin found in food, 
blood and tissues. It functions as a one-carbon donor in several important cellular reactions, including 
the synthesis of nucleotides and methyl transfer reactions important for methylation of DNA, proteins, 
and lipids. Moreover, folate is an important substrate of the homocysteine metabolism (Figure 2).31 
Plasma total homocysteine (tHcy) levels are maintained within narrow ranges by the efficient 
functioning of genes encoding enzymes that participate in the homocysteine metabolism, such as 
methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MS), methionine synthase 
Figure 2. B-vitamin dependent homocysteine metabolism.
B2 
B12
Dihydrofolate 
Methionine 
Homocysteine
S-adenosylmethionine
S-adenosylhomocysteine
5 - methylTHF
THF 
5,10 – methylene - THF 
Cystathionine 
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MTHFR 
MTRR
MS
B6 
B6 TC
Folic  
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reductase (MTRR), and cystathionine β-synthase. Moreover, tHcy concentrations depend on the intake 
and concentrations of folate, vitamin B12, vitamin B6 and vitamin B2, because these micronutrients 
are cofactors or substrates in this metabolism.31, 32 In addition, genetic determinants of B-vitamin 
transport proteins and receptors may interfere in the homocysteine metabolism by affecting the 
cellular availability of B-vitamins. For instance, it has been shown that a polymorphism in the 
transcobalamin gene (TC) is a determinant of the TC and tHcy concentrations.33  
Mild to moderate hyperhomocysteinaemia results from inadequate intake of B-vitamins as well as from 
functional polymorphisms in key enzymes involved in the homocysteine metabolism or transport of B-
vitamins. Abnormalities in the homocysteine metabolism or the one-carbon metabolism, e.g., 
hyperhomocysteinaemia or DNA hypomethylation, may contribute to the development of congenital 
anomalies.31, 34-37 Animal studies have indicated the involvement of the homocysteine metabolism in 
heart development. It was shown that homocysteine stimulates the proliferation and migration of 
avian neural crest cells and inhibits their differentiation.38 Most chicken embryos exhibited CHDs after 
injection with homocysteine concentrations comparable to mild hyperhomocysteinaemia in man. It 
was suggested that homocysteine affects cardiac neural crest cell behaviour and, thereby, leads to the 
development of CHDs.39 Interestingly, folic acid supplementation partially rescues these detrimental 
effects of homocysteine on neural crest cell outgrowth.38 In addition, our group showed the 
association between maternal hyperhomocysteinaemia and having a child with a CHD.40  
The mother is the environment of the developing child in utero and, therefore, the maternal 
nutritional status will influence the homocysteine metabolism in the embryonic tissues as well. 
Expression of functional polymorphisms in B-vitamin related genes derived from both parents might 
also be important in the development of the embryonic heart. In addition, interactions should be 
considered between the maternal nutritional status and the polymorphisms in B-vitamin related genes 
of mothers and children. Therefore, we hypothesize that derangements in the homocysteine 
metabolism affecting the developing primitive cardiovascular system are partially responsible for 
CHDs. 
 
Objectives 
In order to develop and implement effective primary prevention programs, risk factors for CHDs have 
to be identified. Preconceptional screening of these risk factors and the development of (nutritional) 
interventions will contribute to future risk assessment and, thereby, prevention of CHDs. The maternal 
nutritional status has been shown to be involved in the pathogenesis of related birth defects, such as 
neural tube defects and orofacial clefting. The overall aim of this thesis is to explore the impact of 
nutritional factors and their interactions with some B-vitamin related genes in the aetiology of CHDs.  
Therefore, our objectives are: 
1) To investigate associations between maternal B-vitamin and homocysteine status determined 
by biomarkers and dietary intake, and the risk of having a child with a CHD (Part I). 
2) To study gene-nutrient interactions between biomarkers, dietary intake, the B-vitamin related 
genes MTHFR, MTRR and TC and CHD risk (Part II).  
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Outline of the thesis 
In Chapter 2 a meta-analysis is presented of published studies that examined maternal 
hyperhomocysteinaemia or polymorphisms of MTHFR genes in association with the risk of a child with 
a CHD or orofacial cleft, which is a related malformation with regard to aetiology. We did not include 
studies of neural tube defects in this meta-analysis, because the folate-dependent pathway has 
already been investigated and reviewed extensively for these congenital anomalies.41, 42 
This thesis presents results of the ongoing HAVEN study, which is a Dutch acronym for the study of 
congenital heart anomalies and the role of genetic and nutritional factors. This case-control study is 
designed to investigate determinants in the pathogenesis and prevention of CHDs and it has been 
conducted from June 2003 onwards at the Department of Obstetrics and Gynaecology/Division of 
Obstetrics and Prenatal Medicine of Erasmus MC, University Medical Centre, Rotterdam, the 
Netherlands, in close collaboration with the Departments of Paediatric Cardiology of the same hospital 
and of Leiden University Medical Centre in Leiden, VU University Medical Centre and Academic Medical 
Centre in Amsterdam, and with the child health centres of ‘Thuiszorg Nieuwe Waterweg Noord’ in the 
surroundings of Rotterdam. The HAVEN study is funded by the Netherlands Heart Foundation (grant 
2002.B027). 
The first part of this thesis describes the maternal nutritional status of B-vitamins in association with 
the risk of having a child with a CHD. Among other factors, the nutritional status is partly determined 
by the metabolism and intake of nutrients. To study the B-vitamin status we measured the 
concentrations of serum vitamin B12, serum and red blood cell folate, and tHcy, because these 
biomarkers partly reflect the effects of the nutritional intake on the homocysteine metabolism 
(Chapter 3). An existing food frequency questionnaire was adapted by the Division of Human Nutrition 
of Wageningen University in Wageningen to estimate the intake of folate and vitamin B12. Therefore, 
we performed a validation study for the estimation of the dietary intake of these B-vitamins (Chapter 
4). We assessed the maternal dietary intake of macronutrients and B-vitamins in case and control-
mothers in relation to CHDs in their children (Chapter 5).  
In Part II, gene-nutrient interactions are described regarding folate and vitamin B12 related genes. In 
Chapter 6 we present data of the interactions between nutritional and lifestyle factors, and two 
polymorphisms in the MTHFR gene whereas Chapter 7 shows an analysis of these environmental 
factors in combination with polymorphisms in the MTRR and TC genes. In the general discussion, the 
results of this case-control study are discussed and our objectives are evaluated (Chapter 8). 
Furthermore, we recommend future research and discuss the implications regarding clinical practice 
and public health care. 
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Abstract 
Several studies have reported an association between hyperhomocysteinaemia, 5,10-
methylenetetrahydrofolate reductase (MTHFR) polymorphisms and cleft lip with or without cleft palate 
(CLP) and congenital heart defects (CHDs). However, findings have been inconsistent. A meta-analysis 
was performed of published studies until September 2006 investigating these associations in both 
mothers and children. Homocysteine data were provided in two CLP and three CHD studies, and 
MTHFR polymorphisms were reported in ten CLP and eight CHD studies. Data were analysed using the 
random effects model in the Cochrane Review Manager.  
The pooled odds ratio (OR) of maternal hyperhomocysteinaemia was 2.3 (95% CI 0.4-11.9) for CLP 
and 4.4 (2.6-7.3) for CHDs. The MTHFR C677T polymorphism and CLP showed pooled ORs of 1.2 
(0.9-1.5) in mothers and 1.0 (0.9-1.2) in children, whereas these estimates for the A1298C 
polymorphism were 1.0 (0.7-1.2) in mothers and 0.9 (0.6-1.2) in children. The MTHFR C677T 
polymorphism in CHD studies demonstrated a pooled OR of 1.0 (0.8-1.3) for mothers and 1.1 (0.9-
1.5) for children. Two studies investigating the maternal A1298C polymorphism in CHDs demonstrated 
a pooled OR of 1.2 (0.8-1.8). Only one CHD study reported an OR of 1.3 (0.8-2.1) for this 
polymorphism in children.  
In conclusion, this meta-analysis demonstrates that maternal hyperhomocysteinaemia is a risk factor 
for CHDs. The MTHFR polymorphisms C677T and A1298C in both mothers and children are not 
independently associated with CLP or CHDs. Future studies should be performed to investigate the 
interactions between maternal hyperhomocysteinaemia, B-vitamin intake, related polymorphisms and 
the risk of CLP and CHDs. 
 
Introduction 
Orofacial clefting (OFC) and congenital heart defects (CHDs) develop during the first weeks after 
conception. These defects are common congenital anomalies of multifactorial origin influenced by 
both genetic and environmental factors.1, 2 Various epidemiologic studies have shown the protective 
effect of maternal use of multivitamins in the periconceptional period on the risk of having a child with 
OFC3 and a child with a CHD.4-6 
However, it is unknown which ingredient(s) in multivitamins are responsible for this risk reduction. 
Indirect evidence that folic acid is a key factor in orofacial and cardiovascular development has been 
suggested by a study of Hernandez-Diaz et al.,7 in which folic acid antagonists were shown to increase 
the risk of a child with OFC or a CHD. Mothers who used multivitamins containing folic acid in addition 
to dihydrofolate reductase inhibitors showed a five-fold lower risk of having a child with OFC or a CHD 
compared with mothers who did not concomitantly use multivitamins.7 Folate contributes to the 
transfer of one-carbon groups as part of nucleotide synthesis, the remethylation of homocysteine to 
methionine, and the subsequent methylation of DNA, proteins, and phospholipids. 
Hyperhomocysteinaemia and DNA hypomethylation contribute to the development of complex 
congenital disorders.8 Therefore, an optimal maternal and embryonic folate status is important for 
normal embryogenesis. 
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The enzyme 5,10-methylenetetrahydrofolate reductase (MTHFR) is an important enzyme in the 
homocysteine metabolism and catalyses the conversion of 5,10-methylenetetrahydrofolate into 5-
methyltetrahydrofolate, the predominant circulating form of folate. The MTHFR gene has at least two 
functional polymorphisms, C677T and A1298C. The MTHFR 677 T-allele is associated with reduced 
enzyme activity, decreased concentrations of folate in serum, plasma, and red blood cells, and mildly 
increased plasma total homocysteine (tHcy) concentrations.9, 10 The second polymorphism, MTHFR 
A1298C, also affects MTHFR activity but without biochemical changes.11 Normal MTHFR activity is 
crucial to maintain the pool of circulating folate and methionine and to prevent the accumulation of 
homocysteine.9 Homocysteine can be considered as a useful and important metabolic marker of the 
overall folate status. 
Several studies have reported inconsistent findings on associations between hyperhomocysteinaemia, 
MTHFR polymorphisms, and both OFC and CHD risk. Therefore, we performed a meta-analysis of all 
published studies until September 2006 investigating in mothers and children the associations 
between hyperhomocysteinaemia, MTHFR C677T and A1298C polymorphisms, and the risk of both 
OFC and CHDs. 
 
Materials and methods 
Studies 
Potential relevant studies were identified by using MESH terms and text words in a search of PubMed 
at the National Library of Medicine, Web of Science, Cochrane library, Scopus and the Genetic 
Association Database through September 1, 2006. The main search terms were ‘cleft lip’, ‘cleft palate’, 
‘heart defects, congenital’, ‘homocysteine’, ‘methylenetetrahydrofolate reductase (nadph2)’ and 
‘MTHFR’.  
We also conducted searches on congenital anomalies and malformations in general, because OFC and 
CHDs may not be specified when a study is related to several congenital malformations. Furthermore, 
we performed manual searches of reference lists in articles found during the electronic searches. If 
studies presented overlapping data, only the study with the largest number was included. All studies 
were published in German or English language. Authors were contacted by email asking them to 
provide data if the content of the paper was insufficient. This meta-analysis is limited to case-control 
and cohort studies that include data of homocysteine concentrations and/or the MTHFR 
polymorphisms. It does not include animal studies and studies of case series.  
Genetics and embryology suggest that clefts of the primary palate that involve the lip and/or palate 
are different in aetiology from clefts that affect the secondary palate and are, therefore, 
developmentally distinct entities.12, 13 Moreover, patients with cleft lip with or without cleft palate 
(CLP) represent the largest and most homogeneous group of oral clefts. Therefore, we included only 
those studies that investigated CLP and excluded the studies concerning isolated cleft palate. 
In total, we identified two CLP and five CHD studies investigating tHcy concentrations, and 23 CLP and 
11 CHD studies that reported on MTHFR polymorphisms. We excluded two CHD studies on tHcy 
concentrations, because one study population14 was part of a larger included study15 and the other 
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study used a different cut-off level for the tHcy concentrations and included older participants as 
well.16 Twelve studies on CLP and MTHFR polymorphisms were excluded, because seven studies used 
a family-based design,17-23 two studies were part of a larger included study,24, 25 and three studies only 
reported allele frequencies26, 27 or incomplete genotype frequencies.28 In respect of MTHFR 
polymorphisms in CHD studies, we excluded three studies that included only cases.29-31 Therefore, the 
meta-analysis was performed on tHcy data provided in two CLP32, 33 and three CHD studies15, 34, 35 and 
on MTHFR polymorphisms reported in ten CLP36-45 and eight CHD studies.41, 46-52 
Statistical Analysis 
Hardy-Weinberg equilibrium (HWE) was examined in all studies that included MTHFR genotype 
frequencies. The available tHcy and polymorphism data for the meta-analysis were entered in Review 
Manager (RevMan [Computer Program], version 4.2 for Windows. Copenhagen: The Nordic Cochrane 
Centre, The Cochrane Collaboration, 2003) and analysed with RevMan Analyses (version 1.0 for 
Windows). This program uses the method of moments to calculate the odds ratio (OR) and 95% 
confidence interval (CI) for the pooled data. The genetic dominant model was used for comparisons of 
the polymorphism data. Heterogeneity was assessed using the Q test.53 Nevertheless, we used the 
random effects model in all analyses. Funnel plots were used to investigate publication bias. 
 
Results 
The included studies were all case-control studies, except for the cohort study of Nurk et al.41 In the 
CLP meta-analysis, we included 263 mothers for tHcy data, 16,772 mothers and 3,341 children for the 
C677T polymorphism, and 15,584 mothers and 1,379 children for the A1298C polymorphism (Table 
1). For the CHD meta-analysis, those numbers were 771, 15,599, 2,167, 14,777 and 303, respectively 
(Table 2). The OR and 95% CI for the individual studies and the pooled analyses are presented in 
Figures 1 to 3. In all tHcy studies, blood samples were drawn after an overnight fast with the 
exception of the study of Hobbs et al.15 The pooled OR (95% CI) for maternal 
hyperhomocysteinaemia and CLP was 2.3 (0.4-11.9) and 4.4 (2.6-7.3) for CHDs (Figure 1). Based on 
the data provided in the study of Kapusta et al., an OR of 4.8 was computed instead of the OR of 5.1 
that is mentioned in their article.34 Only two studies have investigated hyperhomocysteinaemia in 
children with respect to CLP33 and CHDs.35 Therefore, we could not estimate a pooled OR for 
hyperhomocysteinaemia in children with CLP or a CHD. 
The MTHFR genotype frequencies were consistent with HWE in all studies except for the group of 
case-children in the study of Junker et al.49 and the control-children in the study of Wenstrom et al.48 
The MTHFR 677CT + TT genotype and CLP revealed pooled ORs of 1.2 (0.9-1.5) in mothers and 1.0 
(0.9-1.2) in children. For the MTHFR 1298AC + CC genotype, these estimates were 1.0 (0.7-1.2) in 
mothers and 0.9 (0.6-1.2) in children, respectively (Figure 2). In CHD-studies, the MTHFR C677T 
polymorphism showed a pooled OR of 1.0 (0.8-1.3) for the CT + TT genotype in mothers and 1.1 
(0.9-1.5) in children. We considered excluding the studies of Junker et al. and Wenstrom et al., 
because the case and the control-group, respectively, were out of HWE.48, 49  The CT + TT genotype 
in children then demonstrated a pooled OR of 1.0 (0.8-1.2). Two studies investigated the maternal 
  Hyperhomocysteinaemia and MTHFR polymorphisms in CLP and CHDs  21 
 
Table 1. MTHFR genotype frequencies in CLP studies. 
 
MTHFR A1298C polymorphism in association with CHDs and the pooled OR was 1.2 (0.8-1.8) for the 
AC + CC carriers (Figure 3). Only one CHD study reported of this polymorphism in children and 
showed an OR of 1.3 (0.8-2.1).46 The funnel plots were asymmetrical for tHcy concentrations in both 
CLP and CHD studies, the C677T polymorphism in CHD studies, and the A1298C polymorphism in CLP 
and CHD studies (data not shown).   
References Subjects Frequency in mothers, n (%) Frequency in children, n (%) 
C677T polymorphism   CC CT TT CC CT TT 
Shaw et al. [1998] Case NA NA NA 143 (46) 127 (41) 40 (13) 
   California, USA Control NA NA NA 156 (41) 178 (46) 49 (13) 
Tolarova et al. [1998]  Case 39 (42) 37 (40) 17 (18) 43 (39) 49 (44) 19 (17) 
   Argentina Control 39 (47) 33 (39) 12 (14) 46 (43) 52 (49) 8 (8) 
Martinelli et al. [2001]  Case 14 (22) 36 (57) 13 (21) 22 (34) 30 (47) 12 (19) 
   Italy Control 46 (43) 43 (41) 17 (16) 46 (43) 43 (41) 17 (16) 
Grunert et al. [2002] Case NA NA NA 34 (52) 26 (39) 6 (9) 
   Germany Control NA NA NA 90 (49) 69 (37) 25 (14) 
Shotelersuk et al. [2003]  Case 46 (69) 19 (28) 2 (3) 84 (77) 25 (23) 0 (0) 
   Thailand Control 154 (76) 46 (23) 2 (1) 154 (76) 46 (23) 2 (1) 
van Rooij et al. [2003]  Case 78 (53) 55 (37) 15 (10) 54 (51) 45 (43) 6 (6) 
   the Netherlands Control 84 (49) 74 (44) 12 (7) 70 (55) 54 (42) 4 (3) 
Gaspar et al. [2004]  Case 174 (52) 131 (39) 31 (9) 327 (51) 269 (42) 48 (7) 
   Brazil Control 213 (50) 172 (41) 39 (9) 213 (50) 172 (41) 39 (9) 
Nurk et al. [2004]  Case 12 (55) 8 (36) 2 (9) NA NA NA 
   Norway Control 7153 (49) 6029 (42) 1280 (9) NA NA NA 
Pezzetti et al. [2004]  Case 27 (26) 47 (45) 30 (29) 28 (25) 58 (53) 24 (22) 
   Italy Control 95 (33) 151 (52) 43 (15) 95 (33) 151 (52) 43 (15) 
Mostowska et al. [2006]  Case 60 (50) 46 (38) 15 (12) NA NA NA 
   Poland Control 42 (52) 33 (41) 6 (7) NA NA NA 
A1298C polymorphism  AA AC CC AA AC CC 
Tolarova et al. [1998]  Case 56 (65) 27 (31) 3 (4) 67 (62) 39 (36) 2 (2) 
   Argentina Control 50 (64) 25 (32) 3 (4) 63 (61) 33 (32) 7 (7) 
Grunert et al. [2002] Case NA NA NA 28 (43) 30 (46) 7 (11) 
   Germany Control NA NA NA 77 (42) 80 (43) 27 (15) 
Shotelersuk et al. [2003]  Case 30 (45) 33 (49) 4 (6) 55 (50) 48 (44) 6 (6) 
   Thailand Control 108 (53) 80 (40) 14 (7) 108 (53) 80 (40) 14 (7) 
van Rooij et al. [2003b]  Case 57 (46) 52 (41) 16 (13) 48 (51) 34 (36) 12 (13) 
   the Netherlands Control 76 (48) 67 (42) 16 (10) 61 (53) 43 (37) 11 (10) 
Nurk et al. [2004]  Case 9 (41) 10 (45) 3 (14) NA NA NA 
   Norway Control 6598 (46) 6332 (44) 1522 (10) NA NA NA 
Pezzetti et al. [2004]  Case 57 (55) 36 (35) 11 (10) 56 (51) 46 (42) 8 (7) 
   Italy Control 121 (42) 130 (45) 38 (13) 95 (33) 151 (52) 43 (15) 
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Table 2. MTHFR genotype frequencies in CHD studies. 
 
Discussion 
In this meta-analysis we used the results from studies published until September 2006 to calculate a 
pooled estimate of the reported associations between hyperhomocysteinaemia, MTHFR 
polymorphisms and the risk of CLP and CHDs. Maternal hyperhomocysteinaemia was significantly 
associated with a 4.4-fold increased risk of having a child with a CHD. This finding substantiates the 
hypothesis that maternal hyperhomocysteinaemia is a risk factor for CHDs. The association was not 
significant for CLP, but no firm conclusion can be made based on the results of only two published 
studies. The point estimates for the MTHFR polymorphisms in mothers and children had small 
confidence intervals and were not significant for both CLP and CHDs. These results suggest that the 
mutant MTHFR alleles independently do not contribute to the risk of a child with either CLP or a CHD. 
It is widely recognized that the origin of these congenital malformations is complex and multifactorial 
in nature, with genetic and environmental factors affecting various developmental pathways. Of 
interest, therefore, is that factors like diet and lifestyle can modify the effects of certain genetic 
polymorphisms. Heterozygosity for both MTHFR polymorphisms can result in a lower MTHFR activity 
than heterozygosity for either of the MTHFR mutations  separately.11  Two studies  showed  that  tHcy   
 
References Subjects Frequency in mothers, n (%) Frequency in children, n (%) 
C677T polymorphism   CC CT TT CC CT TT 
Junker et al. [2001] Case NA NA NA 51 (45) 42 (37) 21(18) 
   Germany Control NA NA NA 129 (57) 78 (34) 21 (9) 
Wenstrom et al. [2001]  Case NA NA NA 17 (65) 8 (31) 1 (4) 
   Alabama, USA Control NA NA NA 104 (90) 9 (8) 3 (2) 
Storti et al. [2003] Case 27 (26) 53 (52) 23 (22) 28 (27) 55 (53) 20 (20) 
   Italy Control 52 (26) 108 (54) 40 (20) 52 (26) 108 (54) 40 (20) 
Nurk et al. [2004]  Case 12 (48) 12 (48) 1 (4) NA NA NA 
   Norway Control 7153 (49) 6025 (42) 1281 (9) NA NA NA 
Lee et al. [2005]  Case NA NA NA 110 (51) 89 (42) 14 (7) 
   Taiwan Control NA NA NA 114 (58) 68 (35) 13 (7) 
Shaw et al. [2005]  Case NA NA NA 69 (45) 68 (44) 16 (11) 
   California, USA Control NA NA NA 180 (42) 202 (46) 52 (12) 
Hobbs et al. [2006] Case 127 (46) 118 (43) 30 (11) NA NA NA 
   Arkansas, USA Control 48 (41) 56 (47) 14 (12) NA NA NA 
van Beynum et al. [2006] Case 72 (46) 68 (43) 18 (12) 79 (48) 66 (40) 20 (12) 
   the Netherlands Control 131 (50) 107 (41) 23 (9) 98 (45) 104 (47) 18 (8) 
A1298C polymorphism  AA AC CC AA AC CC 
Storti et al. [2003]  Case 49 (48) 46 (45) 8 (8) 45 (44) 47 (45) 11 (11) 
   Italy Control 101 (50) 86 (43) 13 (7) 101 (50) 86 (43) 13 (7) 
Nurk et al. [2004] Case 9 (36) 13 (52) 3 (12) NA NA NA 
   Norway Control 6598 (46) 6329 (44) 1522 (10) NA NA NA 
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Figure 1. Association between maternal hyperhomocysteinaemia and the risk of cleft lip 
with or without cleft palate and congenital heart defects.   
 
concentrations were significantly higher in individuals with a combined heterozygosity for the MTHFR 
polymorphisms than those who were heterozygous for either the C677T or the A1298C genotype.11, 54 
Shotelersuk et al. demonstrated a significant increased risk of having a child with CLP if the mother 
was heterozygous for both MTHFR polymorphisms.38 The risk of a child with CLP39 or a CHD47 was 
only significantly increased if mothers, carrying the MTHFR 677TT or MTHFR 1298CC genotype, also 
had a low periconceptional intake of dietary folate and/or folic acid supplements. These examples of 
gene-gene and gene-nutrient interactions explain why neither of the two MTHFR polymorphisms is an 
independent risk factor for CLP and CHDs. Moreover, these previously published articles give insight in 
the protective effect of maternal use of multivitamins containing folic acid in the periconceptional 
period on the risk of having a child with CLP3 or a CHD.4-6 Dietary intake and use of B-vitamin 
supplements can compensate for the reduced activity of the MTHFR enzyme and lower tHcy 
concentrations, thereby decreasing the risk of these congenital defects. 
We have to consider some strengths and limitations of this meta-analysis. The use of a meta-analysis 
can overcome the low power of small sample size studies, and, therefore, reconcile previously 
conducted studies with inconsistent results. Although, the number of included tHcy studies in this 
meta-analysis is quite low for both congenital defects, all tHcy concentration measurements were 
performed by the high performance liquid chromatography method. The risk estimates for maternal 
hyperhomocysteinaemia in CLP and CHDs are consistent and, therefore, laboratory errors are not 
likely. In the pooled analysis of hyperhomocysteinaemia in mothers and CLP risk only two studies 
were included with evidence of heterogeneity. This heterogeneity might be caused by the pilot study 
of Wong et al.32 In this study the cut-off value of the 97.5th percentile was used instead of the 90th 
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Figure 2. Association between the MTHFR C677T (A) and A1298C (B) polymorphism in 
mothers and children and cleft lip with or without cleft palate. 
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Figure 3. Association between the MTHFR C677T (A) and A1298C (B) polymorphism in 
mothers and children and congenital heart defects. 
 
percentile that was used by the other tHcy studies, resulting in a low number of hyperhomo-
cysteinaemic mothers. Moreover, they included both methionine afterload and fasting tHcy 
concentrations.  
With concern to the genotyping of MTHFR polymorphisms, laboratory errors are not likely because the 
genotyping has been done using standard protocols with polymerase chain reactions and restriction 
enzyme digestion in all studies. Moreover, all studies showed genotype frequencies that were 
consistent with HWE for both cases and controls with an exception of the cases in the study of Junker 
et al. and the controls in the study of Wenstrom et al.48, 49 The study of Wenstrom et al. in particular 
was the source of heterogeneity in the analysis of CHDs and the MTHFR C677T genotype in children, 
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possibly because their control-group was out of HWE. We considered exclusion of both studies, but 
the point estimates did not substantially change. The analysis of CHDs and MTHFR C677T 
polymorphisms in children, and the analysis of CLP and A1298C polymorphisms in children 
demonstrated P values less than 0.10 for the Q test for heterogeneity (Figures 2 and 3). We used the 
random effects model in all analyses, thereby accounting for the heterogeneity. In addition, the point 
estimates of the fixed and the random effects model are nearly identical, which suggests that 
heterogeneity is not a big issue.  
Differences in risk estimates for MTHFR polymorphisms can also be caused by aetiologic heterogeneity 
between populations, geographical variations of the studied populations, different selection of controls 
or even by the folate intake of the population.55 The 677TT and 1298CC genotype frequencies of the 
included studies demonstrate the known geographical variations.56-59 Regarding the selection of 
controls, most studies included unrelated and unaffected controls. We considered the influence of the 
studies that used another selection of controls, but these studies did not significantly alter the point 
estimates. 
Publication bias has to be addressed in meta-analyses because it can be a substantial cause of bias. 
The funnel plots are asymmetrical for the A1298C polymorphism and tHcy concentration in both CLP 
and CHDs, and the C677T polymorphism in CHDs suggesting publication bias towards overestimation 
of the results. Asymmetry might be due to the low number of published studies.  Furthermore, 
asymmetric funnel plots can also be caused by language and citation bias, if studies with non-
significant results are published in non-English languages, and are thereby less likely to be cited. 
However, the studies with non-significant findings have also been included in the analyses, thereby 
reducing the chance of publication bias. 
In conclusion, we demonstrated in this meta-analysis that maternal hyperhomocysteinaemia is a risk 
factor for CHDs. The MTHFR polymorphisms C677T and A1298C did not show to be significantly 
associated with CLP or CHDs. Further research should be performed to investigate the interactions 
between maternal hyperhomocysteinaemia, B-vitamin intake, related polymorphisms and the risk of 
CLP and CHDs. 
 
References 
1. Botto LD, Correa A, Erickson JD. Racial and temporal variations in the prevalence of heart defects. Pediatrics 
2001;107:E32. 
2. Wyszynski DF, Beaty TH. Review of the role of potential teratogens in the origin of human nonsyndromic oral 
clefts. Teratology 1996;53:309-17. 
3. Krapels IP, Vermeij-Keers C, Muller M, de Klein A, Steegers-Theunissen RP. Nutrition and genes in the 
development of orofacial clefting. Nutr Rev 2006;64:280-8. 
4. Shaw GM, O'Malley CD, Wasserman CR, Tolarova MM, Lammer EJ. Maternal periconceptional use of 
multivitamins and reduced risk for conotruncal heart defects and limb deficiencies among offspring. Am J 
Med Genet 1995;59:536-45. 
5. Czeizel AE. Periconceptional folic acid containing multivitamin supplementation. Eur J Obstet Gynecol Reprod 
Biol 1998;78:151-61. 
  Hyperhomocysteinaemia and MTHFR polymorphisms in CLP and CHDs  27 
6. Botto LD, Mulinare J, Erickson JD. Occurrence of congenital heart defects in relation to maternal multivitamin 
use. Am J Epidemiol 2000;151:878-84. 
7. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk 
of birth defects. N Engl J Med 2000;343:1608-14. 
8. McKay JA, Williams EA, Mathers JC. Folate and DNA methylation during in utero development and aging. 
Biochem Soc Trans 2004;32:1006-7. 
9. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, 
van den Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in 
methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3. 
10. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R. Relation 
between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma 
homocysteine concentrations. Circulation 1996;93:7-9. 
11. van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, van den Heuvel LP, Blom HJ. A 
second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for 
neural-tube defects? Am J Hum Genet 1998;62:1044-51. 
12. Fraser FC. Thoughts on the etiology of clefts of the palate and lip. Acta Genet Stat Med 1955;5:358-69. 
13. Fogh-Andersen P. Inheritance of hare lip and cleft palate. Munksgaard, Copenhagen, Denmark, 1942. 
14. Hobbs CA, Cleves MA, Melnyk S, Zhao W, James SJ. Congenital heart defects and abnormal maternal 
biomarkers of methionine and homocysteine metabolism. Am J Clin Nutr 2005;81:147-53. 
15. Hobbs CA, Cleves MA, Zhao W, Melnyk S, James SJ. Congenital heart defects and maternal biomarkers of 
oxidative stress. Am J Clin Nutr 2005;82:598-604. 
16. Vollset SE, Refsum H, Irgens LM, Emblem BM, Tverdal A, Gjessing HK, Monsen AL, Ueland PM. Plasma total 
homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine 
study. Am J Clin Nutr 2000;71:962-8. 
17. Shi M, Caprau D, Dagle J, Christiansen L, Christensen K, Murray JC. Application of kinetic polymerase chain 
reaction and molecular beacon assays to pooled analyses and high-throughput genotyping for candidate 
genes. Birth Defects Res A Clin Mol Teratol 2004;70:65-74. 
18. Prescott NJ, Winter RM, Malcolm S. Maternal MTHFR genotype contributes to the risk of non-syndromic cleft 
lip and palate. J Med Genet 2002;39:368-9. 
19. Jugessur A, Wilcox AJ, Lie RT, Murray JC, Taylor JA, Ulvik A, Drevon CA, Vindenes HA, Abyholm FE. Exploring 
the effects of methylenetetrahydrofolate reductase gene variants C677T and A1298C on the risk of orofacial 
clefts in 261 Norwegian case-parent triads. Am J Epidemiol 2003;157:1083-91. 
20. Vieira AR, Murray JC, Trembath D, Orioli IM, Castilla EE, Cooper ME, Marazita ML, Lennon-Graham F, Speer 
M. Studies of reduced folate carrier 1 (RFC1) A80G and 5,10-methylenetetrahydrofolate reductase (MTHFR) 
C677T polymorphisms with neural tube and orofacial cleft defects. Am J Med Genet A 2005;135:220-3. 
21. Zhu J, Ren A, Hao L, Pei L, Liu J, Zhu H, Li S, Finnell RH, Li Z. Variable contribution of the MTHFR C677T 
polymorphism to non-syndromic cleft lip and palate risk in China. Am J Med Genet A 2006;140A:551-7. 
22. Beaty TH, Hetmanski JB, Zeiger JS, Fan YT, Liang KY, VanderKolk CA, McIntosh I. Testing candidate genes 
for non-syndromic oral clefts using a case-parent trio design. Genet Epidemiol 2002;22:1-11. 
23. Jugessur A, Lie RT, Wilcox AJ, Murray JC, Taylor JA, Saugstad OD, Vindenes HA, Abyholm FE. Cleft palate, 
transforming growth factor alpha gene variants, and maternal exposures: assessing gene-environment 
interactions in case-parent triads. Genet Epidemiol 2003;25:367-74. 
 28 Chapter 2 
24. Wyszynski DF, Diehl SR. Infant C677T mutation in MTHFR, maternal periconceptional vitamin use, and risk of 
nonsyndromic cleft lip. Am J Med Genet 2000;92:79-80. 
25. Gaspar DA, Pavanello RC, Zatz M, Passos-Bueno MR, Andre M, Steman S, Wyszynski DF, Matiolli SR. Role of 
the C677T polymorphism at the MTHFR gene on risk to nonsyndromic cleft lip with/without cleft palate: 
results from a case-control study in Brazil. Am J Med Genet 1999;87:197-9. 
26. Blanton SH, Patel S, Hecht JT, Mulliken JB. MTHFR is not a risk factor in the development of isolated 
nonsyndromic cleft lip and palate. Am J Med Genet 2002;110:404-5. 
27. Blanton SH, Kolle BS, Hecht JT, Mulliken JB, Martin ER. No evidence supporting MTHFR as a risk factor in the 
development of familial NSCLP. Am J Med Genet 2000;92:370-1. 
28. Mills JL, Kirke PN, Molloy AM, Burke H, Conley MR, Lee YJ, Mayne PD, Weir DG, Scott JM. 
Methylenetetrahydrofolate reductase thermolabile variant and oral clefts. Am J Med Genet 1999;86:71-4. 
29. McBride KL, Fernbach S, Menesses A, Molinari L, Quay E, Pignatelli R, Towbin JA, Belmont JW. A family-
based association study of congenital left-sided heart malformations and 5,10 methylenetetrahydrofolate 
reductase. Birth Defects Res A Clin Mol Teratol 2004;70:825-30. 
30. Pereira AC, Xavier-Neto J, Mesquita SM, Mota GF, Lopes AA, Krieger JE. Lack of evidence of association 
between MTHFR C677T polymorphism and congenital heart disease in a TDT study design. Int J Cardiol 
2005;105:15-8. 
31. Hobbs CA, James SJ, Parsian A, Krakowiak PA, Jernigan SL, Greenhaw JJ, Lu Y, Cleves MA. Congenital heart 
defects and genetic variants in the methylenetetrahydrofolate reductase gene. J Med Genet 2006;43:162-6. 
32. Wong WY, Eskes TK, Kuijpers-Jagtman AM, Spauwen PH, Steegers EA, Thomas CM, Hamel BC, Blom HJ, 
Steegers-Theunissen RP. Nonsyndromic orofacial clefts: association with maternal hyperhomocysteinemia. 
Teratology 1999;60:253-7. 
33. van Rooij IA, Swinkels DW, Blom HJ, Merkus HM, Steegers-Theunissen RP. Vitamin and homocysteine status 
of mothers and infants and the risk of nonsyndromic orofacial clefts. Am J Obstet Gynecol 2003;189:1155-
60. 
34. Kapusta L, Haagmans ML, Steegers EA, Cuypers MH, Blom HJ, Eskes TK. Congenital heart defects and 
maternal derangement of homocysteine metabolism. J Pediatr 1999;135:773-4. 
35. Verkleij-Hagoort AC, Verlinde M, Ursem NT, Lindemans J, Helbing WA, Ottenkamp J, Siebel FM, Gittenberger-
de Groot AC, de Jonge R, Bartelings MM, Steegers EA, Steegers-Theunissen RP. Maternal 
hyperhomocysteinaemia is a risk factor for congenital heart disease. BJOG 2006;113:1412-8. 
36. Tolarova MM, van Rooij IA, Pastor M, van der Put NM, Goldberg AC, Hol F, Capozzi A, Thomas CM, Pastor L, 
Mosby T, Ferrari C, Eskes TK, Steegers-Theunissen RP. A common mutation in the MTHFR gene is a risk 
factor for nonsyndromic cleft lip and palate anomalies [abstract]. Am J Hum Genet 1998;63:A27. 
37. Martinelli M, Scapoli L, Pezzetti F, Carinci F, Carinci P, Stabellini G, Bisceglia L, Gombos F, Tognon M. C677T 
variant form at the MTHFR gene and CL/P: a risk factor for mothers? Am J Med Genet 2001;98:357-60. 
38. Shotelersuk V, Ittiwut C, Siriwan P, Angspatt A. Maternal 677CT/1298AC genotype of the MTHFR gene as a 
risk factor for cleft lip. J Med Genet 2003;40:e64. 
39. van Rooij IA, Vermeij-Keers C, Kluijtmans LA, Ocke MC, Zielhuis GA, Goorhuis-Brouwer SM, van der Biezen 
JJ, Kuijpers-Jagtman AM, Steegers-Theunissen RP. Does the interaction between maternal folate intake and 
the methylenetetrahydrofolate reductase polymorphisms affect the risk of cleft lip with or without cleft 
palate? Am J Epidemiol 2003;157:583-91. 
40. Gaspar DA, Matioli SR, de Cassia Pavanello R, Araujo BC, Alonso N, Wyszynski D, Passos-Bueno MR. Maternal 
MTHFR interacts with the offspring's BCL3 genotypes, but not with TGFA, in increasing risk to nonsyndromic 
  Hyperhomocysteinaemia and MTHFR polymorphisms in CLP and CHDs  29 
cleft lip with or without cleft palate. Eur J Hum Genet 2004;12:521-6. 
41. Nurk E, Tell GS, Refsum H, Ueland PM, Vollset SE. Associations between maternal methylenetetrahydrofolate 
reductase polymorphisms and adverse outcomes of pregnancy: the Hordaland Homocysteine Study. Am J 
Med 2004;117:26-31. 
42. Pezzetti F, Martinelli M, Scapoli L, Carinci F, Palmieri A, Marchesini J, Carinci P, Caramelli E, Rullo R, Gombos 
F, Tognon M. Maternal MTHFR variant forms increase the risk in offspring of isolated nonsyndromic cleft lip 
with or without cleft palate. Hum Mutat 2004;24:104-5. 
43. Shaw GM, Rozen R, Finnell RH, Todoroff K, Lammer EJ. Infant C677T mutation in MTHFR, maternal 
periconceptional vitamin use, and cleft lip. Am J Med Genet 1998;80:196-8. 
44. Grunert RR, Braune A, Schnackenberg E, Schloot W, Krause HR. Genetic differences in enzymes of folic acid 
metabolism in patients with lip-jaw-palate clefts and their relatives. In German. (Genetische Unterschiede 
von Enzymen des Folsaurestoffwechsels bei Patienten mit Lippen-Kiefer-Gaumen-Spalten und ihren 
Angehorigen). Mund Kiefer Gesichtschir 2002;6:131-3. 
45. Mostowska A, Hozyasz KK, Jagodzinski PP. Maternal MTR genotype contributes to the risk of non-syndromic 
cleft lip and palate in the Polish population. Clin Genet 2006;69:512-7. 
46. Storti S, Vittorini S, Lascone MR, Sacchelli M, Collavoli A, Ripoli A, Cocchi G, Biagini A, Clerico A. Association 
between 5,10-methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and conotruncal heart 
defects. Clin Chem Lab Med 2003;41:276-80. 
47. van Beynum IM, Kapusta L, den Heijer M, Vermeulen SH, Kouwenberg M, Daniels O, Blom HJ. Maternal 
MTHFR 677C>T is a risk factor for congenital heart defects: effect modification by periconceptional folate 
supplementation. Eur Heart J 2006;27:981-7. 
48. Wenstrom KD, Johanning GL, Johnston KE, DuBard M. Association of the C677T methylenetetrahydrofolate 
reductase mutation and elevated homocysteine levels with congenital cardiac malformations. Am J Obstet 
Gynecol 2001;184:806-17. 
49. Junker R, Kotthoff S, Vielhaber H, Halimeh S, Kosch A, Koch HG, Kassenbohmer R, Heineking B, Nowak-Gottl 
U. Infant methylenetetrahydrofolate reductase 677TT genotype is a risk factor for congenital heart disease. 
Cardiovasc Res 2001;51:251-4. 
50. Lee CN, Su YN, Cheng WF, Lin MT, Wang JK, Wu MH, Hsieh FJ. Association of the C677T 
methylenetetrahydrofolate reductase mutation with congenital heart diseases. Acta Obstet Gynecol Scand 
2005;84:1134-40. 
51. Shaw GM, Iovannisci DM, Yang W, Finnell RH, Carmichael SL, Cheng S, Lammer EJ. Risks of human 
conotruncal heart defects associated with 32 single nucleotide polymorphisms of selected cardiovascular 
disease-related genes. Am J Med Genet A 2005;138:21-6. 
52. Hobbs CA, James SJ, Jernigan S, Melnyk S, Lu Y, Malik S, Cleves MA. Congenital heart defects, maternal 
homocysteine, smoking, and the 677 C>T polymorphism in the methylenetetrahydroflate reductase gene: 
evaluating gene-environment interactions. Am J Obstet Gynecol 2006;194:218-24. 
53. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. 
54. Weisberg IS, Jacques PF, Selhub J, Bostom AG, Chen Z, Curtis Ellison R, Eckfeldt JH, Rozen R. The 1298A--
>C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with 
homocysteine. Atherosclerosis 2001;156:409-15. 
55. Fohr IP, Prinz-Langenohl R, Bronstrup A, Bohlmann AM, Nau H, Berthold HK, Pietrzik K. 5,10-
Methylenetetrahydrofolate reductase genotype determines the plasma homocysteine-lowering effect of 
 30 Chapter 2 
supplementation with 5-methyltetrahydrofolate or folic acid in healthy young women. Am J Clin Nutr 
2002;75:275-82. 
56. Botto LD, Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a 
HuGE review. Am J Epidemiol 2000;151:862-77. 
57. Gueant-Rodriguez RM, Gueant JL, Debard R, Thirion S, Hong LX, Bronowicki JP, Namour F, Chabi NW, Sanni 
A, Anello G, Bosco P, Romano C, Amouzou E, Arrieta HR, Sanchez BE, Romano A, Herbeth B, Guilland JC, 
Mutchinick OM. Prevalence of methylenetetrahydrofolate reductase 677T and 1298C alleles and folate status: 
a comparative study in Mexican, West African, and European populations. Am J Clin Nutr 2006;83:701-7. 
58. Angchaisuksiri P, Pingsuthiwong S, Sura T, Aryuchai K, Busabaratana M, Atichartakarn V. Prevalence of the 
C677T methylenetetra- hydrofolate reductase mutation in Thai patients with deep vein thrombosis. Acta 
Haematol 2000;103:191-6. 
59. Schnakenberg E, Mehles A, Cario G, Rehe K, Seidemann K, Schlegelberger B, Elsner HA, Welte KH, Schrappe 
M, Stanulla M. Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and susceptibility to 
pediatric acute lymphoblastic leukemia in a German study population. BMC Med Genet 2005;6:23. 
 
 
  
 
 
     
Part I 
 
 
 
 
B-vitamin and homocysteine status  
     
     
Chapter 3 
 
 
 
 
Maternal hyperhomocysteinaemia is a risk factor  
for congenital heart disease  
  
 
 
 
 
 
 
 
 
 
 
 
Anna C. Verkleij-Hagoort 
Monica Verlinde 
Nicolette T.C. Ursem 
Jan Lindemans 
Willem A. Helbing 
Jaap Ottenkamp 
Franciska M.H. Siebel 
Adriana C. Gittenberger-de Groot 
Robert de Jonge 
Margot M. Bartelings 
Eric A.P. Steegers 
Régine P.M. Steegers-Theunissen 
 
 
BJOG 2006;12:1412-18 
 34 Chapter 3 
Abstract 
Objective: To investigate the inter-relation between mother and infant homocysteine, folate and 
vitamin B12 status, and the risk of a child with congenital heart disease (CHD). 
Design: Case-control study. 
Setting: Erasmus MC, University Medical Centre, Rotterdam, the Netherlands. 
Population: Participants were 149 case-mothers and their children with CHD (n = 151) and 183 
control-mothers with their children (n = 175).  
Methods: Approximately 17 months after the index-pregnancy maternal fasting and children’s random 
venous blood samples were drawn to measure plasma total homocysteine, serum and red blood cell 
folate, and serum vitamin B12 concentrations. Data were compared between cases and controls using 
the Mann-Whitney U test. The biochemical parameters were dichotomised according to the cut-off 
value of the 10th percentile of vitamin concentrations and the 90th percentile of homocysteine 
concentrations based on control data. Risk estimates for the association between CHD and the 
biochemical parameters were estimated in a logistic regression model.  
Main outcome measures: Medians (minimum-maximum) and odds ratios (95% confidence intervals). 
Results: The odds ratio (95% confidence interval) of having a child with CHD was 2.9 (1.4-6.0) for 
maternal hyperhomocysteinaemia (> 14.3 μmol/L). This finding is substantiated by a significant 
concentration-dependent risk (Ptrend = 0.004). Hyperhomocysteinaemic case-mothers showed 
significantly lower serum folate and vitamin B12 concentrations than normohomocysteinaemic case-
mothers. Serum and red blood cell folate concentrations were significantly higher in case-children than 
in control-children.  
Conclusions: Maternal hyperhomocysteinaemia is associated with an increased risk of CHD partially 
due to low folate and vitamin B12 status. The folate status of children warrants further investigation.  
  
Introduction 
Congenital heart disease (CHD) occurs in six per 1,000 live births in the Netherlands and in 
approximately nine per 1,000 newborns in the United States of America.1, 2 These malformations are 
amongst the most common congenital malformations in newborns and account for more than one-
third of infant deaths due to congenital anomalies.2 The most common CHD comprises of outflow 
defects, such as membranous ventricular septal defects, pulmonary valve stenosis, tetralogy of Fallot 
and transposition of the great arteries.3 
Although genetic and environmental factors are involved in the aetiology of CHD, only approximately 
15% can be attributed to a known cause.2 Previous epidemiological studies showed that 
periconceptional use of multivitamins containing folic acid reduces the risk of having a child with 
CHD.4 Shaw et al. were the first to show that the maternal use of these vitamins during the sensitive 
period of heart development reduced the risk of conotruncal heart defects in particular.5 Hernandez-
Diaz et al. suggested that folate is a key factor in cardiovascular development by showing an 
increased risk of CHD after maternal exposure to folate antagonists during the first trimester of 
pregnancy. In addition, the use of multivitamin supplements containing folic acid diminished this risk.6 
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The B-vitamins folate and vitamin B12 are involved in the remethylation of homocysteine into 
methionine. A limited supply of folate impairs the methylation cycle, and thereby the methylation of 
DNA, proteins and lipids. Moreover, a compromised folate and/or vitamin B12 status also results in a 
mild hyperhomocysteinaemia. Homocysteine can be harmful to cells because it evokes oxidative 
stress through the production of reactive oxygen species, binds to nitric oxide, or leads to the 
accumulation of its precursor, S-adenosylhomocysteine, a potent inhibitor of biological 
transmethylations.7 Studies in chicken embryos showed 83% subarterial ventricular septal defects 
after injection of 30 μM homocysteine into the neural tube lumen at the time point of neural crest cell 
migration.8, 9 This homocysteine concentration resembles mild hyperhomocysteinaemia in human. 
Dietary deficiencies in folate have been observed to decrease genome-wide methylation both in 
humans and animal models, which is corrected after folate repletion. Moreover, derangements in the 
DNA methylation patterns can lead to developmental malformations.10 
These findings support a critical role for homocysteine and B-vitamins in the development of CHD. 
The embryo and fetus are dependent on the maternofetal nutrient transfer. Thus, it can be expected 
that the maternal homocysteine and B-vitamin status before conception and during the first weeks 
following conception, e.g. periconceptional, influences pregnancy outcome. Therefore, we performed 
a case-control study to investigate whether the mother and infant homocysteine, folate and vitamin 
B12 status influences the risk of CHD. 
 
Materials and methods 
Study population 
The HAVEN study, a Dutch acronym for the study of heart anomalies and the role of genetic and 
nutritional factors, is a case-control study designed to investigate determinants in the pathogenesis 
and prevention of CHD. The study has been conducted from June 2003 onwards at the Department of 
Obstetrics and Gynaecology/Division of Obstetrics and Prenatal Medicine of Erasmus MC in Rotterdam. 
Children with CHD and both parents were recruited in collaboration with the Departments of Paediatric 
Cardiology of the same hospital, and of Leiden University Medical Centre in Leiden, VU University 
Medical Centre and Academic Medical Centre in Amsterdam. Healthy control-children and both parents 
were enrolled in collaboration with the child health centres of ‘Thuiszorg Nieuwe Waterweg Noord’ 
nearby Rotterdam. The domain population comprised case and control-children born from June 2002 
onwards and living in the Western part of the Netherlands. The paediatric cardiologists diagnosed and 
recruited case-children with tetralogy of Fallot (n = 19), transposition of the great arteries (n = 28), 
atrioventricular septal defect (n = 9), perimembranous ventricular septal defect (n = 44), coarctation 
of the aorta (n = 14), aortic valve stenosis (n = 5), pulmonary valve stenosis (n = 30), and 
hypoplastic left heart syndrome (n = 2). Diagnoses were confirmed after birth by echocardiography, 
and/or cardiac catheterization and/or surgery. Children were eligible as controls if they did not have a 
major congenital malformation or chromosomal defects according to the medical record and regular 
health checks by the physician of the child health centre. There was no familial relationship between 
cases and controls. Invited cases and controls were all aged 11 to 18 months and both groups had 
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corresponding proportions of males and females. Participating parents had to be familiar with the 
Dutch language in writing and reading.  
Between October 2003 and January 2005 183 control-families and 151 case-families participated in 
the study. We evaluated the biochemical and questionnaire data of mothers and children that were 
collected during the hospital visit at Erasmus MC in Rotterdam. The Central Committee of Research in 
Human and the Medical Ethics Committees of the participating hospitals approved the study protocol. 
In addition, written informed consent was obtained from both parents.  
Study timing 
In general, metabolism and nutritional habits are rather constant and do not change except for 
episodes of illnesses, dieting and increased needs during pregnancy and breastfeeding.11-13 The study 
timing between 11 and 18 months after the index-pregnancy is sufficient to mimic the preconceptional 
biochemical status of the mother and to minimise the risk of undiagnosed less severe CHD in the 
control-group. At the study moment the general questionnaire was filled out and blood samples were 
obtained to determine the biochemistry of the mother and her child.   
Questionnaire data and anthropometrics 
We extracted the following information from the questionnaire administered. The parameters at the 
study moment included maternal age, body mass index (BMI), educational level, ethnicity, cigarette 
smoking, use of alcohol, oral contraceptives and medication, age and gender of the child. Ethnicity 
was classified according to the definitions of Statistics Netherlands.14 Mothers were classified as Dutch 
natives, Western or non-Western immigrants. The questionnaire data have been checked on 
completeness and consistency by the researcher during the hospital visit. Standardised 
anthropometric measurements were performed, which included maternal height (anthropometric rod, 
SECA, Hamburg, Germany) up to 0.1 cm accuracy and weight (weighing scale, SECA, Hamburg, 
Germany) with 0.5 kg accuracy.  
Blood sampling and biochemistry 
Venous blood samples were drawn from all mothers and children to measure the concentrations of 
red blood cell (RBC) and serum folate, serum vitamin B12 and plasma total homocysteine (tHcy). 
Blood sampling was done as described before.15 The concentrations of serum folate and vitamin B12 
were routinely determined by immunoelectrochemiluminescence assay on the Roche Modular E170 
(Roche Diagnostics GmbH, Mannheim Germany). Out of an ethylenediamine tetraacetate (EDTA)-
treated Vacutainer tube (BD Biosciences, Plymouth, UK) 0.1 mL full-blood was haemolysed with 0.9 
mL freshly prepared 1.0% ascorbic acid directly after blood sampling. Subsequently, the haematocrit 
of the EDTA full-blood was determined on an ADVIA 120 Haematology Analyser (Bayer Diagnostics, 
Leverkusen, Germany). 
The haemolysate was centrifuged at 1,000 x g for five minutes at 18 oC shortly before folate 
measurement. The haemolysate folate concentration was recalculated in RBC folate using the 
following formula: (nM haemolysate folate*10/hematocrit) - (nM serum folate*{1- 
haematocrit}/haematocrit) = nM RBC folate. The tHcy concentration was routinely measured by high 
performance liquid chromatography with reverse phase separation and fluorescence detection.15 
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The between-run coefficient of variation for vitamin B12 was 5.1% at 125 pmol/L and 2.9% at 753 
pmol/L; for folate these coefficients of variation were 9.5% at 8.3 nmol/L and 3.2% at 20.2 nmol/L 
and for tHcy 5.9% at 15.3 µmol/L and 3.4% at 39.3 µmol/L. All samples were analysed anonymously 
within three months after collection. Up to the moment of measurement, samples were kept frozen at 
–80 oC.  
Data analysis 
Maternal age and BMI, and age of the children are presented as medians and compared between 
cases and controls by using the Mann-Whitney U test. Differences in frequencies were tested using 
the Chi-square test.  
We present the biochemical parameters as medians and ranges and the differences between cases 
and controls were evaluated by the Mann-Whitney U test, because of the skewed distributions even 
after transformation. The parameters considered as confounders comprised of pregnancy, non-fasting 
state and use of folic acid containing vitamin supplements at the study moment. Therefore, we 
excluded all pregnant, non-fasting and vitamin supplement using mothers as well as children using 
vitamin supplements. Thus, the final analysis was based on data of 98 case and 134 control-mothers, 
and 149 case and 173 control-children. Missing results occurred in approximately 2% of the 
participants because of failures in blood sampling or laboratory testing. 
The risk of CHD was estimated using odds ratios (OR) and 95% confidence intervals (CI) in a logistic 
regression model. We created the 10th percentile of vitamin concentrations and the 90th percentile of 
tHcy concentrations based on the data of the control-group. Quintiles of maternal tHcy concentration 
were computed from the data of the control-mothers. Risk estimates were calculated in a logistic 
regression model with the lowest quintile as a reference. We performed a trend analysis across the 
quintiles after modelling the quintiles into five categories ranging from one (reference) to five (highest 
quintile of tHcy). Probability values P < 0.05 were considered statistically significant. All analyses were 
performed using SPSS for Windows software (version 11.0; SPSS Inc, Chicago, IL, USA). 
 
Results 
The median ages of mothers and children were comparable in both cases and controls, 32.1 and 32.8 
years for mothers and 17.1 and 17.9 months for children, respectively. At the study moment case-
mothers demonstrated a significantly higher median BMI than controls (25.0 and 24.4 kg/m2, P < 
0.05). The distributions of ethnicity (78% Dutch native, 5% Western and 17% non-Western 
immigrant for cases and 81%, 5% and 14% respectively for controls) and educational level (low in 
64% of cases and 65% of controls) were comparable in case and control-mothers. Moreover, there 
were no significant differences in the maternal use of alcohol (cases and controls 44% and 56%, 
respectively), cigarettes (21% and 22%), oral contraceptives (52% and 48%) and medication (18% 
and 20%), and the gender of the children (63% and 53% male) at the standardised study moment.   
The median tHcy concentration was significantly higher in case-mothers than in control-mothers (P < 
0.01). The other biochemical parameters were comparable in both groups (Table 1). Stratified 
analysis of the biochemical concentrations for the several types of CHD did not reveal significant diffe- 
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Table 1. Biochemical parameters at the study moment of mothers and children with CHD 
and controls. Values are given in median (minimum-maximum).  
a Serum vitamin B12, serum and RBC folate, n = 97.  
b P < 0.05 (Mann-Whitney U test).  
c Control-children n = 166. 
d Case-children n = 149, control-children n = 172. 
 
rences. The serum folate and vitamin B12 concentrations were significantly lower in 
hyperhomocysteinaemic case-mothers than in normohomocysteinaemic case-mothers, whereas RBC 
folate concentrations were comparable. The median (range) serum folate concentrations were 11.1 
(6.2-24.1) and 15.1 (8.0-27.8) nmol/L (P = 0.01), and vitamin B12 concentrations were 178 (96-411) 
and 275 (82-602) pmol/L (P < 0.01), respectively. In 12 out of 23 hyperhomocysteinaemic case-
mothers, serum folate, RBC folate and/or serum vitamin B12 concentrations were below the 10th 
percentile based on the data of the control-group. In the remaining 11 case-mothers, educational 
level was significantly lower (P = 0.01) and the percentage of smoking mothers was significantly 
higher (P < 0.01) compared with the normohomocysteinaemic case-mothers.  
Serum and RBC folate concentrations were significantly higher in children with CHD than in controls 
(11%, P = 0.02 and 12%, P = 0.001). However, significantly more cases than controls were formula-
fed (36% and 21%, P < 0.01). After pooling of case and control-children, serum (37.7 and 27.6 
nmol/L, P < 0.001) and RBC folate concentrations (1076 and 953 nmol/L, P = 0.002) were 
significantly higher in the 85 formula-fed children than in the 228 children who were fed otherwise. 
Fifty case-children who were formula-fed still showed significantly higher median serum folate (42.4 
and 33.5 nmol/L, P = 0.02) and RBC folate concentrations (1146 and 1015 nmol/L, P = 0.01) 
compared with formula-fed controls (n = 35). 
A high maternal tHcy concentration above 14.3 μmol/L was associated with an increased risk of CHD 
in their children (OR 2.9, 95% CI 1.4-6.0) (Table 2). The risk increased with increasing maternal tHcy 
concentrations (Ptrend = 0.004, Table 3). Significantly more mothers were smoking in the subgroup of 
hyperhomocysteinaemic  case-mothers  with the  normal vitamin  concentrations. After adjustment  of  
Mothers Cases (n = 98) a Controls (n = 134) 
Folate, serum (nmol/L) 15.0 (6.2-27.8) 14.1 (6.4-40.3) 
Folate, RBC (nmol/L) 646 (299-1343) 630 (163-1549) 
Vitamin B12, serum (pmol/L) 263 (82-602) 248 (89-777) 
Homocysteine, plasma (μmol/L) 11.2 (5.1-31.2) 10.3 (5.6-42.0) b 
Children Cases (n = 146) Controls (n = 167) 
Folate, serum (nmol/L) 32.2 (11.3-114.8) 28.7 (11.2-99.6) b 
Folate, RBC (nmol/L) c 1046 (397-2353) 921 (522-1954) b 
Vitamin B12, serum (pmol/L) 508 (149-1147) 492 (135-1232) 
Homocysteine, plasma (μmol/L) d 6.3 (3.9-12.3) 6.0 (3.7-12.1) 
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Table 2. Associations between the risk of having a child with CHD and the lowest 10th 
percentile of maternal vitamin concentrations or the highest 10th percentile of maternal 
plasma total homocysteine concentration. 
a Serum vitamin B12, serum and RBC folate, case-mothers n = 97. 
b No use of vitamin supplement containing folic acid in the period of 4 weeks before until 8 weeks 
after conception  
 
 
the tHcy concentration for maternal smoking the OR was 3.0 (95% CI 1.4-6.5). Stratification for 
maternal use of vitamin supplements containing folic acid in the periconceptional period demonstrated 
even higher risk estimates for a high tHcy and a low serum vitamin B12 concentration in non-
supplement users (Table 2). Risk estimates for vitamin and homocysteine concentrations in children 
were 0.6 (0.3-1.4) for tHcy and serum vitamin B12, 1.2 (0.6-2.4) for serum folate and 0.5 (0.2-1.2) 
for RBC folate concentrations. 
 
 
Homocysteine, plasma (μmol/L) a Cases/Controls n = 98/134 OR 95% CI  
5.6-8.6 13/28 1.0 Reference 
8.6-9.7 14/26 1.2 0.5-2.9 
9.7-10.9 17/29 1.3 0.5-3.1 
10.9-12.5 16/26 1.3 0.5-3.3 
12.5-42.0 37/25 3.2 1.4-7.3 
Ptrend  0.004  
 
Table 3. CHD risk in association with maternal plasma total homocysteine concentration. 
a Quintiles of plasma homocysteine concentrations based on the control-mothers. 
 
Total group of mothers Cut-off value Cases/Controls (n = 98/134) a OR 95% CI 
Folate, serum (nmol/L) < 10.1 11/12 1.3 0.5-3.1 
Folate, RBC (nmol/L) < 431 10/13 1.1 0.4- 2.6 
Vitamin B12, serum (pmol/L) < 159 16/13 1.8 0.8-4.0 
Homocysteine, plasma (μmol/L) > 14.3 23/13 2.9 1.4-6.0 
Non-supplement users in  
the periconceptional period b 
Cut-off value Cases/Controls (n = 38/53) OR 95% CI 
 
Folate, serum (nmol/L) < 10.1 6/5 1.8 0.5-6.6 
Folate, RBC (nmol/L) < 431 5/8 0.9 0.3-2.9 
Vitamin B12, serum (pmol/L) < 159 11/6 3.3 1.1-10.0 
Homocysteine, plasma (μmol/L) > 14.3 10/4 4.4 1.3-15.3 
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Discussion 
In our study based on the population of children with CHD and controls with a median age of 17 
months living in the Western part of the Netherlands, we demonstrated that a high maternal fasting 
tHcy concentration is associated with an approximately three-fold higher risk of a child with CHD in a 
concentration-dependent manner. This finding is in line with the five and ten-fold increased risk of 
CHD as demonstrated by Kapusta et al. and Hobbs et al., respectively.16, 17 The much higher OR in the 
latter study can partly be explained by the fact that they determined the maternal tHcy concentrations 
in random blood samples, thereby not considering the confounding by the non-fasting state. 
Moreover, we standardised the investigation at a fixed study moment for both cases and controls, 
which is in contrast to their design in which controls were investigated at around 24.5 months and 
cases at 14.9 months after the index pregnancy. In addition, the included diagnoses were not 
described in detail. In addition to the differences that will exist between the Dutch and Arkansas 
populations, these arguments may explain the differences in ORs. In both studies controls were 
excluded if the medical record indicated any congenital malformation. Echocardiograms, however, 
were not required to rule out a cardiac defect, which may have underestimated the risk in both 
studies. 
The hyperhomocysteinaemia in the case-mothers can largely be explained by the significantly lower 
folate and/or vitamin B12 status, even after adjustment for smoking. Therefore, malnutrition and 
polymorphisms in folate and vitamin B12 genes may play a role. Other causes of the maternal 
hyperhomocysteinaemia however, have to be considered as well, such as low vitamin B2 or B6 levels, 
high BMI, or glucose intolerance. The BMI has to be considered as an independent risk factor, 
because BMI was not only significantly higher in all case-mothers compared with controls but also in 
the subgroup of hyperhomocysteinaemic case-mothers compared with normohomocysteinaemic case-
mothers. Obese women are more prone to an impaired glucose tolerance or overt diabetes. Both 
phenotypes are associated with an increased risk of CHD in the offspring.18-21 In our study, only two 
case-mothers suffered from diabetes and both were normohomocysteinaemic. In addition, the 
correlation between BMI and tHcy was not significant, which is in contrast to Panagiotakos who 
showed that BMI is associated with homocysteine concentration.22 
This is the first study investigating biochemical vitamin and tHcy parameters of children in an attempt 
to unravel its contribution to the development of CHD. Children with CHD showed significantly higher 
serum and RBC folate concentrations than controls. This is not due to the use of folic acid containing 
vitamins, because they were excluded from the analysis. However, significantly more cases than 
controls were formula-fed. Although formula feeding contains folic acid, this only partially explained 
the differences between cases and controls, because the formula-fed case-children still showed higher 
folate concentrations than the formula-fed controls. Nevertheless, the individual B-vitamin status is 
not only determined by food intake, but also by metabolism, clearance and genetic polymorphisms 
encoding enzymes in the folate and homocysteine metabolism. The higher folate concentrations in 
both serum and red blood cells may be explained by the random blood samples taken in children and 
alterations in the binding of folate to transport proteins and receptors. Other explanations are 
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differences in the prevalence of genetic polymorphisms encoding these proteins and the enzymes 
involved in the folate and homocysteine metabolism. In addition, changed concentrations of cofactors, 
variations in the activity of liver enzymes and renal function affecting folate clearance may play a role 
as well.  
Our findings contribute to the knowledge of the vitamin and homocysteine status in the pathogenesis 
of CHD in man. However, we have to consider the strengths and weaknesses of our study. Our 
assumption is that the maternal nutritional status at the study moment is the best reflection of the 
nutritional status in the preconceptional period of the index-pregnancy. This hypothesis is supported 
by previous research.13, 23 The value of a fixed study moment to increase the validity of the 
biochemical and questionnaire data is shown in our previous studies.11, 12 We have chosen for a study 
moment between 11 and 18 months after the index-pregnancy for the following reasons. It takes 
approximately 12 months after pregnancy and breastfeeding to return to the preconceptional 
hormonal, metabolic and nutritional status. In general, there is no difference in preconceptional 
dietary habits and those of one year post partum.11, 12, 23 Moreover, the seasons of the pre- and 
periconceptional period and the moment of blood sampling, i.e., approximately two years after 
conception, are taken into account. Other factors that could have influenced the biomarkers were 
excluded from analysis, such as vitamin use, pregnancy and non-fasting state at the study moment. 
However, still some misclassification of vitamin supplement use could have occurred. Therefore, we 
repeated the analyses after exclusion of serum folate concentrations above 22.5 nmol/L. This cut-off 
value was based on the study of Brouwer et al. showing that folate concentrations increased to a 
mean value of 22.5 nmol/L in women of reproductive age receiving 250 μg folic acid daily during four 
weeks.24 These additional analyses substantiate our findings by showing comparable results.  
The potential for recall and selection bias is another issue inherent to the case-control design of 
studies on congenital malformations. To minimise the recall, we have chosen for one fixed study 
moment relatively soon after pregnancy in both cases and controls compared with other studies. An 
earlier study moment after birth would imply a significant interference of the maternal physiology and 
endocrinology on the biomarkers as well as some misclassification of the CHD and controls, because 
most malformations are detected and completely diagnosed during the first postnatal year. These 
issues have been raised in other studies that collected blood samples between three and six months 
or even up to 4.5 years post partum.16, 17 Importantly, the concentrations of tHcy, folate and vitamin 
B12 in our study were comparable to the concentrations measured in the preconceptional period as 
described by Cikot et al.25  
Our study is unique in the way that we only included patients with a type of CHD that has been 
associated with folate or other environmental factors before in order to increase the homogeneity of 
the case group.4 Furthermore, the number of cases included was comparable to the number of 
controls. This is in contrast to the study of Hobbs et al. who included relatively more cases than 
controls.17 The sample size of the study of Kapusta et al. was much smaller than ours.16  
In conclusion, we demonstrate that a high maternal tHcy concentration is associated with an 
increased risk of having a child with CHD in a concentration-dependent manner, partially due to low 
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serum folate and vitamin B12. The folate status of the child might be involved as well and should be 
investigated together with other pathways implicated in CHD. 
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Abstract  
Objective: To validate the folate and vitamin B12 intakes estimated by a food frequency questionnaire 
(FFQ) designed to be used in a case-control study on the association between maternal dietary intake 
and the risk of having a child with a congenital heart defect. 
Design and subjects: The FFQ was filled out by 53 women of reproductive age. Immediately 
thereafter, blood samples were taken to determine serum and red blood cell (RBC) folate and serum 
vitamin B12 concentrations. Subsequently, three dietary 24-hour recalls (24HR) were completed 
during a period of three successive weeks and used as a reference method. The recalls comprised two 
weekdays and one weekend day. Using the method of triads validity coefficients were calculated by 
comparing nutrient intakes derived from the FFQ and 24HR with the corresponding nutritional 
biomarkers in blood. The validity coefficient is the correlation between the dietary intake reported by 
the FFQ and the unknown ‘true’ dietary intake.  
Results: The comparison of B-vitamin intakes reported by the FFQ and the mean of the 24HR revealed 
deattenuated correlation coefficients of 0.98 for folate and 0.66 for vitamin B12. The correlation 
coefficients between the B-vitamin intakes estimated by the FFQ and concentrations of serum folate, 
RBC folate and serum vitamin B12 were 0.20, 0.28, and 0.21, respectively. The validity coefficients for 
serum folate, RBC folate and serum vitamin B12 were 0.94, 0.75 and 1.00, respectively. The 
estimated folate and vitamin B12 intakes were comparable with the results of the most recent Dutch 
food consumption survey.  
Conclusions: The adapted FFQ is a reliable tool to estimate the dietary intake of energy, 
macronutrients, folate and vitamin B12 in women of reproductive age. Therefore, this FFQ is suitable 
for the investigation of nutrient-disease associations in future. 
  
Introduction 
Accurate and objective estimates of dietary intake are necessary in order to assess any effects of 
nutritional status in epidemiologic studies. In general, validation studies of food frequency 
questionnaires (FFQ) are based on comparisons with reference methods, such as multiple food 
records or dietary recalls. Traditionally, the validity coefficient between dietary questionnaire data and 
the unknown ‘true’ habitual intake is assessed by the correlation between the intakes achieved by the 
FFQ and the mean value obtained from reference methods. However, the correlation between the 
reference method and the FFQ may be overestimated, if the sources of errors in these two methods 
are related. Therefore, the use of biomarkers of nutritional intake is increasingly important in dietary 
validation studies. Nutritional biomarkers are objective measures of exposure to a certain nutrient and 
they are not influenced by factors related to misreporting. Therefore, Kaaks described that at least 
two additional measurements are necessary to determine the validity coefficient of the FFQ 
measurements, for instance, nutritional biomarkers and 24-hour recalls (24HR). The validity 
coefficient is the correlation between the dietary intake reported by the FFQ and the unknown ‘true’ 
dietary intake.1 The method of triads is a triangular approach that uses the correlations between each 
of the three methods to estimate the validity coefficient. Moreover, this model corrects for bias due to 
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correlated errors in the repeated measurements from the reference method.2  
The aim of this study was to validate a FFQ, which was adapted for the estimation of B-vitamin intake 
in women of childbearing age. We examined the association between the biomarkers and two dietary 
assessment methods for the intake of folate and vitamin B12. The method of triads was applied to 
validate the intake of folate and vitamin B12, estimated by the FFQ and 24HR and the corresponding 
biomarkers of nutritional intake. 
 
Materials and methods 
A subset of women of reproductive age was recruited from an ongoing case-control study designed to 
investigate determinants in the pathogenesis and prevention of congenital heart defects. Exclusion 
criteria were pregnancy, breastfeeding, use of vitamin supplements and non-fasting state at the 
moment of blood sampling, which was approximately 17 months after the index-pregnancy. From 
October 2004 until January 2005, 53 women fulfilled the study protocol, which included filling out the 
questionnaires at home, an immediate blood sample during a hospital study visit thereafter, followed 
by the completion of three 24HR by phone.  
The National Central Committee of Research in Human and the Medical Ethics Committees of all 
participating hospitals approved the study protocol and written informed consent was obtained of 
every participant. 
Food frequency questionnaire 
The FFQ is developed at the Division of Human Nutrition of Wageningen University to estimate the 
dietary intake of energy, fat and fatty acids.3 It is a 104-item questionnaire in which participants 
report their dietary intake during the previous four weeks. Preparation methods, portion sizes and 
additions can be indicated as well as the frequency of using foods per day, per week, per month or 
not at all. The FFQ has been updated twice based on data of Dutch national food consumption 
surveys in 1992 and 1998.4, 5 This FFQ is validated for energy and fat intake and has been adapted to 
estimate the intake of folate and vitamin B12. Food items rich in these B-vitamins were added when 
they contributed more than 0.1% to the intake of each of the nutrients of interest according to the 
food consumption survey of 1998.5 In a final step, foods were clustered into food groups and foods 
were added to guarantee face validity. After all, the FFQ consisted of 121 items and covered the daily 
intake of each nutrient or food of interest for at least 90% of the population mean intake. The 
average daily nutrient intake was calculated by multiplying the frequency of consumption of food 
items by portion size and nutrient content per gram based on the 2001 Dutch food composition table.6 
The existence of underreporting was evaluated by calculating the physical activity level defined by the 
ratio of reported energy intake (EI) and mean basal metabolic rate (BMR).7, 8 The BMR was estimated 
according to the Schofield equations.9  
Twenty four hour recall  
After training by a research dietician, a researcher of the Division of Human Nutrition of Wageningen 
University contacted the participants for a 24HR within one week after the hospital visit. The 
standardised telephone interview took on average 20 min. Women reported the dietary intake from 
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breakfast of the day before till breakfast the next morning. Each subject was contacted three times 
for a 24HR of two days during the week and one weekend day covering a period of three weeks.  
Pictures of household measures were used for specific information on portion sizes. The reported 
foods in the 24HR were coded according to standardised coding procedures. Codes for new foods 
were added in consultation with a research dietician. The dietary intakes were calculated using the 
computer programs Komeet and Orion (BaS Nutrition Software, the Netherlands), which are based on 
the 2001 electronic version of the Dutch food composition table.6 
Biomarkers  
Venous blood samples were taken after an overnight fast. Blood was collected in an 8.5 mL 
Vacutainer Serum Separator Tube and in a four mL Vacutainer ethylenediaminetetraacetic acid (EDTA) 
tube (BD Diagnostics, Plymouth, UK) for the determination of serum folate and vitamin B12, and of 
red blood cell (RBC) folate concentrations, respectively. Directly after blood sampling, the 
haemolysate was prepared by diluting 0.1 mL full blood in 0.9 mL freshly prepared 1.0 % ascorbic 
acid. Subsequently, the haematocrit of the remaining EDTA full blood was determined on an ADVIA 
120 Haematology Analyser (Bayer Diagnostics, Leverkusen, Germany). The concentrations of folate 
and vitamin B12 were determined as described before.10 The haemolysate was centrifuged at 1,000 x 
g for five min at 18 oC, just before the folate measurement. The haemolysate folate concentration was 
recalculated into RBC folate concentration using the following formula: (nM haemolysate folate * 10 / 
haematocrit) - (nM serum folate * {1- haematocrit} / haematocrit) = nM RBC folate.  All samples were 
analysed within three months after collection. Up to the moment of measurement, samples were kept 
frozen at –80 oC.  
General and anthropometric information 
The general questionnaire provided data on maternal age, educational level, and the use of a diet, 
vitamin supplements or cigarettes. Anthropometry was performed without shoes and jacket, including 
height (anthropometric rod, SECA, Hamburg, Germany) and weight (weighing scale, SECA, Hamburg, 
Germany) to the nearest 0.1 cm and 0.5 kg, respectively. 
Statistical analysis  
The dietary intakes and biomarker concentrations of B-vitamins were log-transformed. The mean 
dietary nutrient intake was adjusted for total energy intake using the residual method.11 Differences in 
intake between the FFQ and 24HR were compared using the paired t test. Pearson correlation 
coefficients were calculated to evaluate the linear association between the data of the FFQ and the 
24HR, and the biomarkers. We deattenuated the crude correlation coefficients by multiplying them 
with the factor (1 + (σ2intra / σ2inter) / n)1/2, where n is the number of repeated 24HR, σ2intra is the 
intraindividual variance and σ2inter is the interindividual variance between the 24HR.12 The method of 
triads was used to calculate the validity coefficient of the FFQ for folate and vitamin B12 intake. The 
validity coefficient is the correlation between the dietary intake reported by the FFQ and the unknown 
‘true’ dietary intake. The estimate is interpreted as the upper limit whereas the correlation coefficient 
between the FFQ and biomarker is considered as lower limit of the true validity coefficient. Confidence 
intervals were estimated using bootstrap sampling where 1,000 samples of equal size (n = 53) were 
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obtained by random sampling with replacement.2 All analyses were performed using SPSS for 
Windows version 11.0 (SPSS Inc, Chicago, IL, USA). 
 
Results 
The study group consisted of 21 case and 32 control-mothers aged 24-44 years with a median body 
mass index of 23.6 kg/m2. Other general characteristics and the biomarker concentrations are 
presented in Table 1. All women fulfilled the whole protocol, but 11 women completed the 24HR on 
three weekdays. 
 
Table 1: General characteristics and biomarker concentrations of the 53 women. Values are 
median (interquartile range) or number (percentage).  
a Defined as ≥ 1 cigarette per day.  
b Primary/lower vocational/intermediate secondary/intermediate vocational education. 
 
The FFQ produced significantly higher estimates of energy and fat intake than the average of the 
three 24HR (Table 2). The mean difference was 12% for energy intake and 19% for fat intake. The 
calculated ratio of EI and BMR was 1.45 for the cases and 1.44 for the control-group. In general, the 
dietary intake met the Dutch dietary reference intakes, but folate intake was considerably lower. 
The correlation coefficients of the dietary intakes estimated by the FFQ and the average of the three 
24HR are shown in Table 3. After energy-adjustment, all correlation coefficients decreased, except for 
carbohydrates. Correlation coefficients ranged from 0.60 to 0.98 after correction for day-to-day 
variation, with a lower correlation of 0.41 for carbohydrates. The correlations between the FFQ data 
and the biomarkers were 0.20 for serum folate, 0.28 for RBC folate, and 0.21 for serum vitamin B12, 
respectively (Table 4).  
General characteristics  
Age (years) 32.0 (27.8-36.3) 
Weight (kg) 71.0 (66.0-87.2) 
Height (m) 1.71 (1.66-1.76) 
Body mass index (kg/m2) 23.6 (21.9-29.3) 
Low energy diet 4 (8) 
Vegetarian diet 4 (8) 
Current smokers a 7 (13) 
Low education level b 25 (47) 
Biomarkers  
Serum folate (nmol/L) 13.5 (11.5-18.3) 
RBC folate (nmol/L) 596 (476-745) 
Serum vitamin B12 (pmol/L) 245 (190-339) 
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The validity coefficient of the FFQ was 0.94 for serum folate and 0.75 for RBC folate. The validity 
coefficient between the FFQ and the ‘true’ intake was 1.66 for vitamin B12 (Table 4). 
 
Nutrients Units/day  FFQ 24HR DRI a  
Energy MJ b 9.1 (7.7-10.8) c 8.6 (7.1-10.0) 9.7-10.2 
Total Fat  g 87.2 (68.7-112.3) c 73.8 (61.6-97.1)  
 en% 36.8 (32.7-39.2) c 35.6 (31.2-38.2) 20-40 
Total Protein g 77.6 (67.7-90.5) 81.1 (64.1-87.7) 50-52 
 en% 14.6 (13.1-15.6) c 14.9 (13.3-17.1) 9-25 
Total Carbohydrates g 262 (210-299) 247 (209-281)  
 en% 47.6 (43.2-50.8) 48.4 (43.5-51.4) 40  
Folate d μg 177 (138-222) 169 (148-199) 300 
Vitamin B12 d μg 3.9 (2.7-4.7) 3.4 (2.6-4.3) 2.8 
Vitamin B6 d mg 1.7 (1.5-1.9) 1.6 (1.3-1.9) 1.5 
 
Table 2: The daily intakes estimated by the FFQ and the repeated 24-hour recalls and the 
dietary reference intakes. Values are median (interquartile range).  
a Dutch dietary reference intakes for non-pregnant women between  19 and 50 years of age indicate 
the estimated average requirement for energy, adequate intake for fat, recommended dietary 
allowance (RDA) with the upper level for proteins, and RDA for carbohydrates and B-vitamins.18, 19  
b 1 kcal = 4.184 kJ. 
c Comparison of the estimates of the FFQ and 24HR by the paired t test, P < 0.05.  
d Data are log-transformed for statistical analysis. 
 
 Pearson correlation coefficient 
Nutrient Crude Energy adjusted a Deattenuated b 
Energy (MJ) 0.45 c - 0.60 
Fat (g) 0.53 c 0.35 c 0.82 
Protein (g) 0.55 c 0.40 c 0.81 
Carbohydrates (g) 0.31 c 0.36 c 0.41 
Folate (μg) d 0.40 c 0.36 c 0.98 
Vitamin B12 (μg) d 0.49 c 0.39 c 0.66 
 
Table 3: Correlations between the estimates of the dietary intake by the FFQ and 24HR. 
a Adjusted for energy by the residual method.11 
b Deattenuation implies correction for day-to-day variation of the repeated 24HR.12  
c P < 0.05.  
d Data are log-transformed. 
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 Correlation coefficients Validity coefficient a 
 rQM rRM rQR ρQT 95% CI Range b 
Serum folate 0.20 0.22 0.98 0.94 0.36-1.00 
RBC folate  0.28 0.49 0.98 0.75 0.30-1.00 
Serum vitamin B12 0.21 0.05 0.66 1.00 0.30-1.00 
0.20-0.94 
0.28-0.75 
0.21-1.00 
 
Table 4: Correlation coefficients between each of the dietary assessment methods and 
the validity coefficient calculated by the method of triads. 
rQM, correlation between FFQ and biomarker; rRM, correlation between 24HR and biomarker; rQR, 
correlation between FFQ and 24HR; ρQT, validity coefficient of the questionnaire. 
a Validity coefficients and confidence interval limits above 1 were set to 1.00. 
b The lower limit is rQM and the upper limit is calculated with the method of triads.2 
 
Discussion 
The aim of this study was to validate the adapted FFQ for the assessment of folate and vitamin B12 
intake in women of reproductive age. Therefore, we collected intake data by two dietary assessment 
methods, determined concentrations of nutritional biomarkers and applied the method of triads. 
The differences between the FFQ and 24HR for estimation of energy and fat intake are shown by 
others as well3, 13 and can be explained by underreporting in the 24HR.14-16 The correlation coefficients 
between the FFQ and 24HR for energy and fat were lower3 or comparable with other studies.13, 15 The 
correlation coefficient for carbohydrates was higher13, 15, 17 and the coefficient for proteins was similar 
to13 or even higher than the coefficients reported by others.15, 17 The macronutrient intakes estimated 
by both methods were in line with the Dutch dietary reference intakes for women between 19 and 50 
years of age18, 19 and the data of the Dutch national food consumption survey of 200320 and, 
therefore, we conclude that the FFQ is a valid method to estimate macronutrient intakes.   
The correlation coefficients between the FFQ and 24HR for folate were comparable with other studies 
(0.40 versus 0.37 and 0.49, respectively)13, 21 or even higher (0.29)17 and the correlation coefficient 
for vitamin B12 was slightly lower, i.e., 0.49 versus 0.58.13 In the latter study, more than three 24HR 
have been applied through which the overall day-to-day variation of B-vitamin intake is minimised, 
resulting in a higher correlation coefficient. Despite the high day-to-day variation of these B-vitamin 
intakes that is demonstrated by the increased correlation coefficients after correction for day-to-day 
variation in the 24HR, the correlation coefficients between the FFQ and 24HR were significant. 
Moreover, these B-vitamin intakes were similar to the Dutch dietary reference intakes with the 
exception of folate,18, 19 which is known to be low in the Dutch diet.22-24 
The correlation between the FFQ and the biomarkers is slightly higher for RBC folate than reported by 
others (0.28 versus 0.08 and 0.25, respectively).25, 26 Higher correlation coefficients of 0.38 and 0.39 
were reported for serum folate.25, 26 These differences can be explained by the better reflection of the 
recent dietary intake by serum folate, whereas the RBC folate concentration is a measure of the long-
term folate status in particular.27-29 Our FFQ covers the intake of a reasonably long period of four 
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weeks and may, therefore, demonstrate a higher correlation with RBC folate than with serum folate. 
For vitamin B12, the correlation was comparable with the report (0.19) of Green et al.25 
To our knowledge, this FFQ validation study is the first to assess the validity of the folate and vitamin 
B12 intake using the method of triads. The validation coefficients are rather high, suggesting that the 
adapted FFQ is valid for both the assessment of folate and vitamin B12 intakes. Nevertheless, we 
emphasize that small differences in low sample correlations may result in rather large differences in 
the estimated validity coefficients.2 Furthermore, we cannot rule out the presence of a positive 
correlation between the random errors of the questionnaire and 24HR measurements. Thus, the 
validity coefficients might be overestimated. Therefore, the estimates must be interpreted as the 
upper limits of the unknown ‘true’ validity coefficients.2 However, the FFQ adequately assesses the 
intake of folate and vitamin B12 according to the Dutch national food consumption survey of 2003.20 
The validity coefficient for vitamin B12 is greater than one, which is known as a Heywood case. A 
Heywood case occurs if the product of two correlation coefficients is much larger than the third 
correlation. For vitamin B12, the correlation coefficient between the biomarker and 24HR was much 
lower than the other two correlation coefficients. An explanation for this finding is that vitamin B12 is 
mainly bound to the metabolically inert protein haptocorrin. Only about 20% of vitamin B12 is bound 
to transcobalamin, which represents the biologically active fraction that can be delivered to all tissues 
of the body. Moreover, it has a rapid turnover with a half-life of one to two hours.30 Since blood 
sampling was done in the morning after an overnight fast, this may explain the lower correlation 
between the 24HR and the vitamin B12 concentration as well. The differences in correlation 
coefficients, however, can still be due to random sampling fluctuation between measurements of both 
24HR and biomarkers. 
Despite the demonstrated validity of the adapted FFQ, we have to consider the strengths and 
limitations of our study. The size of the study population is comparable with other validation studies 
(53 versus 34 and 36, respectively).21, 26 However, validation studies have been performed in 100 till 
200 subjects, but in those studies the method of triads was not applied.13, 17 The sample size was 
relatively small with wide confidence intervals of the validity coefficients as a consequence. Validity 
studies with several hundreds of subjects, more accurate biomarkers or both are, therefore, needed to 
estimate validity coefficients with a higher precision. It should be kept in mind, however, that 
Heywood cases can still occur as a result of relatively small sampling fluctuations if the validity 
coefficient of one of the measurements is close to either one or zero.2  
The 24HR estimate the intake of a few days and might, therefore, give an inappropriate assessment 
of the habitual diet. On the other hand, the 24HR were performed during a period of three weeks, 
which is quite comparable with the reference period of the FFQ. Moreover, the 24HR and FFQ 
estimates may contain correlated errors. The advantage of the triangular approach of the method of 
triads is that random errors in biomarker assessment are independent of those in both FFQ and 24HR 
measurements.2  
Dietary assessment methods are known to have a bias towards underestimation of habitual energy 
intake. Therefore, we investigated the overall under-reporting bias. Compared with the cut-off value 
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of 1.55 that allows measurement imprecision arising from day-to-day variability, some under-reporting 
may have been present.7, 8 However, the FFQ covered a four weeks period and therefore, the day-to-
day variability of food intake is minimised. Moreover, the FFQ is representative of long-term habitual 
intake according to the cut-off value of 1.35.7, 8 
The B-vitamin concentrations may be influenced by general characteristics like smoking or the use of 
a vegetarian diet.27, 28 In our study, some women were smoking or used a vegetarian diet, but their 
biomarker concentrations were within the normal ranges.31, 32 The biochemical concentrations reflect 
the individual vitamin status that is not only determined by the metabolism and genes, but as well by 
parameters affecting the food intake, such as seasonal variation and pregnancy. These effects on 
dietary intake are minimised because the study was performed in 53 non-pregnant women between 
October 2004 and January 2005. 
In conclusion, these findings indicate that the FFQ adapted for folate and vitamin B12 intake is a valid 
method to estimate the dietary intake of energy, macronutrients and these B-vitamins in women of 
reproductive age. Moreover, the relative validity of the FFQ for folate and vitamin B12 intake is 
comparable with the validity in other studies. Therefore, this FFQ is suitable for the investigation of 
associations between nutrition and disease in Dutch women in future. 
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Abstract 
Background: Periconceptional use of multivitamins reduces the risk of a child with a congenital heart 
defect (CHD). Data on the impact of maternal diet, however, are lacking.  
Aim of the study: We investigated the association between the maternal dietary intake of B-vitamins 
and having a child with a CHD. 
Methods: A case-control study was performed in 192 mothers of a child with a CHD and 216 mothers 
of a healthy child. Mothers filled out food frequency questionnaires covering the current dietary 
intake, and general questionnaires at 17 months after the index-pregnancy. Maternal blood samples 
were taken to determine B-vitamin and plasma total homocysteine (tHcy) concentrations as nutritional 
biomarkers. Pregnant and lactating mothers and those with another diet compared with the 
preconceptional period were excluded for analysis. Case-mothers and controls were compared using 
the Mann-Whitney U test and logistic regression. 
Results: The dietary intake of macronutrients and B-vitamins was comparable between both groups, 
but all mothers had a substantially lower median folate intake (cases 161 μg, controls 175 μg) than 
the Dutch recommended dietary allowance of 300 μg. Within the case-group, the intake of proteins 
and vitamin B6 and the concentrations of serum vitamin B12 and folate were significantly lower in 
hyperhomocysteinaemics (tHcy ≥ 14.5 μmol/L) than in normohomocysteinaemics. The maternal 
educational level was positively associated with B-vitamin intake, except for vitamin B12 in controls. 
Low educated case-mothers showed a significantly lower median vitamin B12 intake than controls (2.8 
μg and 3.8 μg, P = 0.01). The CHD risk doubled if vitamin B12 intake in these mothers reduced by 
50% (OR 2.0; 95% CI: 1.1-3.5).  
Conclusions: A diet low in vitamin B12 is associated with an increased risk of a child with a CHD, 
especially in low educated women. A disbalance in the maternal intake of proteins and low folate 
intake may play a role as well, but needs further investigation. As hyperhomocysteinaemia is a strong 
risk factor for adult cardiovascular disease, these data may imply that the hyperhomocysteinaemic 
mothers and their children should be targeted for nutritional interventions. 
 
Introduction 
Worldwide, one million children per year are born with a congenital heart defect (CHD).1 These 
complex malformations are responsible for a high infant mortality and morbidity rate and go together 
with substantial health care costs.2, 3 Both genetic and environmental factors, such as nutrition and 
lifestyle, are implicated in the pathogenesis of CHDs. The mother serves as the environment of the 
child during embryogenesis, whereby the maternal dietary intake plays an important role. 
After the Second World War epidemics of congenital malformations and miscarriages were found in all 
European cities that were affected by the famine.4 Recently, low maternal intakes of nutrients, such as 
vegetable proteins, polysaccharides, dietary fibers, iron, and magnesium, were associated with an 
increased risk of a child with a spina bifida or orofacial cleft.5, 6 B-vitamin intakes were also 
significantly lower in mothers of a child with an orofacial cleft than in controls.7, 8 Several 
epidemiological studies demonstrated the preventive effect of periconceptional folic acid 
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supplementation against the development of CHDs.9-11 Among non-vitamin using mothers, the daily 
intake of folic acid fortified cereals significantly reduced the risk of conotruncal heart defects by 
83%.11 
Kapusta et al. firstly reported of the association between a mild maternal hyperhomocysteinaemia and 
CHD risk, which was recently confirmed by others.12, 13 The main cause of mild hyperhomocys-
teinaemia is a low intake of B-vitamins. Folate and vitamin B12 are involved in the remethylation of 
homocysteine and donation of one-carbon groups to proteins, lipids and nucleotides, whereas vitamin 
B6 is important in the transsulphuration of homocysteine.14 Insufficient intake of B-vitamins results in 
biochemical derangements leading to hyperhomocysteinaemia and DNA hypomethylation that may 
contribute to the development of CHDs.15 Interestingly, DNA hypomethylation is minimised at intake 
levels in excess of current recommended dietary folate and vitamin B12 intakes.16  
Therefore, we hypothesise that low maternal B-vitamin intakes detrimentally affect the embryonic 
cardiovascular development. We investigated the maternal dietary intake in a case-control study 
conducted in the Netherlands.  
 
Materials and methods 
Recruitment of subjects 
The Dutch HAVEN study, acronym for the study of heart anomalies and the role of genetic and 
nutritional factors, is an ongoing case-control study designed to identify environmental and genetic 
factors in the pathogenesis of CHDs. The study has been performed at the Department of Obstetrics 
and Gynaecology of Erasmus MC in Rotterdam in close collaboration with the Centres of Paediatric 
Cardiology of the same hospital and of Leiden University Medical Centre in Leiden, VU University 
Medical Centre and Academic Medical Centre in Amsterdam and with the child health centres of 
‘Thuiszorg Nieuwe Waterweg Noord’ in the Rotterdam region. Eligible families are children with a CHD 
and healthy children with both parents living in the Western part of the Netherlands.  
The paediatric cardiologists of the aforementioned Centres of Paediatric Cardiology diagnose and 
recruit the case-children and their parents in collaboration with the research team of the HAVEN 
study. The selected diagnoses comprise transposition of the great arteries, tetralogy of Fallot, 
atrioventricular or perimembranous ventricular septal defect, aortic valve stenosis, pulmonary valve 
stenosis, coarctation of the aorta, and hypoplastic left heart syndrome. Healthy control-children and 
both parents are enrolled in cooperation with the physicians of the child health centres. Control-
children do not have congenital malformations or chromosomal defects according to the medical 
record and regular health checks by the physician of the child health centre. Invited case and control-
children are between 11 and 18 months of age. Case and control-families are not related, and speak, 
read and write the Dutch language.  
We obtained questionnaire and biochemical data of 247 case and 266 control-mothers that were 
collected during the hospital visit at Erasmus MC in Rotterdam between October 2003 and July 2005. 
Mothers who were pregnant, lactating, or those who reported a changed diet compared with the 
preconceptional period were excluded for analysis. This resulted in a dataset of 192 case and 216 
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control-mothers. The Central Committee of Research in Human and the Medical Ethics Committees of 
the participating hospitals reviewed and approved the study protocol. Prior to participation, written 
informed consent was obtained from both parents.  
Study design 
Dietary habits are rather stable and do not change except for increased needs because of 
breastfeeding and pregnancy, and episodes of illnesses and dieting.17-19 In addition, most congenital 
malformations are detected during the first year of life. Therefore, we carried out a standardised 
investigation between 11 and 18 months after the index-pregnancy under the assumption that these 
data reflect the maternal nutritional status in the preconceptional period according to our previous 
studies.5-8 
At home mothers filled out the food frequency questionnaire (FFQ) that covered the intake of the 
previous four weeks, and the general questionnaire. During the study visit we performed maternal 
anthropometry and obtained maternal blood samples as biomarkers of nutritional intake. We checked 
the questionnaire data for completeness and consistency. 
Data collection 
We estimated daily habitual energy, macronutrient, and micronutrient intakes using a modified version 
of the semiquantitative FFQ of Feunekes et al.20 This FFQ has been updated twice based on data of 
Dutch national food consumption surveys in 1992 and 1998.21, 22 Additionally, this FFQ has been 
modified for the estimation of dietary B-vitamin intakes. Food items rich in B-vitamins were added to 
the food list when they contributed more than 0.1% to the intake of each of the nutrients of interest 
according to the food consumption survey of 1998.22 Thus, the FFQ covers the daily intake of each 
nutrient or food of interest for at least 90% of the population mean intake.  
The FFQ consists of 121 items and is structured according to a meal pattern. Participants report the 
intake of foods used during the previous month. Questions about preparation methods, portion sizes 
and additions are also included. The average daily nutrient intake was calculated using the 2001 
electronic version of the Dutch food composition table.23 We evaluated the existence of under-
reporting. The mean basal metabolic rate (BMR) was estimated according to the Schofield equations.24 
The physical activity level was calculated by the ratio of the reported energy intake (EI)/BMR.25 
Extracted data of the general questionnaire included maternal age, time after index-pregnancy, body 
mass index (BMI), educational level, ethnicity, smoking, use of alcohol, oral contraceptives and 
vitamin supplements at the study moment. Mothers were considered smokers or alcohol drinkers 
when any smoking or alcohol consumption was reported. Educational level and ethnicity were 
classified according to the definitions of Statistics Netherlands.26 Educational level was categorised into 
low (primary/lower vocational/intermediate secondary), intermediate (intermediate vocational/higher 
secondary) and high education (higher vocational/university). Mothers were classified as Dutch 
natives, Western or non-Western immigrants.  
We performed standardised maternal measurements of weight (weighing scale, SECA, Hamburg, 
Germany) with 0.5 kg accuracy and height (anthropometric rod, SECA, Hamburg, Germany) up to 0.1 
cm accuracy. Venous blood samples were drawn from all mothers to measure concentrations of red 
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blood cell (RBC) and serum folate, serum vitamin B12 and plasma total homocysteine (tHcy) as 
nutritional biomarkers as described before.27 
Immediately after blood sampling 0.1 mL EDTA whole blood was haemolysed with 0.9 mL freshly 
prepared 1.0% ascorbic acid. Subsequently, the haematocrit of the EDTA whole blood was measured 
(ADVIA 120 Haematology Analyser, Bayer Diagnostics, Germany). Another EDTA-tube was put on ice 
and centrifuged immediately after blood sampling for measurement of the tHcy concentration. Blood 
samples were centrifuged at 4,000 x g for ten min at 4oC and separated within one hour after blood 
sampling. Folate and vitamin B12 concentrations were routinely determined by 
immunoelectrochemiluminescence assay (Roche Modular E170, Roche Diagnostics GmbH, Mannheim, 
Germany).  Shortly before the folate measurement the haemolysate was centrifuged at 1,000 x g for 
five min at 18oC. The folate concentration in the haemolysate was recalculated in RBC folate using the 
following formula: (nM haemolysate folate*10/haematocrit) - (nM serum folate*{1-
haematocrit}/haematocrit) = nM RBC folate. The tHcy concentration was routinely measured by high 
performance liquid chromatography with reverse phase separation and fluorescence detection.27 
The inter-assay coefficients of variation (CV) for vitamin B12 was 5.1% at 125 pmol/L and 2.9% at 
753 pmol/L; for folate these CV were 9.5% at 8.3 nmol/L and 3.2% at 20.2 nmol/L and for tHcy 5.9% 
at 15.3 µmol/L and 3.4% at 39.3 µmol/L. Until measurement, all sera and plasma were stored at –
80oC. Some biomarkers were missing due to failures in blood sampling or laboratory testing. All 
laboratory analyses were performed anonymously in batches within three months after collection.  
Statistical analysis 
Differences in the distributions of categorical variables were tested by the Chi-square test. The dietary 
intakes were approximately normally distributed except for vitamin B12 and folate intake. These two 
variables were log-transformed. The nutritional biomarkers showed skewed distributions even after 
transformation. Therefore, all data are presented as medians with interquartile range and differences 
between cases and controls were evaluated by the Mann-Whitney U test. We compared the data with 
the Dutch dietary recommended intakes (DRIs) for non-pregnant women to check the 
appropriateness of the dietary intakes of our study population.28, 29 Moreover, Pearson correlation 
coefficients were computed to investigate the associations between the B-vitamin intakes and the 
corresponding biomarkers. The B-vitamin intakes were compared between cases and controls 
stratified for educational level using ANOVA. 
The mean dietary B-vitamin intakes were adjusted for total energy intake using the residual method.30 
Shortly, the B-vitamin intakes were regressed on the total energy intake and the predicted mean B-
vitamin intake was calculated for the mean total energy intake of the study population. The energy-
adjusted B-vitamin intake was calculated by adding the individual residuals to the predicted mean B-
vitamin intake.  
We assessed the association between maternal dietary intake of B-vitamins and CHD risk for the crude 
and energy-adjusted data. Because of the complex pathogenesis of CHDs, it is most likely that a low 
dietary intake of B-vitamins might be a risk factor in a subgroup of cases only. Therefore, we created 
the 10th percentile of vitamin B6, vitamin B12 and folate intake based on the control-data and 
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estimated the CHD risk using odds ratios (OR) and 95% confidence intervals (CI) in a logistic 
regression model. In addition, we performed a logistic regression analysis of B-vitamin intake stratified 
for educational level. P values < 0.05 were considered statistically significant. All analyses were 
performed using SPSS-software package version 11.0 (SPSS Inc, Chicago, IL, USA). 
 
Results 
The median maternal age of cases was slightly higher than that of controls (Table 1). The 
distributions of ethnicity and educational level were comparable in case and control-mothers. There 
were no significant differences in BMI, use of vitamin supplements, alcohol and cigarettes at the 
standardised study moment. All CHDs were pooled because subgroup analyses did not reveal 
significant differences in demographics, biomarkers and dietary intakes. 
 
 
Table 1. General characteristics of mothers of a child with a CHD and controls at the study 
moment. Values are median (interquartile range) or number (percentage).  
a P < 0.05 (Mann-Whitney U test).  
b Categorised as low (primary/lower vocational/intermediate secondary education), intermediate 
(higher secondary/intermediate vocational education) or high (higher vocational/university 
education).26  
c Classified according to the definitions of Statistics Netherlands.26 
 
 Cases (n = 192) Controls (n = 216) 
Maternal age (years) 33.3 (29.9-36.7) 32.6 (29.0-34.9) a 
Time after index-pregnancy (months) 17.0 (15.3-20.7) 16.8 (15.2-18.6)
BMI (kg/m²)  24.1 (22.0-27.4) 24.1 (22.0-27.8)
Educational level [n (%)] b  
     low                             58 (30) 53 (25) 
     intermediate                       88 (46) 108 (50) 
     high 46 (24) 55 (25) 
Ethnicity [n (%)] c  
     Dutch native  155 (81) 176 (81) 
     Western immigrants 14 (7) 12 (6) 
     Non-Western immigrants 23 (12) 28 (13) 
Use of  [n (%)]  
     Alcohol 98 (51) 125 (58) 
     Cigarettes  39 (20) 43 (20) 
     Oral contraceptives 78 (41) 102 (47) 
     Vitamin supplements                 35 (18) 41 (19) 
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As shown in Table 2, all mothers had a substantially lower folate intake than the Dutch DRI. The daily 
dietary intake of macronutrients and B-vitamins was comparable between cases and controls. The 
ratio EI/BMR was 1.46 for cases and 1.44 for controls. Among the biomarkers, only the median tHcy 
concentration was significantly higher in case-mothers (10.4 μmol/L) than in controls (10.0 μmol/L).  
 
Table 2. Dietary intake and biomarkers of nutritional intake of mothers of a child with a 
CHD and controls at the study moment. Values are medians (interquartile range).  
a Dutch DRI for non-pregnant women aged 19 to 50 years.28, 29 
b Homocysteine, 151 cases and 209 controls. Serum vitamin B12 and folate, 150 cases and 210 
controls. RBC folate, 149 cases and 210 controls.  
c P < 0.05 (Mann-Whitney U test). 
 
Within the case-group, the intake of proteins and vitamin B6 and the concentrations of serum vitamin 
B12 and folate were significantly lower in hyperhomocysteinaemics (tHcy ≥ 14.5 μmol/L) than in 
normohomocysteinaemics (Table 3). Hyperhomocysteinaemic controls had a significantly lower intake 
of proteins and vitamin B12 and significantly lower biomarker concentrations. The correlation 
coefficient between the intake and serum vitamin B12 concentration in all mothers was 0.27 (P < 
0.001). The correlations between dietary folate intake and the serum and RBC folate concentration 
were 0.12 (P < 0.03) and 0.17 (P = 0.002), respectively. Overall, a low maternal dietary intake of 
vitamin B12 was associated with an increased risk of a child with a CHD. The risk increased 
approximately two-fold (OR 1.9, 95% CI 1.03-3.4) at the 10th percentile of vitamin B12 intake (Table 
4). The energy-adjusted vitamin B12 intake did not show a significant association nor did vitamin B6
Daily intake of nutrients Cases (n = 192) Controls (n = 216) DRI a 
Energy (MJ) 8.5 (7.3-10.3) 8.7 (7.4-10.4) 9.7-10.2 
Fats (g) 82.0 (69.5-105.3) 83.4 (68.2-104.7) 
        (en%) 36.5 (33.7-40.6) 36.8 (32.5-39.4) 20-40
Proteins (g) 75.1 (62.2-85.1) 76.0 (64.4-87.0) 50-52
              (en%) 14.5 (12.8-16.2) 14.5 (13.0-15.7) 9-25
Carbohydrates (g) 238 (203-290) 250 (209-293) 
                        (en%) 47.0 (43.5-51.0) 48.3 (44.4-51.3) 40
Vitamin B6 (mg) 1.5 (1.3-1.8) 1.6 (1.4-1.9) 1.5
Vitamin B12 (μg) 3.6 (2.5-4.5) 3.6 (2.8-4.4) 2.8
Folate (μg) 161 (122-206) 175 (135-210) 300
Biomarkers b 
     tHcy (μmol/L) 10.4 (8.9-12.9) 10.0 (8.4-12.2) c 
     Vitamin B12, serum (pmol/L) 272 (211-359) 247 (200-349) 
     Folate, serum (nmol/L) 15.0 (12.3-18.6) 14.6 (12.1-19.4) 
     Folate, RBC (nmol/L) 666 (535-793) 674 (537-855) 
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Case-mothers Normal tHcy (n = 125) High tHcy (n = 26) 
Energy MJ 9.7-10.2 a 8.4 (7.2-9.9) 8.8 (7.4-11.1) 
Fats g - 80.2 (70.2-98.8) 84.9 (64.4-123.1) 
 en% 20-40 36.5 (33.3-39.9) 35.9 (32.4-40.5) 
Proteins  g 50-52 75.3 (63.8-83.9) 68.5 (54.2-81.0) 
                        en% 9-25 14.8 (13.0-16.5) 12.7 (11.4-14.7) b 
Carbohydrates  g - 232 (202-290) 262 (221-299) 
                               en% 40 47.1 (43.7-51.2) 47.7 (44.1-52.7) 
Vitamin B6 mg 1.5 1.5 (1.3-1.8) 1.3 (1.1-1.7) b 
Vitamin B12 μg 2.8 3.8 (2.5-4.6) 3.4 (2.3-4.0) 
Folate μg 300 165 (122-210) 138 (120-174) 
Vitamin B12, serum c  pmol/L - 285 (229-372) 175 (152-273) b 
Folate, serum c  nmol/L - 15.4 (12.9-19.4) 11.1 (10.0-15.1) b 
Folate, RBC c  nmol/L - 666 (572-790) 627 (466-842) 
Control-mothers Normal tHcy (n = 188) High tHcy (n = 21) 
Energy MJ 9.7-10.2 8.7 (7.4-10.4) 8.7 (7.3-9.5) 
Fats g - 84.1 (67.5-105.9) 80.0 (71.9-90.5) 
 en% 20-40 36.8 (32.6-39.8) 36.8 (32.5-38.0) 
Proteins  g 50-52 76.1 (65.7-88.1) 65.5 (55.1-82.3) b 
                        en% 9-25 14.6 (13.2-15.9) 13.1 (12.0-14.9) b 
Carbohydrates  g - 246 (208-293) 267 (221-291) 
                               en% 40 47.8 (44.2-51.1) 49.2 (46.6-55.1) 
Vitamin B6 mg 1.5 1.6 (1.4-1.9) 1.5 (1.3-1.8) 
Vitamin B12 μg 2.8 3.6 (2.9-4.5) 3.1 (2.3-3.8) b 
Folate μg 300 176 (137-210) 156 (106-202) 
Vitamin B12, serum c pmol/L - 255 (207-358) 200 (150-258) b 
Folate, serum c nmol/L - 14.9 (12.3-19.7) 12.4 (10.6-14.9) b 
Folate, RBC c nmol/L - 679 (547-892) 538 (467-716) b 
 
Table 3. Daily nutrient intakes of the case and control-mothers after stratification for the 
tHcy concentration. Values are medians (interquartile range). Stratification based on the 
90th percentile (i.e. 14.5 μmol/L) of tHcy concentrations in controls. 
a Dutch DRI for non-pregnant women aged 19 to 50 years.28, 29 
b Reflects the comparison of hyper- and normohomocysteinaemics within the case and within the 
control-group, P < 0.05 (Mann-Whitney U test).  
c Hyperhomocysteinaemic cases: serum vitamin B12 and folate, n = 124; RBC folate, n = 123. 
Normo-homocysteinaemic controls: n = 187. 
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  Cut-off value a Case/Control (n = 192/216) OR (95% CI) 
Vitamin B6 (mg) < 1.1 25/21 1.4 (0.8-2.6) 
Vitamin B12 (μg) < 2.1 32/21 1.9 (1.03-3.4) 
Folate (μg) < 103.6 22/21 1.2 (0.6-2.3) 
 Cut-off value b Case/Control (n = 192/216) OR (95% CI) b 
Vitamin B6 (mg) < 1.3 27/21 1.5 (0.8-2.8) 
Vitamin B12 (μg) < 2.2 28/21 1.6 (0.9-2.9) 
Folate (μg) < 117.6 26/21 1.5 (0.8-2.7) 
 
Table 4. Risk estimates for the association between maternal dietary B-vitamin intake per 
day and CHDs. Data of vitamin B12 and folate intake were log-transformed. 
a Cut-off values are based on the lowest 10th percentile of the control vitamin intake.  
b Cut-off values and OR (95% CI) of energy-adjusted dietary intake.30 
 
 
Figure 1. Vitamin B6 (A), vitamin B12 (B) and folate (C) intake in 216 mothers of children 
with a congenital heart defect and 192 control-mothers stratified for educational level. 
Data shown are mean +/- SEM for vitamin B6 and geometric mean +/- SEM for folate and vitamin 
B12. ANOVA P values < 0.05 indicate a significant trend over the educational levels. 
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or folate intake. In both groups, educational level was positively associated with B-vitamin intake, 
except for vitamin B12 intake in controls (Figure 1). The associations were significant for cases only. 
Low educated case-mothers showed a significantly lower median vitamin B12 intake of 2.8 μg per day 
than controls (3.8 μg). The CHD risk doubled if their vitamin B12 intake reduced by 50% (OR 2.0 (1.1-
3.5), Ptrend = 0.01) (Table 5). Median daily intakes of vitamin B6 (1.5 mg and 1.3 mg) and folate (169 
μg and 143 μg) were not significantly lower in low educated cases than in low educated controls. The 
corresponding risk estimates were 1.8 (0.8-3.8) per unit decrease of vitamin B6 intake and 1.5 (0.7-
3.1) per 50% reduction of the folate intake. 
 
Educational level a Case/Control (n = 192/216) OR (95% CI) OR (95% CI) b 
Low  58/53 2.0 (1.1-3.5) 1.9 (1.1-3.3) 
Intermediate 88/108 1.0 (0.6-1.5) 1.0 (0.6-1.6) 
High 46/55 0.7 (0.3-1.5) 0.6 (0.2-1.5) 
 
Table 5. Risk estimates for the association between CHDs and maternal dietary vitamin 
B12 intake per day stratified for educational level. Data of vitamin B12 intake were log-
transformed (base 2). 
a Low (primary/lower vocational/intermediate secondary), intermediate (higher secondary/ 
intermediate vocational) or high education (higher vocational/university).26 
b OR (95% CI) for energy-adjusted dietary intake.30 
 
 
Discussion 
In this study we demonstrate for the first time that a low maternal dietary vitamin B12 intake is 
associated with an approximately two-fold increased risk of a child with a CHD. So far, associations 
between maternal vitamin B12 intake and a child with other malformations have not been found.5, 8 
Our findings are in line with other reports showing an association between a low blood vitamin B12 
concentration and an increased risk of neural tube defects31 and orofacial clefts.32 A low vitamin B12 
intake results in low blood vitamin B12 concentrations and increased homocysteine concentrations. 
Therefore, our finding is consistent with previous reports that showed an association between 
maternal hyperhomocysteinaemia and having a child with a CHD.12, 13 The significant correlation 
between dietary vitamin B12 intake and the corresponding biomarker supports this finding. Moreover, 
experimental studies substantiate the finding of the teratogenic effect of mild hyper-
homocysteinaemia.33 
Our data suggest that hyperhomocysteinaemia in the subgroup of case-mothers can partly be 
explained by the significantly lower vitamin B6 intake and low folate and vitamin B12 status. In 
contrast, hyperhomocysteinaemic controls did not show a lower vitamin B6 intake but their protein 
intake was lower than in normohomocysteinaemic controls. This illustrates the heterogeneous 
aetiology of hyperhomocysteinaemia.34  
The overall diet met the Dutch DRI in both cases and controls except for the low folate intake. The 
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protein intake has to be in balance with the B-vitamin intakes. Dietary protein intake is the main 
source of methionine, which is the sole precursor of homocysteine. A high-protein diet increases tHcy 
concentrations throughout the day,35 and particularly folate is an important substrate for the 
remethylation of homocysteine. Therefore, a disbalance in the maternal intake of proteins and folate 
deranges the homocysteine metabolism and easily leads to mild hyperhomocysteinaemia. The finding 
of low median folate intakes is supported by other Dutch studies and strengthens the recommen-
dation to use a folic acid supplement to achieve an optimal periconceptional folate status.5, 36 
Low educated women more often demonstrated a low dietary vitamin B12 intake that was associated 
with a higher risk of CHDs than women with a higher educational level. This risk was substantiated by 
a significant dose-response relation within these women. This supports the findings of others that 
people with a low education and low income are more likely to engage in poor dietary practice than 
their wealthier and higher educated counterparts.37 Dietary vitamin B12 is only available from animal 
sources like fish and red meat. Therefore, low educated people may not have enough income for 
these more expensive foods or they are not correctly informed to buy and prepare healthy food.  
Interestingly, hyperhomocysteinaemia is also a strong risk factor for adult cardiovascular disease.38 
Our experimental data suggest that prenatal exposure to hyperhomocysteinaemia induces the first 
features of atherosclerosis that are associated with cardiovascular diseases in later life.39 Together 
with our current results this may imply that the hyperhomocysteinaemic mothers and their children 
are both at risk for the development of cardiovascular disease in adulthood. Since B-vitamin intake is 
an important determinant of hyperhomocysteinaemia this group should, therefore, be targeted for 
nutritional interventions. 
We address some issues of our study design. Dietary assessment methods have a strong bias towards 
underestimation of habitual energy intake. Some under-reporting may equally be present in both our 
case and control-group according to the cut-off value of 1.55 that allows measurement imprecision 
arising from day-to-day variability.25 However, the FFQ covered a four weeks period and therefore, the 
day-to-day variability of food intake is minimised. Moreover, the ratio was representative of long-term 
habitual intake according to the cut-off value of 1.35.25 Furthermore, adjustment for energy intake or 
expression of macronutrient intake as percentages of total energy intake minimises the bias generated 
by under-reporting.40 We excluded some mothers from analysis because of conditions that affect the 
nutritional intake, such as pregnancy, lactation or the use of another diet compared with the 
preconceptional period. Moreover, multivitamin users may be more aware of the importance of a 
healthy diet than non-users. However, exclusion of the multivitamin users did not significantly affect 
the results. 
The case-control study is the usually used epidemiological study design for congenital defects due to 
the relatively low birth prevalence rates. Although, recall bias is not frequently present in case-control 
studies on congenital malformations,41 we have chosen for one investigation at a fixed moment 
shortly after pregnancy to reduce the potential for recall bias. A single investigation increases the 
feasibility of the study and compliance of participants and decreases the potential for selection bias as 
well. An earlier study moment after birth would imply a significant interference of the maternal 
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physiology and endocrinology with the biomarkers as well as some misclassification of the cases and 
controls, because most malformations are detected and completely diagnosed during the first 
postnatal year. Moreover, this study moment is around two years after conception of the index-
pregnancy and equals the season of the preconceptional and periconceptional period. Thus, the 
seasonal influences on food intake are comparable in both groups. Therefore, after exclusion of 
pregnant and breastfeeding women and those who changed their diet during the preconceptional 
period, a standardised investigation between 11 and 18 months after the index-pregnancy in both 
cases and controls is the best moment to mimic the maternal nutritional status in the preconceptional 
period and to minimise the risk of misclassification of CHDs. This is substantiated by the 
concentrations of tHcy, folate and vitamin B12 in our study that were comparable to the 
concentrations measured in the preconceptional period by Cikot et al.19 To homogenise the CHD 
group, we only included mothers of patients with a type of CHD that has been associated with folic 
acid or other environmental factors, because periconceptional use of multivitamins containing folic 
acid is suggested to reduce the occurrence of cardiac outflow tract anomalies.9  
Although, the correlation coefficients between folate and vitamin B12 intake, and their blood levels 
were statistically significant, they were rather low. This was not due to time delay in data collection, 
because the FFQ covered the four weeks before the study moment and blood sampling was 
performed directly thereafter. Blood samples were centrifuged and separated within one hour after 
blood sampling and stored at –80 oC until measurement. All laboratory measurements were performed 
within three months after blood sampling. Therefore, it is very unlikely that this procedure has 
affected the blood levels. In addition, the B-vitamin biomarkers are not only determined by intake, but 
also by absorption, metabolism, clearance, and genetic polymorphisms encoding enzymes in the folate 
and homocysteine metabolism.  
In conclusion, we show that a low maternal dietary vitamin B12 intake is associated with an increased 
risk of a child with a CHD, especially in low educated women. A disbalance in the maternal intake of 
proteins and folate may play a role as well, but needs further investigation. If future studies confirm 
our findings, women who are planning a pregnancy should use vitamin supplements containing both 
folic acid and vitamin B12. 
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Abstract  
It is not clear whether the methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C 
polymorphisms involved in the homocysteine pathway are associated with congenital heart defects 
(CHDs). We studied both polymorphisms, the maternal intake of folate and vitamin B2 via food and 
supplements and CHD risk. A case-control family study was conducted in a European population in the 
Netherlands including 230 case and 251 control-children with both parents. Approximately 17 months 
after the index-pregnancy, mothers filled out standardised questionnaires on the periconceptional use 
of folic acid supplements and a validated food frequency questionnaire on current dietary folate and 
vitamin B2 intake. All subjects were genotyped for the MTHFR C677T and A1298C polymorphisms. 
Data were analysed by logistic regression analysis using the dominant model. The MTHFR 677 CT/TT 
genotypes showed odds ratios (ORs) and 95% confidence intervals (CIs) of 1.2 (0.8-1.7) in mothers, 
1.3 (0.9-1.8) in fathers and 1.2 (0.8-1.7) in children. However, the MTHFR 1298 AA genotype in 
fathers and children significantly increased CHD risk, 1.7 (1.2-2.4) and 1.5 (1.1-2.2), respectively. 
Furthermore, a two-fold increased CHD risk was shown in children with the MTHFR 1298 AA genotype 
without periconceptional exposure to folic acid supplements compared with periconceptionally 
exposed MTHFR 1298 AC/CC carriers (OR 2.1 (1.2-3.8)). In conclusion, the MTHFR C677T 
polymorphism is not an independent risk factor for CHDs. Periconceptional folic acid supplementation 
is beneficial, particularly in children carrying the MTHFR 1298 AA genotype.  
 
Introduction 
Congenital heart defects (CHDs) are the most frequent birth defects and account each year for over 
one million affected newborns worldwide.1 Genetic risk factors for CHDs can be identified in both the 
mother, father and the child by a candidate gene approach based on the molecular biologic pathways 
implicated in the embryogenesis of the heart. Since the mother is the environment of the child in 
utero, maternal environmental exposures, such as the intake of vitamins, medicines and smoking, 
influence the development of the unborn child as well. 
Synthetic folic acid has been proven to contribute to the prevention of CHDs. The protective effect 
seems even more distinct for outflow tract defects and ventricular septal defects.2 Evidence from 
experimental studies reveals that during early embryogenesis, hyperhomocysteinaemia deranges the 
migration of neural crest cells from the neural tube to the tissues forming the cardiac outflow tract.3, 4 
Low folate and low vitamin B2 intakes result in a mild hyperhomocysteinaemia.5 In addition, genetic 
factors are also implicated in the folate-homocysteine pathway. The methylenetetrahydrofolate 
reductase (MTHFR) [EC 1.5.1.20] gene is located on chromosome 1p36.3 and encodes for the enzyme 
that catalyzes the conversion of 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate. The 
latter substrate is essential for the remethylation of homocysteine into methionine. Vitamin B2 is a 
cofactor for the MTHFR enzyme. The single nucleotide polymorphisms C677T and A1298C in the 
MTHFR gene cause amino acid changes in the MTHFR enzyme, thereby decreasing MTHFR enzyme 
activity and increasing the homocysteine level. The MTHFR C677T polymorphism is the most widely 
studied genetic polymorphism in many complex diseases.6-8 The association between the MTHFR 
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C677T polymorphism and CHD risk is not clear. Several studies investigated other neural crest cell 
related malformations, such as the cleft lip with or without cleft palate, and found a strong interaction 
between the MTHFR C677T polymorphism and periconceptional folic acid supplementation, but also in 
combination with a low food folate intake.9, 10 Only few studies reported on the association between 
the MTHFR A1298C polymorphism and CHDs.  
Therefore, we hypothesize that the functional MTHFR C677T and A1298C polymorphisms in the 
mother and/or the child result in a higher risk of CHDs, either independently or in combination with 
low intake of folate and vitamin B2. Since it is not yet feasible to test this hypothesis in a 
preconceptional cohort study, we have chosen for the best alternative of conducting a case-control 
study at a fixed study moment between 11 and 18 months after the index-pregnancy. At that study 
moment, the nutritional status of the mother is rather comparable with the periconceptional period, 
because nutritional intake is stable during life except for periods of dieting, breastfeeding and extreme 
growth. We tested the hypothesis in an ethnically homogeneous case-control family study in the 
Netherlands.  
 
Materials and methods 
Study population 
The HAVEN study, which is a Dutch acronym for the study of genetic and environmental factors in the 
aetiology and prevention of CHDs, was conducted from June 2003 onwards at four Academic Medical 
Centres and coordinated by the project team of the Department of Obstetrics and 
Gynaecology/Division of Obstetrics and Prenatal Medicine of Erasmus MC, University Medical Centre in 
Rotterdam, the Netherlands. The methods for this study are extensively described previously and are 
summarized hereafter.11 The study population consisted of case and control-family triads (child, 
mother, father). For analysis, we only included case-families of which DNA was available. These 
families involved 230 children affected with a CHD and both parents and we refer to them as cases, 
case-mothers and case-fathers, respectively (Figure 1). The phenotypes of the CHDs comprised of 
tetralogy of Fallot, transposition of the great arteries, atrioventricular septal defect, perimembranous 
ventricular septal defect, coarctation of the aorta, aortic valve stenosis, pulmonary valve stenosis and 
hypoplastic left heart syndrome. The paediatric cardiologist in each centre confirmed the diagnoses by 
echocardiography, and/or cardiac catheterisation and/or surgery.  
Non-malformed children and both parents (n = 251) served as controls (Figure 1). Controls were 
excluded if they had a congenital malformation or chromosomal abnormality ascertained by their 
physician at the child health centre. Exclusion criteria for both groups were age of the child below 11 
months or above 18 months, participation of a relative in this study and parents that were not familiar 
with the Dutch language in writing and/or reading. General and food frequency questionnaires were 
filled out, blood samples were collected and a signed informed consent form was obtained from every 
parent. The study was approved by the Central Committee on Research in Human and the Medical 
Ethics Committees of all participating hospitals. 
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Available DNA at inclusion
Cases m (274); f (273); c (273)
Controls m (312); f (312); c (312)
Available DNA for univariate analysis
Cases m (230); f (229); c (229)
Controls m (251); f (251); c (251)
Available FFQ+DNA for interaction analysis
Cases (175); Controls (210)
Inconsistent triads
Cases (7); Controls (3)
Pregnant
Cases (29); Controls (21)
Non-European triads
Cases (37); Controls (58)
Breastfeeding
Cases (10); Controls (2)
Dietary difference
Cases (16); Controls (18)
Measurements  
At the fixed study moment of approximately 17 months after the index-pregnancy, both parents filled 
out a general questionnaire at home. In addition, the mother filled out a food frequency questionnaire 
(FFQ). All questionnaires were reviewed and checked for completeness and consistency by the 
researcher during the hospital visit. The general questionnaires were subdivided in parts concerning 
two different periods in time. The first period referred to the periconceptional period, which is defined 
as four weeks before until eight weeks after conception and corresponds to the recommended period 
of folic acid supplementation in the Netherlands. From the general questionnaires, we collected 
supplement intake data of both mother and father during this period. Mothers were considered users 
of folic acid supplements and/or multivitamins containing folic acid when they used a supplement 
every day in the periconceptional period. Inconsistent users or mothers who used supplements only 
during a part of the periconceptional period were considered as non-users. The second period was 
defined as the month prior to the study moment of approximately 17 months after the index-
pregnancy. At this moment, we  collected  the general  characteristics of all  participants, such as age, 
 
Figure 1. Flowchart of the study population.  
The inconsistent and non-European triads were excluded from analysis (m, mothers; f, fathers; c, 
children) with available DNA at inclusion. Therefore, we used the data of 230 case and 251 control-
mothers for the univariate logistic regression analysis of the genotypes. After exclusion of all pregnant 
and lactating women and those who had a different diet at the study moment than in the 
periconceptional period, we used the data of 175 case and 210 control-mothers for the univariate 
regression analysis of nutrients as well as for the interaction analysis.  
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ethnicity, educational level, family history of CHDs and the use of vitamin supplements. Educational 
level was categorized as low (primary/lower vocational/intermediate secondary education), 
intermediate (higher secondary/intermediate vocational education) or high (higher 
vocational/university education).12 With regard to ethnicity, we classified our participants into three 
different groups: Dutch natives (n = 426), European others (n = 55) and non-Europeans (n = 95).13 
The latter group was significantly different from the other two groups with concern to genotype 
frequencies, general characteristics and nutritional intake (data not shown). Therefore, we excluded 
the non-European group from further analysis (Figure 1).  
The standardised and validated FFQ comprised of questions concerning maternal dietary intake of the 
month before the study moment.14 From this FFQ, the total energy intake, folate and vitamin B2 
intake were extracted for analysis. During the hospital visit, maternal weight (weighing scale, SECA, 
Hamburg, Germany) and height (anthropometric rod, SECA, Hamburg, Germany) were measured.  
Laboratory determinations  
The DNA from all mothers, fathers and children was derived from either a blood sample or a buccal 
swab. Genomic DNA was isolated from 0.2 mL ethylenediamine tetra-acetate (EDTA) whole blood with 
the Total Nucleic Acid Extraction kit on a MagNA Pure LC (Roche Molecular Biochemicals, Mannheim, 
Germany). The DNA yields were estimated by comparison with a lambda ladder. From eight cases, 
two case-fathers and one control-father, the DNA isolation was performed from buccal swabs instead 
of blood samples due to logistic problems or failure in blood sampling. The DNA isolation was carried 
out using the QuickExtract DNA Extraction Solution 1.0 according to the manufacturers’ instructions 
(Epicentre, Madison, Wisconsin, USA). We determined the C677T polymorphism in the MTHFR gene 
from isolated DNA using real-time polymerase chain reaction (PCR) (Taqman®, Applied Biosystems, 
Foster City, CA, USA) and PCR-Restriction Fragment Length Polymorphism (PCR-RFLP) with Hinf1 
digestion.15 The PCR-RFLP was also applied to detect the MTHFR A1298C polymorphism.16 Three 
percent of the determinations served as positive controls and over two percent were negative 
controls. The genotyping success rate was 100%. 
Data analysis 
Some of the continuous variables had skewed distributions even after transformation. Therefore, all 
continuous variables are presented as medians with interquartile range and compared between cases 
and controls using the Mann-Whitney U test. Categorical variables were tested with the Chi-square 
test. Genotype data were checked for Mendelian segregation errors and inconsistent triads (n = 10) 
were excluded from analysis (Figure 1). Using the Chi-square test, we tested deviation of the 
genotype frequencies from those expected under Hardy Weinberg Equilibrium.  
Allele and genotype frequencies were compared between cases and controls. Odds ratios (OR) with 
95% confidence intervals (CI) were computed for the associations of case-control status and genotype 
using univariate logistic regression analysis. We used the dominant model for both MTHFR 
polymorphisms based on the functional effects of the polymorphisms. We excluded all pregnant (n = 
50) and lactating women (n = 12) as well as those who had a different diet at the study moment 
compared with the periconceptional period (n = 24) in order to analyse associations between dietary 
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intake of folate and vitamin B2 and the risk of a CHD. For the nutritional and interaction analyses, this 
resulted in a dataset of 175 cases with their mothers and 210 controls with their mothers (Figure 1). 
We tested both the crude and the energy adjusted nutrient data by univariate logistic regression 
analysis and used the nutrient residual method to adjust for total energy intake.17 Multiplicative 
interactions were tested between genotype and periconceptional supplement use and between 
genotype and (energy adjusted) dietary intake using a comparison between joint expected and joint 
observed associations.18 For this analyses, dietary intakes of folate and vitamin B2 were dichotomised 
into low and high intakes. The cut-off values were based on the median intakes of the control-
mothers. We used the groups with the lowest expected risk as reference categories, i.e., the MTHFR 
677 CC genotype combined with periconceptional supplement use or high dietary intake of folate and 
vitamin B2 and the MTHFR 1298 AC or CC genotype in combination with periconceptional supplement 
use or a high dietary intake of folate and vitamin B2. All analyses were done with SPSS for Windows 
software (version 11.5; SPSS Inc., Chicago, IL, USA). 
 
Results  
General characteristics of case and control-triads both at the study moment and in the 
periconceptional period and maternal nutritional data are presented in Table 1. Case-mothers were 
0.7 years older than control-mothers. However, this small difference did not confound the association 
between the polymorphisms and intake of folic acid supplements or dietary intake of folate and 
vitamin B2 and CHD risk. Other potential confounders, such as education, family history of CHDs, 
gender of the child and ethnicity, were not significantly different between case and control-mothers 
and between case and control-fathers. Although not significantly different, the prevalence of family 
history of CHDs was twice as high in cases as in controls.  
Table 2 presents the genotype frequencies of the MTHFR polymorphisms using the dominant model. 
All genotype distributions of mothers, fathers and children with or without a CHD were in Hardy 
Weinberg Equilibrium. Univariate logistic regression analysis was performed to test for the 
independent effects of the MTHFR genotypes. Slightly more case-mothers, case-fathers and cases 
carried the MTHFR 677 CT and TT genotype compared with controls, although these numbers were 
not significantly different. The MTHFR A1298C polymorphism in case-mothers was not significantly  
associated with CHD risk. However, the MTHFR 1298 AA genotype in case-fathers showed a 
significant association with CHD risk (P = 0.006). The MTHFR 1298 AA genotype in cases showed a 
comparable significant effect (P = 0.024).  
Gene - environment interaction 
The periconceptional use of supplements and the dietary intakes of total energy, folate and vitamin B2 
were not significantly different between case and control-mothers. In addition, energy-adjusted 
dietary intakes of folate and vitamin B2 did not show a significant difference between case and 
control-mothers (Table 1). We investigated the interactions between genotypes of the mother or the 
child and maternal periconceptional supplement use and between the genotypes and maternal 
(energy-adjusted) dietary intake of folate and vitamin B2. In Table 3, the risk estimates are shown for 
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Table 1. General characteristics. Values are median (interquartile range) or number 
(percentage).  
a Periconceptional period is defined as 4 weeks before until 8 weeks after conception.  
b Supplement use is defined as daily use of folic acid containing vitamin supplements.  
c P = 0.042 (Mann-Whitney U test).  
d Categorized as low (primary/lower vocational/intermediate secondary), intermediate (higher secon-
dary/intermediate vocational) or high education (higher vocational/university).22  
e Cases: n = 175; Controls: n = 210.  
f Energy-adjustment by the residual method of Willett.27  
g Family members with a CHD in the first, second and third degree.  
h Dutch Natives: Both parents and grandparents are born in the Netherlands or one of the parents is 
born in another country, but both grandparents are born in the Netherlands. European Others: One of 
the parents or grandparents is born in a European country, Indonesia, or is from European origin and 
living in the USA or Australia.23  
 Mothers Fathers 
Periconceptional period a Cases (n = 230) Controls (n = 251) Cases (n = 230) Controls (n = 251) 
Supplement use [n (%)] b 125 (54) 149 (59) 32 (14) 33 (13) 
Study moment     
Age (years) 33.5 (30.6-36.7) 32.8 (29.2-35.4) c 35.3 (32.2-38.7) 35.7 (32.8-39.0) 
Body mass index (kg/m2) 24.4 (22.0-27.7) 24.1 (22.1-27.3) - - 
Educational level [n (%)] d     
Low 60 (26) 48 (19) 59 (26) 58 (23) 
Intermediate 102 (44) 125 (50) 79 (34) 108 (43) 
High 68 (30) 78 (31) 92 (40) 85 (34) 
Dietary intake of e     
Total energy (MJ) 8.4 (7.3-10.2) 8.6 (7.3-10.3) - - 
Folate (μg)  157 (118-200) 165 (129-198) - - 
Folate (μg) f 152 (128-186) 160 (134-191) - - 
Vitamin B2 (mg) 1.4 (1.0-1.6) 1.4 (1.1-1.6) - - 
Vitamin B2 (mg) f 1.3 (1.1-1.6) 1.4 (1.1-1.5) - - 
 Children   
Study moment Cases (n = 230) Controls (n = 251)   
Age (months) 16.8 (15.4-20.0) 16.7 (15.3-18.4)   
Male gender [n (%)] 133 (58) 142 (57)   
Family history of CHDs [n (%)] g 20 (9) 11 (4)   
Ethnicity h     
Dutch Natives 201 (87) 225 (90)   
European Others 29 (13) 26 (10)   
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 Table 2. Distribution of the MTHFR C677T and A1298C genotypes. Values are numbers 
(percentages). 
 
the MTHFR A1298C polymorphism in the mother and child, which are stratified for periconceptional 
supplement use of the mother and adjusted for maternal age. To investigate multiplicative interaction 
between the MTHFR A1298C polymorphism and periconceptional supplement use, we compared the 
expected joint effect with the observed joint effect. The MTHFR 1298 AA genotype in the child 
demonstrated a non-significant OR of 1.1 (Table 3). The risk estimate is 1.1 if the mother did not use 
periconceptional supplements. The expected joint OR would be 1.1 x 1.1 = 1.2. The observed OR for 
the combined effect is 2.1 (P = 0.015), which is higher than the expected OR, thereby indicating 
interaction. Thus, children who carried the MTHFR 1298 AA genotype and who were not 
periconceptionally exposed to folic acid supplements, showed a more than two-fold increased risk of a 
CHD compared with children carrying either the MTHFR 1298 AC or CC genotype without 
periconceptional exposure to folic acid supplements. No significant interaction was found for the 
MTHFR A1298C polymorphism in the mother and periconceptional folic acid supplementation. 
Moreover, no interaction could be found between the MTHFR C677T polymorphism and supplement 
Genotypes Cases Controls OR (95% CI) 
 Mothers  
 (n = 230) (n = 251)  
MTHFR 677 CT or TT 139 (60) 140 (56) 1.2 (0.8-1.7) 
MTHFR 677 CC 91 (40) 111 (44) 1.0 (Reference) 
 (n = 230) (n = 251)  
MTHFR 1298 AA 104 (45) 116 (46) 1.0 (0.7-1.4) 
MTHFR 1298 AC or CC 126 (55) 135 (54) 1.0 (Reference) 
 Fathers  
 (n = 229) (n = 251)  
MTHFR 677 CT or TT 124 (54) 122 (49) 1.3 (0.9-1.8) 
MTHFR 677 CC 105 (46) 129 (51) 1.0 (Reference) 
 (n = 228) (n = 251)  
MTHFR 1298 AA 111 (49) 91 (36) 1.7 (1.2-2.4) 
MTHFR 1298 AC or CC 117 (51) 160 (64) 1.0 (Reference) 
 Children  
 (n = 229) (n = 251)  
MTHFR 677 CT or TT 130 (57) 132 (53) 1.2 (0.8-1.7) 
MTHFR 677 CC 99 (43) 119 (47) 1.0 (Reference) 
 (n = 229) (n = 251)  
MTHFR 1298 AA 112 (49) 97 (39) 1.5 (1.1-2.2) 
MTHFR 1298 AC or CC 117 (51) 154 (61) 1.0 (Reference) 
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use of the mother and between both polymorphisms and dietary intake of folate or vitamin B2 (data 
not shown). 
 
Supplement use a Children Cases (n = 175) Controls (n = 209) OR (95% CI) b 
MTHFR 1298 AA 44 33 2.1 (1.2-3.8)  
No 
MTHFR 1298 AC+CC  38 52 1.1 (0.6-2.0) 
MTHFR 1298 AA 40 51 1.1 (0.6-2.0)  
Yes  
MTHFR 1298 AC+CC  52 73 1.0 (Reference) 
 Mothers    
MTHFR 1298 AA 48 38 1.5 (0.8-2.5)  
No  MTHFR 1298 AC+CC  34 47 0.8 (0.5-1.4) 
MTHFR 1298 AA 31 58 0.5 (0.3-1.0)  
Yes  
MTHFR 1298 AC+CC  62 66 1.0 (Reference) 
 
Table 3. Interaction between the MTHFR A1298C genotype in mothers or children and 
periconceptional supplement use of the mother. 
a Supplement use in the periconceptional period is defined as daily use of folic acid containing vitamin 
supplements by the mother in the period of four weeks before until eight weeks after the conception. 
b Adjusted for maternal age 
 
Discussion  
In this case-control family study in an ethnically homogeneous European population, we examined the 
impact of two polymorphisms in the MTHFR gene on CHD risk. The genetic polymorphisms were 
analysed, both independently and in combination with maternal periconceptional vitamin supplement 
use and dietary intake of B-vitamins. We demonstrated that the MTHFR 1298 AA genotype of the 
father and the child is significantly associated with an increased CHD risk. Furthermore, the MTHFR 
A1298C polymorphism in children and maternal periconceptional folic acid supplementation as a gene-
nutrient interaction is significantly associated with CHD risk.  
No significant association was observed between CHD risk and the MTHFR C677T polymorphism, 
neither independently nor in combination with maternal periconceptional supplement use or dietary 
intake of folate or vitamin B2. The meta-analysis by Verkleij-Hagoort et al. revealed an overall OR of 
1.0 (0.8-1.3) in mothers and 1.1 (0.9-1.5) in children for the MTHFR C677T polymorphism and CHD 
risk, thereby supporting our finding.19 So far, only four studies20-23 were performed on the association 
between the MTHFR A1298C polymorphism and CHD risk and in only two of them a similar case-
control family design was used.21, 23 In two of those studies, no significant association was found 
between the MTHFR A1298C polymorphism in the mother and the risk of CHD offspring. This might 
have been due to smaller sample sizes of 10323 and 25 cases21, respectively, or ethnic heterogeneity 
or differences in the included phenotypes. Two case-only family studies used the Transmission 
Disequilibrium Test (TDT) approach, in which only the heterozygous case-parents are informative.20, 22 
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McBride et al. did not show a significant association between the MTHFR A1298C polymorphism in the 
mother and CHD risk. Hobbs et al., however, demonstrated a protective effect of the fetal MTHFR 
1298 C-allele on CHD risk. Moreover, they confirmed the TDT results with a log-linear analysis after 
inclusion of the data of all available case-families. However, a parent-of-origin effect could not be 
demonstrated.20 These results are in line with our finding of the significant association between the 
MTHFR 1298 AA genotype of the child and increased CHD risk. The significant CHD risk in association 
with the paternal MTHFR 1298 AA genotype is herewith in line and may suggest genetic imprinting.  
The MTHFR A1298C is extensively studied in relation with other complex diseases, such as colorectal 
cancer and acute leukaemia. For these diseases, the MTHFR 1298 CC genotype is more consistently 
associated with an overall risk reduction, albeit not significantly.7, 8 However, recent reports showed a 
strong and significant inverse association between the MTHFR 1298 C-allele and colon cancer.24, 25 The 
cancer researchers hypothesize that the MTHFR 1298 CC genotype causes decreased activity of the 
MTHFR enzyme. The MTHFR enzyme determines the balance between the different forms of folate for 
DNA synthesis and DNA methylation.26 Therefore, a decreased MTHFR enzyme activity inhibits the 
conversion of 5,10-methylenetetraydrofolate to 5-methyltetrahydrofolate, thereby producing an 
abundant 5,10-methylenetetrahydrofolate pool level that leads to less misincorporation of uracil during 
DNA synthesis. Error-free DNA synthesis is also critically important during cardiovascular development 
and, therefore, the proposed biological pathway may also be involved in the pathogenesis of CHDs. 
On the other hand, low MHTFR enzyme activity may also lead to DNA hypomethylation, thereby 
contributing to the development of congenital anomalies.27 The MTHFR A1298C polymorphism has a 
small influence on enzyme activity compared with the C677T polymorphism.16 This may implicate that 
the functional effect of the MTHFR 1298 C-allele is only a slightly lower MTHFR enzyme activity that 
delicately affects the balance between DNA synthesis and DNA methylation towards a protective effect 
in cardiovascular development. Nevertheless, one has to keep in mind that selective survival could 
have diluted our findings. Children with the MTHFR 1298 A-allele might be more viable due to the 
wide spread use of folic acid supplements.28, 29 
Methylation reactions are important in the regulation of gene expression by chemical modification of 
DNA. Unlike the irreversible nature of genetic events, which introduce permanent changes in the 
primary DNA sequence, epigenetic modifications are reversible. Maternal nutritional status can alter 
the epigenetic state of the fetal genome.30 Folic acid treatment restores DNA methylation and corrects 
the patterns of abnormal gene expression.31 Herewith in line, a significant gene-nutrient interaction 
was demonstrated between the MTHFR A1298C polymorphism in children and maternal use of a folic 
acid supplement in the periconceptional period. This finding suggests that the maternal nutritional 
status is of major importance compared with the small and non-significant effects of maternal 
polymorphisms, which fits with the multifactorial aetiology of CHDs. 
We have to consider the limitations of our study inherent to the case-control study design. Concerning 
selection bias, the main question is whether exposed subjects are more likely to be included in the 
study. We do not expect that individuals with a high risk genotype were more likely to be included in 
the study, because they did not know their genotype beforehand. Moreover, the allele frequencies in 
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controls were comparable with the allele frequencies in the European population. For example, Nurk 
et al. found allele frequencies in 14,449 control-mothers of 30% for the MTHFR 677 T-allele and 32% 
for the MTHFR 1298 C-allele.21 In our study, allele frequencies were 35% and 33%, respectively. 
Secondly, non-differential misclassification might have occurred, because periconceptional supplement 
use was based on retrospective questionnaire data. On the other hand, differential misclassification is 
not likely, because vitamin B2 or folate intake via supplements and food was independent of genotype 
distributions within both the case and the control-families. These arguments are in line with the report 
of Infante-Rivard et al. who showed that differential misclassification is rare in case-control studies.32 
Moreover, participants were unaware of the detailed study objectives. 
Our study has several strengths too. The large sample size of 230 cases and 251 controls enabled us 
to detect a 40% significant risk reduction with a power of 78% (risk allele frequency of 0.34, type 1 
error of 0.05, CHD population risk of 0.006). Our results are based on a controlled and standardised 
study design, which has successfully been used for many times in the investigation of gene-
environment interactions in other complex malformations.9, 33, 34 We used a fixed study moment of 
approximately 17 months after the index-pregnancy, which is especially important with regard to the 
nutritional parameters. Several authors demonstrated reasonable correlations between FFQ data that 
are determined before pregnancy and two to four years later. In general, no differences occur in the 
dietary patterns between the periconceptional period and one year postpartum.35, 36 Moreover, at this 
study moment, most of the CHD diagnoses are completed, and thereby, the risk of undiagnosed, less 
severe CHDs in the control group is minimised and, thereby, misclassification is reduced. Regarding 
nutrition, our food is not yet fortified by folic acid in contrast to other countries, which assures the 
reliability of the estimation of the true dietary folate intake. Furthermore, we only included Dutch 
natives and European families to increase the homogeneity of the study population.  
In conclusion, our findings suggest that the MTHFR 1298 AA genotypes of fathers and children are 
independent risk factors for the investigated CHDs. Of interest is the observed interaction between the 
MTHFR A1298C polymorphism and periconceptional folic acid supplementation. Future studies with 
larger sample sizes should be performed to investigate the maternal–fetal interactions with regard to 
the most favourable balance between DNA synthesis and DNA methylation, thereby affecting fetal 
cardiovascular embryogenesis. New evidence is given to stimulate the periconceptional use of folic 
acid supplements in public health programs. A periconceptional high methyl diet should be considered 
in future studies as well. 
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Abstract   
Maternal hyperhomocysteinaemia is associated with congenital heart defects (CHDs) in the offspring. 
A low periconceptional vitamin B12 status determined by genetic and lifestyle factors causes 
hyperhomocysteinaemia. We investigated the methionine synthase reductase (MTRR) and 
transcobalamin (TC) genes and maternal intake and serum concentrations of vitamin B12 in 
association with CHD risk. Seventeen months after the index-pregnancy, we studied 230 children with 
a CHD and 251 non-malformed children and their parents. Data were collected on current and 
periconceptional maternal vitamin supplement use and maternal dietary vitamin B12 intake of the 
month before the study moment. Blood samples were taken for the determination of MTRR A66G and 
TC C776G genotypes in families and serum vitamin B12 concentrations in mothers. Transmission 
disequilibrium tests and univariate and multivariate analyses were applied. Allele transmissions were 
not significantly distorted and MTRR and TC genotypes did not significantly affect CHD risk. Neither 
polymorphisms in mothers and/or children did reveal significant interactions nor in combination with a 
low vitamin B12 intake. Low maternal serum vitamin B12 combined with the maternal or child’s MTRR 
66 GG genotype resulted in odds ratios (ORs) of 1.4 (95% confidence interval 0.6-3.5) and 1.3 (0.5-
3.4), respectively. The TC 776 GG genotype in mothers or children and a low maternal serum vitamin 
B12 resulted in ORs of 2.2 (0.7-7.1) and 1.9 (0.5-7.4), respectively. We conclude that larger sample 
sizes are required to demonstrate whether MTRR 66 GG and TC 776 GG genotypes and maternal 
vitamin B12 status significantly contribute to the development of CHDs. 
 
Introduction 
Congenital heart defects (CHDs) are the most common congenital malformations in newborns and 
account for more than one-third of infant deaths due to congenital anomalies.1 In humans, the 
embryonic heart develops between the third and eighth weeks after conception.2 Since the mother is 
the environment of the developing embryo and fetus, interactions between genetic and lifestyle 
factors in early pregnancy are assumed to be involved in the pathogenesis of complex malformations, 
including CHDs. 
We and others demonstrated a strong association between maternal hyperhomocysteinaemia and the 
risk of CHD offspring.3-5 Increased homocysteine levels are caused by a low status of one or more of 
the B-vitamins, which is determined by genetic polymorphisms and lifestyle factors, such as low intake 
of B-vitamins by food and supplements.6 Experimental studies support the teratogenicity of moderate 
hyperhomocysteinaemia.7, 8 A part of the preventive effect of periconceptional folic acid 
supplementation on the occurrence of CHDs and other malformations can be explained by the 
normalisation of decreased folate and elevated homocysteine blood levels.9, 10 Besides the substrate 
folate, vitamin B12 is also an important determinant in the homocysteine pathway. A compromised 
vitamin B12 status leads to mild hyperhomocysteinaemia due to a reduced conversion of 
homocysteine into methionine by the enzyme methionine synthase, whereby vitamin B12 serves as a 
cofactor. Methionine synthase reductase (MTRR) regenerates the functional status of methionine 
synthase via the chemical reduction of vitamin B12.11 In addition, vitamin B12 is important for the 
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conversion of folate monoglutamates into polyglutamates, the stored form of folate in red blood 
cells.12 Vitamin B12 in blood is mainly bound to the metabolically inert protein haptocorrin. 
Approximately 10-25% of vitamin B12 in blood is bound to transcobalamin (TC), which is the 
biologically active fraction required for the cellular uptake of vitamin B12.13 
The MTRR and TC polymorphisms result in a decreased activity of methionine synthase due to a 
diminished cellular uptake and decreased cellular availability of reduced vitamin B12, respectively.11, 14 
So far, few studies showed a significant effect of the MTRR A66G and TC C776G polymorphisms on 
the vitamin B12 and homocysteine concentrations. It was shown that MTRR 66 AA homozygotes had 
36% higher vitamin B12 concentrations than individuals with the AG or GG genotypes (P < 0.05).15 
Others observed hyperhomocysteinaemia in TC 776 CG heterozygotes14 and reported 15% (P = 
0.021)16 and 39% (P = 0.002)17  higher transcobalamin concentrations for the CC genotype compared 
with the GG genotype.  
A low maternal vitamin B12 status is associated with a higher risk of neural tube defects (NTD)18, 19 
and orofacial clefts.20 Neural crest cells are not only involved in the embryogenesis of the neural tube, 
lip and palate, but in cardiovascular development as well. We have demonstrated that the migration 
and differentiation of neural crest cells is influenced by homocysteine.21 Since vitamin B12 is an 
important determinant in the homocysteine pathway, it may thereby contribute to the embryogenesis 
of the heart in the first weeks after conception. In that period, the maternal and embryonic vitamin 
B12 status are determined by genetic polymorphisms of vitamin B12-related genes in the mother and 
the embryo as well as maternal lifestyle factors, such as vitamin B12 intake by food and supplements. 
Prospective studies on congenital malformations are not yet feasible and, therefore, a case-control 
study is the best alternative. For many years, we have successfully conducted our studies on neural 
crest related malformations at a fixed study moment after the index-pregnancy in order to reduce 
recall bias when estimating the exposures of interest in the periconceptional period.19, 20, 22 From this 
background, the aim of the current case-control family study was to investigate associations between 
CHD risk and MTRR A66G and TC C776G genetic polymorphisms, periconceptional vitamin B12 intake 
and biochemical determinants of the homocysteine pathway. 
 
Materials and methods  
Study population 
The ongoing HAVEN study, a Dutch acronym for the study of heart anomalies and the role of genetic 
and nutritional factors, is a case-control family (child, mother, father) study conducted in the Western 
part of the Netherlands, which has previously been described.3, 23 In summary, 274 cases were 
included with the following phenotypes: tetralogy of Fallot (n = 31), transposition of the great arteries 
(n = 44), atrioventricular septal defect (n = 27), perimembranous ventricular septal defect (n = 73), 
coarctation of the aorta (n = 22), aortic valve stenosis (n = 8), pulmonary valve stenosis (n = 54), 
and hypoplastic left heart syndrome (n = 8). Diagnoses were confirmed after birth by 
echocardiography and/or cardiac catheterisation and/or surgery. The 312 children who were eligible 
as controls, did not have a major congenital malformation or chromosomal defect according to the 
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medical records and regular health checks by the physician at the child health centre. Families visited 
the hospital at the standardised study moment of around 17 months after the index-pregnancy. The 
Central Committee on Research in Humans and the Medical Ethics Committees of the participating 
hospitals approved the study protocol and written informed consent was obtained from every parent.  
Questionnaire data 
At the study moment, the general characteristics, maternal food frequency data and lifestyle 
exposures were collected by questionnaires. The data comprised of the following information at the 
study moment: maternal age, time after index-pregnancy, body mass index, ethnicity, education, 
dietary intake of energy and vitamin B12. Maternal ethnicity was classified as Dutch natives, 
Europeans and non-Europeans.24 Educational level was categorised according to the definitions of 
Statistics Netherlands.25  
Importantly, we estimated the daily maternal dietary intakes of energy and vitamin B12 of the month 
before the study moment to reflect the regular food intake and, thereby, during the periconceptional 
period of the index-pregnancy as well. We used a validated semiquantitative food frequency 
questionnaire (FFQ).26 In a standardised manner, the questionnaire data were checked for 
completeness and consistency by the researcher during the hospital visit. Standardised 
anthropometric measurements were performed including maternal height (anthropometric rod, SECA, 
Hamburg, Germany) up to 0.1 cm accuracy and weight (weighing scale, SECA, Hamburg, Germany) 
with 0.5 kg accuracy. The maternal lifestyle factors of interest included the use of B-vitamin 
supplements, tobacco and alcohol, which were evaluated both at the study moment and during the 
periconceptional period. The periconceptional period was defined as four weeks before until eight 
weeks after conception. The B-vitamin supplements contained folic acid and/or vitamin B12 and were 
used daily. 
Biochemical measurements and analysis of the polymorphisms  
Maternal blood samples were used to determine the concentrations of serum vitamin B12, plasma 
total homocysteine (tHcy), and serum and red blood cell (RBC) folate. Blood sampling and 
measurements were described before.3, 23 Blood samples were obtained of the child, mother and 
father for DNA-analysis. Genomic DNA was isolated from 0.2 mL EDTA whole blood with a Total 
Nucleic Acid Extraction kit on a MagNA Pure LC (Roche Molecular Biochemicals, Mannheim, Germany). 
DNA yields were estimated by comparison with a lambda ladder. We obtained buccal swabs from 
three fathers and nine children because of logistic problems or failures in blood sampling. The DNA 
isolation from buccal swabs was performed using the QuickExtract DNA Extraction Solution 1.0 
according to the manufacturers’ instructions (Epicentre, Madison, Wisconsin, USA). The MTRR A66G 
(rs1801394) and TC C776G (rs1801198) polymorphisms were analysed by the Taqman® system, 
according to protocols provided by the manufacturer (Taqman, Applied Biosystems, Foster City, CA, 
USA). Approximately three percent of the samples were re-genotyped to check for genotype calling 
consistency. The genotyping success rate was more than 96%. 
 
  Vitamin B12 related genetic and lifestyle factors in CHDs 91 
Statistical analysis 
Maternal age, time after index-pregnancy and body mass index are presented as medians and were 
compared between cases and controls using the Mann-Whitney U test. Differences in frequencies of 
categorical variables were tested by the Chi-square test. The mean dietary vitamin B12 intakes were 
adjusted for total energy intake using the residual method.27 The vitamin B12 intakes and biomarkers 
are shown as medians with interquartile range and were compared by the Kruskal-Wallis and Mann-
Whitney U tests. Biomarkers are stratified for MTRR A66G and TC C776G genotypes. For the analyses 
concerning the vitamin B12 intake and biomarkers, we excluded all pregnant and lactating mothers 
and those with a changed diet compared with the periconceptional period to minimise confounding of 
these parameters. The median daily dietary intake of vitamin B12 in controls was used as a cut-off 
value for low (≤ 3.4 μg/day) or normal (>3.4 μg/day) vitamin B12 intake. The 15th percentile of the 
control serum vitamin B12 concentration was used as a cut-off value for low (≤ 175 pmol/L) or normal 
(>175 pmol/L) serum vitamin B12. 
Hardy-Weinberg equilibrium (HWE) was examined for all genotype frequencies, separately for cases 
and controls. The transmission disequilibrium test (TDT) was applied to analyse transmission of the 
parental MTRR 60 G-allele and the TC 776 G-allele in case-families.28 The risk of CHD was estimated 
for the MTRR A66G and TC C776G genotypes of all family members using a univariate logistic 
regression model.  
We examined these polymorphisms in mothers and children and their interaction with periconceptional 
vitamin B12 intake by food and periconceptional B-vitamin supplement use in association with CHD 
risk. We used a recessive model for the genetic analyses.11, 16, 17, 29 Odds ratios (ORs) and 95% 
confidence intervals (CI) were calculated in a logistic regression model with the lowest category as a 
reference. We performed a trend analysis across the four categories ranging from reference (wild type 
or heterozygous genotype in combination with normal vitamin B12 intake) to high risk (homozygous 
mutant genotype and low vitamin B12 intake). In multivariate logistic regression analyses, we studied 
interactions between the two polymorphisms in mothers and children, maternal dietary vitamin B12 
intake and serum vitamin B12 with adjustment for periconceptional B-vitamin supplementation. 
Stratified analyses were executed for the effects of the polymorphisms on the maternal biochemistry 
for all pooled data as well as for case and control-data separately. In a multivariate model, we 
adjusted the biochemical data for use of B-vitamin supplements, tobacco and alcohol at the study 
moment. A P value ≤ 0.05 was considered statistically significant. All analyses were performed using 
SPSS for Windows software (version 11.0; SPSS Inc, Chicago, Illinois, USA) with an exception for the 
transmission disequilibrium test.28 
 
Results  
In the study population of 274 case and 312 control-families, inconsistent triads (n = 10) were 
excluded from all analyses. The distributions of the three ethnic groups were comparable between 
cases (Dutch natives 75%, Europeans 11%, non-Europeans 14%) and controls (73%, 8% and 19%), 
respectively. However, the distributions of the genetic polymorphisms were significantly different in 
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non-Europeans compared with Dutch natives and Europeans, particularly for MTRR genotypes in 
control-mothers, case and control-fathers, and case-children. Therefore, non-European families (n = 
95) were excluded from further analysis, which resulted in a dataset of 230 case and 251 control-
families. 
In Table 1, the general characteristics and lifestyle factors are presented of 230 case and 251 control-
mothers. The median age of case-mothers was 0.7 years higher than of controls (P = 0.042). The 
time after the index-pregnancy, body  mass  index  and  educational level  were  comparable  in  both  
 
Table 1. Maternal characteristics and lifestyle factors at the study moment and during the 
periconceptional period. Values are median (interquartile range) or number (percentage). 
a P = 0.042 (Mann-Whitney U test) or P = 0.026 (Chi square test). 
b Primary, lower vocational and intermediate secondary education. 
c Family members with a CHD in the first, second or third degree. 
d B-vitamin supplements contained folic acid and/or vitamin B12. 
e Dietary intakes are based on 175 cases and 210 controls, after exclusion of pregnant and lactating 
mothers and those with a changed diet compared with the periconceptional period. 
f Energy-adjustment by the residual method. 27 
g Defined as four weeks before until eight weeks after conception. 
Study moment Cases (n = 230) Controls (n = 251) 
Maternal age (years) 33.5 (30.6-36.7) 32.8 (29.2-35.4) a 
Time after index-pregnancy (months) 16.8 (14.4-20.0) 16.7 (15.3-18.4) 
Body mass index (kg/m²)  24.4 (22.0-27.7) 24.1 (22.1-27.3) 
Educational level, low [n (%)] b 60 (26) 48 (19) 
Family history of CHD [n (%)] c 20 (9) 11 (4) 
Use of  [n (%)]   
    B-vitamin supplements d 60 (26) 64 (26) 
    Tobacco 41 (18) 46 (18) 
    Alcohol 118 (51) 154 (61) a 
Daily dietary intake of  e   
   Energy (MJ) 8.4 (7.3-10.2) 8.6 (7.2-10.3) 
   Vitamin B12, crude (μg) 3.6 (2.5-4.5) 3.4 (2.7-4.3) 
   Vitamin B12, energy-adjusted (μg) f 3.6 (2.5-4.5) 3.4 (2.7-4.3) 
Periconceptional period g   
Use of  [n (%)]   
     B-vitamin supplements 125 (54) 149 (59) 
     Tobacco 46 (20) 57 (23) 
     Alcohol 94 (41) 97 (39) 
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groups. There were no significant differences in the use of B-vitamin supplements and tobacco at the 
study moment. However, compared with cases, 10% more control-mothers used alcohol (P = 0.026). 
After exclusion of the pregnant and lactating mothers and those with a changed diet compared with 
the periconceptional period, the analyses of energy and vitamin B12 intake and biomarkers were 
based on 175 case and 210 control-mothers. The dietary intake of energy and the crude and energy-
adjusted vitamin B12 intakes were comparable in both groups. At the study moment, the use of B-
vitamin supplements, tobacco and alcohol was comparable between cases and controls. In the 
periconceptional period, there were no significant differences either concerning the use of B-vitamin 
supplements, tobacco or alcohol. A positive family history of CHD was associated with a CHD risk of 
2.1 (95% CI 0.97-4.4). 
The MTRR and TC genotype frequencies were consistent with HWE in mothers, fathers and children, 
both in the case-group and in the control-group. The frequencies of the MTRR 66 G-allele in cases and 
controls, respectively, were 55% and 56% for mothers, 61% and 57% for fathers, and 59% and 55% 
 
Table 2. The MTRR A66G and TC C776G genotype frequencies of the families and the 
association with CHD risk. 
Genotypes Cases Controls OR (95% CI) 
 Mothers  
 (n = 230) (n = 251)  
MTRR 66 AG or GG 181 (79) 201 (80) 1.0 (0.7-1.5) 
MTRR 66 AA 49 (21) 50 (20) 1.0 (Reference) 
 (n = 221) (n = 238)  
TC 776 CG or GG 147 (67) 167 (70) 1.0 (0.6-1.5) 
TC 776 CC 74 (33) 71 (30) 1.0 (Reference) 
 Fathers  
 (n = 229) (n = 251)  
MTRR 66 AG or GG 196 (86) 206 (82) 1.3 (0.9-1.9) 
MTRR 66 AA 33 (14) 45 (18) 1.0 (Reference) 
 (n = 225) (n = 242)  
TC 776 CG or GG 148 (66) 156 (64) 1.0 (0.6-1.6) 
TC 776 CC 77 (34) 86 (36) 1.0 (Reference) 
 Children  
 (n = 229) (n = 251)  
MTRR 66 AG or GG 191 (83) 199 (79) 1.3 (0.9-1.8) 
MTRR 66 AA 38 (17) 52 (21) 1.0 (Reference) 
 (n = 218) (n = 246)  
TC 776 CG or GG 139 (64) 163 (66) 0.9 (0.6-1.5) 
TC 776 CC 79 (36)  83 (34) 1.0 (Reference) 
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for children. The frequencies of the TC 776 G-allele in cases and controls, respectively, were 44% and 
46% for mothers, 40% and 39% for fathers, and 42% and 42% for children. Allele transmissions 
were not significantly distorted in case-families. The MTRR 66 A-allele was transmitted 105 times and 
the G-allele 113 times (Chi-square 1.467, P = 0.23). For the TC 776 C and G-allele, these data were 
107 and 90 times (Chi-square 0.294, P = 0.59). Logistic regression analyses did not show significant 
associations between the MTRR and TC genotypes in mothers, fathers or children and CHD risk (Table 
2). The MTRR genotypes of fathers and children showed slightly higher CHD risks, albeit not 
significantly. The analyses of the various CHD phenotypes did not reveal significant associations for 
any of the genotypes. 
 
Table 3. Maternal biochemistry at the study moment stratified for MTRR A66G and TC 
C776G genotypes. 
a RBC folate, n = 42. 
b P = 0.042 (Mann-Whitney U test) for comparison between cases and controls. 
c P = 0.006 (Kruskal-Wallis test); P = 0.007 and P = 0.002 (Mann-Whitney U test) for comparison 
between CG and GG, and between CC and GG genotypes. 
d GG vitamin B12, n = 60; AA homocysteine, n = 41; GG homocysteine, n = 60. 
e CG vitamin B12, n = 93 ; CG homocysteine, n = 95 ; GG homocysteine, n = 44. 
 
 Case-mothers 
MTRR A66G All (n = 137) AA (n = 26) AG (n = 68) GG (n = 43) 
Folate, serum (nmol/L) 15.3 (12.0-19.4) 14.2 (11.9-19.0) 15.0 (11.3-18.4) 15.5 (14.1-21.5)
Folate, RBC (nmol/L) 676 (533-802) 645 (494-880) 676 (543-813) 679 (536-777) a
Vitamin B12, serum (pmol/L)  276 (222-366) 284 (212-343) 274 (225-372) 272 (185-397) 
Homocysteine, plasma (μmol/L) 10.6 (8.9-13.2) b 10.1 (8.7-12.2) 11.1 (9.5-13.3) 10.2 (8.1-13.1) 
TC C776G  All (n = 130) CC (n = 45) CG (n = 58) GG (n = 27) 
Folate, serum (nmol/L) 15.3 (12.1-19.3) 15.7 (12.4-20.4) 15.0 (11.6-19.0) 15.3 (11.4-18.1)
Folate, RBC (nmol/L)  678 (536-798) 679 (550-821) 682 (521-836) 640 (539-770) 
Vitamin B12, serum (pmol/L) c 278 (222-371) 285 (238-420) 299 (235-378) c 234 (171-272) c
Homocysteine, plasma (μmol/L) 10.6 (8.9-13.1) 10.4 (8.5-12.6) 10.3 (8.8-13.3) 11.4 (9.4-13.7) 
 Control-mothers 
MTRR A66G All (n = 203) AA (n = 40) AG (n = 102) GG (n = 61) 
Folate, serum (nmol/L) 14.3 (12.1-19.2) 16.2 (11.5-22.2) 13.4 (11.9-18.2) 14.7 (12.8-19.1)
Folate, RBC (nmol/L) 670 (533-819) 728 (565-1044) 645 (521-793) 671 (537-770) 
Vitamin B12, serum (pmol/L) 249 (202-359) 241 (205-367) 266 (206-370) 245 (187-319) d
Homocysteine, plasma (μmol/L) 10.3 (8.4-12.1) 10.1 (8.4-11.7) d 10.0 (8.4-12.2) 10.7 (8.4-12.3) d
TC C776G  All (n = 193) CC (n = 54) CG (n = 94) GG (n = 45) 
Folate, serum (nmol/L) 14.1 (12.1-19.2) 14.4 (12.3-17.6) 14.0 (12.0-19.0) 16.0 (12.1-20.2)
Folate, RBC (nmol/L)  670 (533-808) 673 (530-773) 639 (531-792) 702 (543-948) 
Vitamin B12, serum (pmol/L) 253 (202-364) 239 (195-334) 249 (201-341) e 281 (203-420) 
Homocysteine, plasma (μmol/L) 10.3 (8.5-12.3) 10.5 (8.8-11.8) 10.3 (8.2-11.8) e 10.2 (8.5-13.3) e
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The maternal biochemistry in the pooled group of cases and controls did not show significant 
differences within the group of MTRR genotypes and within the group of TC genotypes. The same 
data are stratified for case/control status and presented in Table 3. The tHcy concentration was 
significantly higher in cases than in controls (P = 0.042). The MTRR genotypes in case-mothers did 
not significantly affect the folate, vitamin B12 and tHcy concentrations. 
 
Figure 1. Interaction between maternal serum vitamin B12 and the MTRR A66G and TC 
C776G genotypes of mothers and children, and CHD risk. The risk estimates are shown for the 
combination of maternal serum vitamin B12 concentrations and the MTRR A66G (mothers in panel A, 
children in panel B) and TC C776G (mothers in panel C, children in panel D) genotypes in mothers. 
The cut-off value for a low serum vitamin B12 concentration is the 15th percentile (175 pmol/L) of 
serum vitamin B12 concentrations in control-mothers.  
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Compared with the CC and CG genotypes, the maternal TC 776 GG genotype in cases demonstrated 
significantly lower vitamin B12 concentrations (P = 0.006) and slightly higher tHcy concentrations (P 
= 0.50). No significant findings were observed in the control-group. In a multivariate model, we 
adjusted the biomarker concentrations for MTRR and TC genotypes and the use of B-vitamin 
supplements, tobacco and alcohol at the study moment, which did not significantly change the 
biochemistry results. The multivariate logistic regression analyses showed no significant interactions 
between the MTRR and TC genotypes, low maternal periconceptional vitamin B12 intake by food and 
supplements and the association with CHD risk. Risk estimates ranged between 0.5 and 1.4 in 
mothers and between 0.6 and 1.7 in children. Figure 1 shows the subtle interactions between the 
maternal serum vitamin B12 and MTRR and TC genotypes of mothers and children. A low serum 
vitamin B12 in combination with the MTRR 66 GG genotype in mothers and children, respectively, 
demonstrated ORs of 1.4 (95% CI 0.6-3.5) and 1.3 (0.5-3.4). For the TC 776 GG genotype of mothers 
and children, the CHD risk estimates were 2.2 (0.7-7.1) and 1.9 (0.5-7.4), respectively. 
 
Discussion  
In this case-control study conducted in the Western part of the Netherlands, we showed that the 
MTRR and TC genetic polymorphisms in mothers and children are no independent CHD risk factors. 
The maternal TC genotype significantly influenced serum vitamin B12 in case-mothers only, which was 
not due to confounding by the use of B-vitamins at the study moment. However, a low maternal 
serum vitamin B12 and the TC 776GG genotype in mothers or children may increase CHD risk. This 
risk estimate was higher than the risk estimate for the combination of a low maternal vitamin B12 
concentration with the MTRR 66GG genotype. Both results, however, should be very carefully 
interpreted, because the associations are weak and not significant. These associations have to be 
further investigated in larger sample sizes. 
We could not demonstrate a significant association between the MTRR and TC polymorphisms in 
families and CHD risk. Only one smaller study than ours investigated the MTRR genotypes and CHD 
risk before without significant results.30 Studies investigating MTRR and TC polymorphisms in related 
malformations, such as NTD and orofacial clefting, show inconclusive results as well.11, 17, 29, 31-36 
The maternal biomarker analyses stratified for maternal TC genotypes showed a significantly lower 
serum vitamin B12 in case-mothers with the GG genotype compared with the CC or CG genotype. This 
is in line with studies of others.14, 16, 17 Moreover, Afman et al. reported in mothers of NTD offspring 
that the proportion of vitamin B12 bound to TC was significantly lower in women with the GG 
genotype than in women with the CC genotype.17 Since the serum vitamin B12 concentration 
represents the total of holo-haptocorrin and holo-TC concentrations, this may imply that in our study 
the lower serum vitamin B12 concentrations in case-mothers with the GG genotype coincide with 
lower holo-TC concentrations. This is substantiated by von Castel-Dunwoody et al., who reported 
lower holo-TC concentrations in TC 776 GG homozygotes than in CC homozygotes.16 
The weak trend for hyperhomocysteinaemia across the TC genotypes confirm the data of other 
studies.14, 17 The functional consequences of this TC polymorphism are a lower cellular vitamin B12 
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availability, either due to reduced transcription or conformational changes in the protein, thereby 
affecting its affinity for the receptor or the binding of vitamin B12 to TC.14, 17 Thus, this TC 
polymorphism may affect cellular vitamin B12 availability, thereby increasing tHcy concentrations, 
particularly in individuals with a low vitamin B12 status. This substantiates our previous finding and 
that of others that maternal hyperhomocysteinaemia is associated with increased CHD risk.3-5 
We found a significant effect of the TC genotypes on the vitamin B12 concentration in the case-group 
only, despite the reversed non-significant effect on vitamin B12 concentrations in controls. Overall 
comparisons of the MTRR genotypes and the biochemistry in cases and controls did not reveal 
significant differences, except for the tHcy concentration. Therefore, it is very likely that other factors 
are involved as well, such as differences in other vitamin B12-related polymorphisms and lifestyle 
factors. We could not show significant interactions between the MTRR and TC polymorphisms, 
maternal dietary intake of vitamin B12 and CHD risk. As serum vitamin B12 is a stronger indicator of 
vitamin B12 status than vitamin B12 intake, we investigated interactions between a low maternal 
serum vitamin B12 and the MTRR and TC polymorphisms in both mothers and children. The risk 
estimates may suggest a weak trend only towards a higher risk across the categories of the TC 
genotype in mothers and children. For the MTRR genotype in mothers and children, this is less clear. 
Thus, in addition to the MTRR and TC genotypes, the maternal vitamin B12 status is suggested to be 
important for the cardiovascular development of the child in utero.  
A high plasma methylmalonic acid concentration is a sensitive indicator of a low vitamin B12 status. 
Van Beynum et al. described that the maternal MTRR 66 GG genotype in combination with a high 
plasma methylmalonic acid concentration was associated with a three-fold increased CHD risk, albeit 
not significantly.30 Studies on NTD risk support the observed interaction between both polymorphisms 
and vitamin B12 status in our study, but the sample sizes of these NTD studies are much smaller.11, 29 
In addition, the ethnic background was not clear for 25% of the study population11 or not described at 
all.29 This is important information, because differences in allele frequencies of genetic polymorphisms 
are striking between and within continents.24 With concern to confounders, Wilson et al. excluded 
vitamin supplement users.11 Van der Linden et al. adjusted for significant differences in maternal age, 
but did not consider use of vitamin supplements at the study moment.29 
One of the strengths of our study is that we standardised the data collection at a fixed study moment 
relatively soon after pregnancy for both cases and controls. This is in contrast to the designs of 
others, in which subjects were investigated at a mean time interval of 10 to 11 years11 or even at 
different time intervals in controls and cases (8 and 16 years after pregnancy).29 We previously 
showed the importance of considering the time-interval between delivery and the post partum study 
moment.37 A standardised study moment relatively soon after the index-pregnancy is important with 
regard to nutritional and biochemical parameters. For many years, we have shown the value of a fixed 
study moment between 11 and 18 months after the index-pregnancy to estimate the nutritional status 
of the periconceptional period, and to reduce recall bias.3, 19, 20, 22, 23 An earlier study moment after 
birth would significantly interfere with the maternal physiology and biochemistry and it might cause 
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misclassification of cases and controls, because most malformations are detected and completely 
diagnosed in the first year of life.  
Other strengths of the HAVEN study are the recruitment of patients with a CHD phenotype that has 
been associated with maternal hyperhomocysteinaemia and the inclusion of only Dutch native as well 
as European families in the analyses in order to increase the homogeneity of the study population. In 
addition, we performed all analyses separately for CHD phenotypes. These analyses showed 
comparable results, thereby substantiating the homogeneity of our study population. However, we 
have to consider the limitations of our study as well. With regard to laboratory issues, it has been 
suggested that MMA or holo-TC concentrations are better predictors of vitamin B12 status than serum 
vitamin B12, but the determination of MMA concentrations is quite complex and expensive. Holo-TC is 
a sensitive marker for vitamin B12 deficiency and has a reasonable specificity as well and might be a 
better metabolic indicator of vitamin B12 status than serum vitamin B12.38 Moreover, measurement of 
both holo-TC and total vitamin B12 concentrations may be a better predictor of the vitamin B12 status 
than either assay alone.39 Finally, we only showed weak associations, which may be due to our 
sample size. Calculations revealed that the sample size of both the case and the control-group should 
be 416 for the MTRR polymorphism and 495 for the TC polymorphism to find a significant OR of 2.5 
for the gene-serum vitamin B12 interaction with a power of 70%.  
In conclusion, our findings suggest that interactions between TC 776 GG and MTRR 66 GG genotypes, 
and low periconceptional vitamin B12 status may be involved in the pathogenesis of CHDs with very 
small effects on the risk estimates. This suggestion is substantiated by our previous report that a 
maternal diet low in vitamin B12 is associated with an increased CHD risk in the offspring.23 Therefore, 
it might be favourable to advise women to use a diet rich in vitamin B12 and eventually a vitamin B12 
supplement in addition to a folic acid supplement in the periconceptional period to achieve an optimal 
vitamin B12 status. Future research may focus on other polymorphisms in the MTRR and TC genes, 
their functional and biochemical effects and the implications of lifestyle factors in order to gain insight 
into the role of vitamin B12 in the pathogenesis of CHDs. 
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Introduction 
The overall aim of this thesis was to investigate associations between some biomarkers of the 
homocysteine metabolism, nutritional factors, polymorphisms in B-vitamin related genes and the risk 
of congenital heart defects (CHDs) in man. Moreover, gene-nutrient interactions were studied 
between the biomarkers, dietary intake and polymorphisms in the methylenetetrahydrofolate 
reductase (MTHFR), methionine synthase reductase (MTRR) and transcobalamin (TC) genes and CHD 
risk.  
In this thesis, we demonstrate that maternal hyperhomocysteinaemia, defined as a plasma total 
homocysteine (tHcy) concentration above 14.3 μmol/L, nearly three-fold increases the risk of CHD 
offspring. This is substantiated by the establishment of higher risk estimates when tHcy 
concentrations rise. Maternal hyperhomocysteinaemia shows to be partially due to low folate and low 
vitamin B12 status. Moreover, a low dietary intake of vitamin B12 is associated with a significantly 
higher CHD risk, particularly in low educated women. The dietary intakes are estimated with an 
adapted food frequency questionnaire (FFQ), which was validated in the HAVEN study (i.e., a Dutch 
acronym for the study of heart anomalies and the role of genetic and nutritional factors) for the 
estimation of the dietary intake folate and vitamin B12. The adapted FFQ shows to be a reliable tool 
to estimate the dietary intake of energy, macronutrients, folate and vitamin B12 in women of 
reproductive age. The investigation of folate-related genes reveals that the MTHFR A1298C 
polymorphism in children and fathers is independently associated with a lower CHD risk. Moreover, 
the interaction between the MTHFR 1298 AA genotype in children and no periconceptional use of folic 
acid supplements is significantly associated with a two-fold increased CHD risk. The MTRR A66G and 
TC C776G polymorphisms are not associated with CHD risk, but the TC 776 GG genotype in case-
mothers significantly decreases the serum vitamin B12 concentrations. In addition, subtle interactions 
between serum vitamin B12 and TC 776 GG genotypes in mothers and children produce risk estimates 
of 2.2 (0.7-7.1) and 1.9 (0.5-7.4), respectively, and interactions between serum vitamin B12 and 
MTRR 66 GG genotypes in mothers and children show CHD risks of 1.4 (95% confidence interval 0.6-
3.5) and 1.3 (0.5-3.4). These interactions may therefore be involved in the complex pathogenesis of 
CHDs. 
We have to consider several methodological issues of the studies that are described in this thesis and 
put our results into the perspective of known and relevant literature. Consecutively, we can make 
inferences about the identified nutritional risk factors, e.g., maternal hyperhomocysteinaemia, a low 
vitamin B12 diet, the contribution of the MTHFR A1298C polymorphism in children and fathers to the 
development of CHDs, and the gene-nutrient interactions between the polymorphisms in the MTRR 
A66G and TC C776G genes and serum vitamin B12. At the end of this chapter, we recommend future 
research and discuss the implications regarding clinical practice and public health care. 
 
Methodological issues 
Ascertainment of the cases 
Case-families consist of a mother, father and child and are recruited in collaboration with the 
  General Discussion  105 
Departments of Paediatric Cardiology of Erasmus MC in Rotterdam, Leiden University Medical Centre 
in Leiden, VU University Medical Centre and Academic Medical Centre in Amsterdam. The two 
paediatric cardiologists who cooperate in the study recruit the families in collaboration with the project 
team and have diagnosed the case-children with tetralogy of Fallot, transposition of the great arteries, 
atrioventricular septal defect, perimembranous ventricular septal defect, coarctation of the aorta, 
aortic valve stenosis, pulmonary valve stenosis, and hypoplastic left heart syndrome. Both paediatric 
cardiologists are trained in Paediatric Cardiology at Leiden University Medical Centre through which 
the uniformity of the diagnoses is enhanced. We select these specific CHDs, because their association 
with folate or other environmental factors has previously been shown.1, 2 Diagnoses are confirmed 
after birth by echocardiography and/or cardiac catheterisation and/or surgery. The paediatric 
cardiologists again verify the diagnoses before the families are invited for the HAVEN study. Most 
CHDs are detected and completely diagnosed during the first postnatal year. Although, still some 
misclassification of less severe CHDs might occur, the study moment of approximately 17 months 
after the index-pregnancy is, therefore, an appropriate moment for the inclusion of cases. Male 
gender is present in a higher proportion of cases than female and this predominance has been noted 
in several cardiovascular malformations, especially in transposition of the great arteries and left-sided 
obstructions.3 Compared with controls, the rate of close-related family members with a CHD is higher 
in the case-group (9% and 4%, respectively, P = 0.06). These data further substantiate the validity of 
our case-group.  
 
Ascertainment of the controls 
Control-families consist of healthy control-children and both parents. They are enrolled in collaboration 
with a physician of the child health centres in the surroundings of Rotterdam. Children are eligible as 
controls if they do not have a major congenital malformation or chromosomal defects according to the 
medical record and regular health checks by the physician of the child health centre. Control-families 
are not related to case-families. 
 
Comparability of cases and controls 
In January 2005, 274 cases and 312 controls were enrolled in the ongoing HAVEN study. The 
response rates are 45% for cases and 17% for controls. Most of the invited families refuse to 
participate due to emotional or medical reasons and practical problems, such as the distance to the 
hospital and difficulties to take a day off for this reason. The differences in response rates between 
cases and controls can partially be explained by different motivations to participate in the HAVEN 
study. Case-parents often want to know more about the aetiology of CHDs and the possibilities of 
prevention if they want to become pregnant again. The motivation of control-families to participate is 
either because somebody in their family or neighbourhood has a child with a CHD, they want a check-
up of their health status or they want to contribute to the prevention of CHDs. 
At the start of this study, we aimed to recruit children with an indication for grommet insertion and 
their parents as controls via the Departments of Otorhinolaryngology of the participating hospitals 
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through which both cases and controls would be derived from the same domain population. However, 
the Medical Ethics Committees of some of these hospitals did not give permission to recruit control-
families in this way. Therefore, we enrol the controls via the child health centres in the surroundings 
of Rotterdam and thereby, we increase the compliance rates. Thus, case and control-families are 
derived from the Western part of the Netherlands.   
All general characteristics are comparable between cases and controls, except for maternal age. 
Compared with controls, the median age of case-mothers is significantly, though only slightly higher 
than in controls (33.5 and 32.8 years, respectively). One might expect that there would be an 
overrepresentation of non-Western immigrants in the case-group due to motivation and mode of 
recruitment. However, the distributions of the ethnic groups (Dutch natives, Western and non-
Western immigrants)4 are comparable for cases and controls. Moreover, these distributions are 
corresponding to the numbers for the Western part of the Netherlands (75%, 10% and 15% in 
2006).5 Several reports have described socioeconomic trends of higher risks in lower social classes for 
CHDs in general, for septal defects and for some specific cardiac defects.6, 7 Besides employment, 
neighbourhood, occupation and rental occupancy, education is a measure of socioeconomic status. 
One might assume that parents with a higher education are more motivated to participate in 
comparison with low educated people. On the other hand, the low educated parents might have more 
time to participate than the high educated counterparts. However, in our study the distributions of the 
maternal and paternal educational level are comparable between cases and controls. This is the likely 
explanation that we do not demonstrate a significant association between parental educational level 
and CHD risk. With concern to the nutritional parameters, the overall dietary intakes are comparable 
between cases and controls. However, a maternal diet low in vitamin B12 is associated with a higher 
risk of a child with a CHD, especially in low educated women. It is known that people with a low 
education and low income are more likely to engage in poor dietary practice than their wealthier and 
higher educated counterparts.8 Therefore, these findings subscribe that educational level is a 
determinant of nutritional status and lifestyle factors. Nevertheless, the parental educational levels do 
not differ between case and control-families and therefore, adjustment of the risk estimates for 
educational level would have led to overadjustment. In conclusion, we assume that selection bias is 
not an important issue, because of the comparability of both cases and controls with regard to the 
general characteristics. 
Our main hypothesis is that the environmental factors involved in CHD pathogenesis are mainly 
derived from the mother and are considered to be much stronger determinants than the studied 
genetic polymorphisms. The latter determinants should be more regarded as subtle risk modifiers. In 
the studies concerning environmental factors, such as biochemistry and dietary intake, we have based 
the classification of ethnicity on the definitions of Statistics Netherlands.4 We thereby categorise case 
and control-families by the assumed lifestyle and nutrition of the mother. Population admixture is a 
major confounder in investigating associations between genetic markers and disease. Therefore, we 
have used another classification for ethnicity in our studies concerning the genetic polymorphisms of 
MTHFR, TC and MTRR. This classification recognizes continental population structure and continental 
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genetic ancestry.9 It is only slightly different from the classification used by Statistics Netherlands4 as 
it incorporates the genetic background of the grandparents of the index-child as well. Using this 
genetic classification of ethnicity, participating families are categorised into three different groups: 
Dutch natives, European others and non-Europeans. However, the non-European group is significantly 
different from the other two groups concerning genotype frequencies, general characteristics and 
nutritional intake and is, therefore, excluded from the genetic analyses. In addition, all genotype data 
are checked for Mendelian segregation errors and inconsistent triads are excluded from analysis. 
Therefore, the study population is rather homogeneous with regard to the genetic backgrounds and, 
thereby, confounding due to population admixture is minimised. 
 
Comparability of information 
The potential for information bias is an issue inherent to the case-control design of studies 
investigating congenital malformations. Therefore, we have to consider recall bias and subsequent 
misclassification of exposures in the periconceptional period. Parents of affected children may have a 
better recall, because they actively search for an explanation of the disease of their child or have an 
assumption about its underlying cause. We have chosen for one fixed study moment relatively soon 
after pregnancy in both cases and controls compared with other studies to minimise the recall bias. 
Periconceptional exposures, e.g., the use of vitamin supplements, tobacco and alcohol, are equally 
distributed in cases and controls. Thus, it is not likely that our findings are distorted by these 
exposures. Moreover, differential misclassification is not likely, because participants are not aware of 
the specific hypotheses of this study. Although, random misclassification might have occurred, it may 
have attenuated our findings. These arguments are in line with the study of Infante-Rivard et al., who 
demonstrated that in case-control studies inaccuracies are frequent but recall bias is rare and is found 
only for very specific exposures, such as when an association is published or when the exposure is 
socially undesirable.10 
As we investigate current dietary intake, recall bias is not an important issue. However, dietary 
assessment methods have a strong bias towards underestimation of habitual energy intake and, 
therefore, we have evaluated the existence of reporting bias. Some under-reporting may equally be 
present in both cases and controls, but the dietary intakes are representative of long-term habitual 
intake (Chapter 4 and 5). Furthermore, adjustment for energy intake or expression of macronutrient 
intake as percentages of total energy intake minimises the bias generated by under-reporting.11  
 
Accuracy 
Considering dietary intake, we assume that the maternal nutritional status around 17 months after the 
index-pregnancy is the best estimate of the nutritional status in the periconceptional period, which is 
the crucial period of embryogenesis and cardiovascular development. This hypothesis is supported by 
previous research12, 13 substantiating the assumption that there are no strong differences in the 
preconceptional dietary habits and those of one year post partum.13-15 In addition, it takes 
approximately 12 months after pregnancy and breastfeeding to return to the preconceptional 
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hormonal, metabolic and nutritional status. Moreover, the season of the pre- and periconceptional 
period and the study moment, i.e., approximately two years after conception, is the same.  
All blood samples are analysed anonymously within three months after collection. The samples are 
analysed in batches and, thereby, possible measurement errors are random. Moreover, all blood 
samples are separated within one hour after blood sampling to reduce the risk of haemolytic samples. 
One EDTA-tube is put on ice and centrifuged immediately after blood sampling. This is extremely 
important for accurate measurement of the fasting tHcy concentration.16 The between-run coefficients 
of variation (CVs) are all below 10%: for vitamin B12, e.g., 5.1% at 125 pmol/L and 2.9% at 753 
pmol/L; for folate these CVs are 9.5% at 8.3 nmol/L and 3.2% at 20.2 nmol/L and for tHcy 5.9% at 
15.3 µmol/L and 3.4% at 39.3 µmol/L. Importantly, the concentrations of tHcy, folate and vitamin B12 
in our study are comparable with the concentrations that are measured in the preconceptional period 
as described by Cikot et al.17 Hereby, we substantiate the value of our fixed and standardised study 
moment. 
The questionnaire data have been checked for completeness and consistency by the researcher during 
the hospital visit. The dietary intakes of macronutrients and B-vitamins are in line with the Dutch 
dietary reference intakes18, 19 and the data of the Dutch national food consumption survey of 2003.20 
Although, random measurement errors may still have occurred, the estimated dietary intakes are 
adjusted for nutrient loss due to processing and cooking of the food. Therefore, our FFQ produces 
valid data of dietary intake in women of reproductive age, which has been proven by our validation 
study as well.21 
With regard to the DNA analysis, all genotype frequencies in controls are in Hardy Weinberg 
Equilibrium and they are in line with other European studies that have investigated MTHFR,22, 23 TC24-26 
and MTRR27, 28 genetic polymorphisms. More than three percent of the samples were re-genotyped to 
check for genotype calling consistency. The genotyping success rate is more than 96%. Laboratory 
errors are not likely because the genotyping has been done using Taqman® techniques according to 
protocols provided by the manufacturer (Taqman, Applied Biosystems, Foster City, CA, USA). We have 
restricted the analyses to complete and consistent triads only, thereby increasing the accuracy of our 
genotype data and minimising the risk of including non-biological fathers. 
 
Power 
In all power calculations, we have used a population CHD risk of six per 1000 live births and a type I 
error of 0.05. Calculations reveal that we have identified maternal hyperhomocysteinaemia as a risk 
factor for CHD in the offspring with a power of 77% (control prevalence of 10%, cases n = 98 , OR 
2.9) and a low dietary intake of vitamin B12 with a power of 57% (control prevalence 10%, cases n = 
192, OR 1.9). The sample size of 229 cases and the MTHFR 1298 A allele frequency of 0.34 enables 
us to detect a 40% significant risk reduction with a power of 78%. The risk allele frequencies are 0.46 
for the MTRR polymorphism and 0.56 for the TC polymorphism, respectively. We would be able to find 
a significant OR of 2.5 for the interaction between these genetic polymorphisms and serum vitamin 
B12 with a power of 70% if the sample size of both the case and the control-group would have been 
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416 for the MTRR polymorphism and 495 for the TC polymorphism, respectively. The ongoing 
recruitment for the HAVEN study will solve this problem to investigate interactions between 
polymorphisms and environmental factors as risk or preventive factors of CHD offspring.  
 
Inferences of the main findings 
Biomarkers and dietary intake  
Previous epidemiological studies show that periconceptional use of multivitamins containing folic acid 
reduces the risk of having a child with CHD.1 However, it is unknown which ingredient(s) in 
multivitamins are responsible for this risk reduction. We do not show an independent and significant 
association between periconceptional use of B-vitamin supplements and CHD risk, but we 
demonstrate that a high maternal tHcy concentration is associated with an increased risk of a child 
with CHD. If mothers did not use a folic acid containing vitamin supplement in the periconceptional 
period, the risk estimate is even higher (Chapter 3). These findings are in line with the reported 
preventive effect of multivitamin use, because a compromised folate and/or vitamin B12 status results 
in mild hyperhomocysteinaemia. Hyperhomocysteinaemic case-mothers indeed show significantly 
lower serum folate and vitamin B12 concentrations than normohomocysteinaemic case-mothers. 
Moreover, they have a lower dietary intake of proteins and vitamin B6. Overall, a diet low in vitamin 
B12 is associated with an increased risk of a child with a CHD (Chapter 5). Thus, we show that 
derangements of several parameters in the homocysteine metabolism are associated with maternal 
hyperhomocysteinaemia (Figure 1). 
Dietary protein intake is the main source of methionine, which is the sole precursor of homocysteine. 
A high-protein diet increases tHcy concentrations throughout the day29 and particularly folate is an 
important substrate for the remethylation of homocysteine. Therefore, a disbalance in the maternal 
intake of proteins and folate deranges the homocysteine metabolism and easily leads to mild 
hyperhomocysteinaemia. Our study results concerning biomarkers and dietary intake suggest that 
several nutrients or maybe a specific dietary pattern are important and not just a single nutrient. This 
is in line with the various B-vitamins that are often correlated and present in the same foods.30 This 
hypothesis is substantiated by the work of Gerber, who reported that the effect of diet does not occur 
through the addition of single nutrients. Each food combines many nutrients that allow for a 
synergistic action when present in a certain balance. Variety in daily food intake will avoid the 
repetitious intake of unfavourable food and provide the largest array of protective nutrients.31 Our 
data suggest that an adequate intake of B-vitamins is necessary as well as a delicate balance between 
the intake of macronutrients and micronutrients. Future studies should precisely unravel which 
nutrients in the diet provide beneficial or teratogenic effects on cardiovascular development. 
Derangements in the DNA methylation patterns can lead to developmental malformations.32 Folate 
plays a critical role in the prevention of chromosome breakage and hypomethylation of DNA. These 
processes are compromised when the vitamin B12 concentration is low resulting in the folate trap, 
reduced  methionine synthase activity and low levels of S-adenosylmethionine that particularly leads 
to hypomethylation of proteins, lipids and DNA. The DNA hypomethylation can be prevented by intake 
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levels of more than 300 microgram folate per day and more than 2 microgram vitamin B12 per day.33 
These dietary intakes above the current dietary reference intakes may be important, particularly in 
those people with derangements in the metabolism of these vitamins and homocysteine, such as the 
case-mothers in our studies. 
People with a low education and low income are more likely to engage in poor dietary practice than 
their wealthier and higher educated counterparts.8 In our study, low educated women more often 
demonstrate a low dietary vitamin B12 intake that is associated with a higher risk of CHDs than 
women with a higher educational level. Educational level is also positively associated with the intake 
of vitamin B6 and folate. Therefore, low educated people may not have enough income to buy these 
generally more expensive foods or do not have the knowledge about the importance of nutrition on 
health. Moreover, others show that maternal obesity is also associated with CHD risk.34, 35 These 
reports subscribe the importance of a varied and healthy diet, because a diet low in energy density 
coincides with a more favourable body weight. A dietary profile with a low energy density includes low 
fat intake and high intake of fresh fruit and vegetables being rich sources of particularly folate.36 
We have also measured the concentrations of folate, vitamin B12 and tHcy in children. Serum and red 
blood cell folate concentrations are significantly higher in case-children than in controls, which is 
partially explained by formula feeding (Chapter 3). Moreover, randomly taken blood samples, 
alterations in the binding of folate to transport proteins and receptors, differences in the prevalence of 
genetic polymorphisms encoding these proteins, changed concentrations of cofactors, variations in the 
activity of liver enzymes and renal function affecting folate clearance may play a role as well. 
However, it is most likely that the folate status determined in the blood of children at the age of 
Figure 1. B-vitamin dependent homocysteine metabolism.
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around 17 months is not comparable to the folate status in the tissues forming the cardiovascular 
system during embryogenesis. 
 
Folate and vitamin B12 related genes and gene-nutrient interactions 
We showed that subtle genetic factors are involved in the pathogenesis of CHDs, especially the 
MTHFR A1298C genetic polymorphisms (Chapter 6 and 7). The almost significant association between 
a positive family history of CHD and a two-fold increased risk substantiates the involvement of genetic 
polymorphisms. Much stronger genetic factors for CHDs are chromosomal abnormalities, such as 
trisomy 21 and the 22q11 deletion.37 This might explain why the MTHFR C677T, MTRR A66G and TC 
C776G genotypes do not affect CHD risk independently. As CHDs are comprised of complex 
malformations, both genetic and environmental factors, such as nutrition and lifestyle, are implicated 
in the pathogenesis and, thereby, possibly in prevention as well. Therefore, we focus on gene-nutrient 
interactions. 
The studied polymorphisms in the MTHFR, MTRR and TC genes slightly affect the metabolic 
availability of folate and vitamin B12, respectively.38-41 It is likely, therefore, that food intake and 
lifestyle factors, such as the use of vitamin supplements, tobacco and alcohol, interact with the 
genetic polymorphisms leading to altered biochemical concentrations of folate and vitamin B12. 
Significant interactions are not demonstrated between the genotypes and dietary intake of vitamin B2, 
folate and vitamin B12, and the association with CHD risk. However, the gene-nutrient interaction 
concerning the child’s MTHFR A1298C polymorphism and maternal use of a folic acid containing 
vitamin supplement proves to be significantly associated with CHD risk. The bioavailability of natural 
folates in foods is lower compared with the synthetic folic acid form. Apart from the much lower 
bioavailability of food folates, the poor stability of folates in foods due to heating during cooking can 
substantially reduce the amount of vitamins ingested and, thereby, it can be an additional factor 
limiting the bioavailability of food folates to improve folate status.42 For vitamin B12, as for many 
nutrients, absorption is dependent on available transport mechanisms and the load put on the body. 
Estimates of vitamin B12 absorption from food indicate that with normal gastric function, 
approximately 50% of dietary vitamin B12 intake is absorbed.43 These arguments may explain the 
differences in significance levels for the investigated gene-nutrient interactions. With regard to vitamin 
B12, the interactions between the MTRR and TC genotypes and the use of B-vitamin supplements are 
not significant, which might be explained by the content of the supplements that contain not only 
vitamin B12 but also other multivitamins or solely folic acid. We have reanalysed the data using serum 
vitamin B12 as the environmental factor, because it is a stronger metabolic indicator of the vitamin 
B12 status than vitamin B12 intake. A possible trend towards a higher risk is revealed for the 
interaction of serum vitamin B12 with the maternal and child’s TC genotype, that is less clear for the 
maternal and child’s MTRR genotype. However, the P values for trend are not significant, which might 
be caused by a power problem as biochemical measurements are available in only 137 case-mothers 
and 203 controls. Nevertheless, these studies suggest that respectively strong and subtle gene-
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nutrient interactions concerning the maternal folate and vitamin B12 status are involved in the 
pathogenesis of CHDs. 
 
Future research   
Our results clearly demonstrate that derangements in homocysteine metabolism are involved in the 
pathogenesis of CHDs. However, it is not yet known whether hyperhomocysteinaemia disturbs the 
normal cardiogenesis by a direct teratogenic effect or by indirect effects via a low folate and/or low 
vitamin B12 status. Hyperhomocysteinaemia is associated with decreased concentrations of B-
vitamins, which may suggest that the nutrient status in the embryonic tissues is decreased as well. 
Moreover, homocysteine evokes oxidative stress through the production of reactive oxygen species, 
produces homocysteinylated proteins, and leads to the accumulation of its precursor, S-
adenosylhomocysteine, a potent inhibitor of biological transmethylations.44 With regard to oxidative 
stress, the developing embryo may be exposed to potentially teratogenic reactive oxygen species. 
Depending on the timing and duration of exposure, the functional consequences of oxidative injury 
may induce embryopathy and dysmorphogenesis.45 However, disturbances in the DNA methylation 
patterns are also associated with developmental malformations.32 An adequate supply of both folate 
and vitamin B12 is essential in preventing DNA hypomethylation. Interestingly, Fenech postulated that 
DNA hypomethylation can be prevented at intake levels in excess of current dietary reference 
intakes.33 Therefore, the data that are presented in this thesis justify additional research into the role 
of hyperhomocysteinaemia and its underlying determinants in the pathogenesis of CHDs. Further 
investigations have to be performed on the critical balance between antioxidant activity and 
prooxidant exposures that are modifiable by genetic and/or environmental factors. Moreover, the 
beneficial and teratogenic effects of both excessive and deficient intakes of nutrients should be 
explored as well. 
Both human and animal studies are necessary to investigate the effects of hyperhomocysteinaemia. A 
prospective cohort study is the best study design for investigation of the nutritional status in the 
periconceptional period and, thus, during embryogenesis. Moreover, in the prospective study design, 
recall bias is not a problem. However, a large prospective cohort study is not feasible, because it 
requires far more study subjects due to the low prevalence of CHDs, it is highly time-consuming and 
expensive, and it cannot be as cost-effective as the case-control study design.46 The study design of 
randomised clinical trials has to deal with the same problems as the cohort study. Furthermore, it is 
immoral to refrain women in the reproductive age from the use of folic acid supplements, for example, 
because of the protective effect with regard to risk of congenital malformations in the offspring. 
Therefore, case-control studies in high risk populations are the best alternative. 
In the past decade remarkable progress has been made within the development of genetic analyses 
and the unveiling of the genetic aetiologies of human disease. Nowadays, it is possible to identify 
disease genes by linkage analyses, positional cloning and analysis of candidate genes.47, 48 These 
techniques give the opportunity to study genetic determinants in the homocysteine and related 
pathways. Because of the multifactorial aetiology of CHDs, gene-environmental interactions with a 
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biological rationale may have a greater impact on cardiovascular development than independent 
effects of genetic polymorphisms. Moreover, gene-environmental interactions are amendable by 
environmental factors and, thereby, the investigation of these interactions may provide clues for 
primary prevention of CHDs by the adjustment of lifestyle and nutritional habits. Nevertheless, to 
detect relevant gene-environmental interactions and to be able to investigate these interactions in the 
CHD subgroups, sample sizes have to be increased. As the HAVEN study is an ongoing study, sample 
sizes are currently being increased to be able to study the more subtle risk estimates and interactions. 
Moreover, multicentre collaborations between all Departments of Paediatric Cardiology in the 
Netherlands should be encouraged for this goal. 
Our case-control study demonstrates a significant association between hyperhomocysteinaemia and 
CHD risk. However, it remains to be elucidated whether the association is causative or not. Therefore, 
experimental studies at the time of embryogenesis are needed. Our group has already reported that 
the migration and differentiation of neural crest cells can be influenced by homocysteine and folic 
acid.49 Besides the development of the neural tube, lip and palate, neural crest cells are also involved 
in the embryogenesis of the cardiac outflow tract. Moreover, studies in chicken embryos have shown 
83% subarterial ventricular septal defects after injection of homocysteine into the neural tube lumen 
at the time point of neural crest cell migration.49, 50 The chicken embryo shares morphological features 
of the human embryo during early cardiac development and it is also very accessible for experiments. 
Therefore, this chicken embryo model makes it possible to mimic the human cardiovascular 
development and to perform interventions in vivo. Thereby, the complex homocysteine metabolism 
can be studied during cardiogenesis to explore the induction of oxidative stress, DNA hypomethylation 
and other processes induced by hyperhomocysteinaemia. 
In conclusion, the reports of the association between hyperhomocysteinaemia and CHD risk provide a 
lot of arguments for further research in several homocysteine-related pathways. Moreover, the 
influence of gene-nutrient interactions in cardiovascular development suggest a wide spectrum of 
nutritional and lifestyle interventions to prevent CHDs in future. 
 
Implications for public health and clinical practice 
This thesis demonstrates that maternal hyperhomocysteinaemia is associated with an increased CHD 
risk. This risk is even higher if the mothers do not use a folic acid containing vitamin supplement in 
the periconceptional period. Moreover, all mothers have a substantially lower folate intake than the 
Dutch recommended dietary allowance of 300 μg. These findings substantiate the recommendation to 
use a folic acid supplement in the periconceptional period not only to prevent neural tube defects, but 
CHDs as well. In our study population, 54% of the case-mothers and 59% of the control-mothers 
have used folic acid in the advised period of four weeks before until eight weeks after conception. 
This is higher than the percentage of 36% in 2002 that is reported in a Dutch study, but compliance 
to proper use is quite poor, especially in low educated women.51, 52 Therefore, these data show again 
that all women who are planning a pregnancy should be urged to use a folic acid supplement. 
Recently, the Dutch government has initiated some projects to stimulate the use of folic acid.53 Firstly, 
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pharmacies in the Netherlands are informing non-pregnant women in the reproductive age about the 
proper use of folic acid in the campaign ‘Zorg voor Foliumzuur’. Secondly, within a pilot-study 
midwives are investigating how to stimulate the periconceptional use of folic acid, particularly in 
immigrants and low educated women. Moreover, in 2006 ERFO-centre has developed new brochures 
on folic acid and a website too (www.slikeerstfoliumzuur.nl). The rather low use of folic acid raises the 
question whether foods should be fortified with folic acid. Besides the beneficial effects, folic acid use 
can mask vitamin B12 deficiency, but it may also enhance tumour growth in laboratory animals and 
humans and have negative effects on cancer through genetic selection.54, 55 Therefore, at this 
moment, overall food fortification is still not present in the Netherlands but it is an issue of continuous 
discussion.56  
The association between a low maternal dietary vitamin B12 intake and CHD risk supports the 
hypothesis that other nutrients may play a role as well. However, our data do not show enough 
evidence for a tailored advice concerning the optimal overall nutritional intake in the periconceptional 
period to every woman. Nevertheless, we demonstrate the beneficial effect of periconceptional 
exposure to folic acid supplements, particularly in children carrying the MTHFR 1298 AA genotype. 
Furthermore, our findings suggest that subtle interactions between TC 776 GG and MTRR 66 GG 
genotypes and low periconceptional vitamin B12 status might be involved in the pathogenesis of CHDs 
as well. Therefore, for the time being, it might be favourable to advise women to use a diet rich in 
vitamin B12 and maybe a vitamin B12 supplement in high risk groups in addition to the daily folic acid 
supplement intake in the periconceptional period. The use of B-vitamin supplements along with a 
healthy diet is a rational approach to prevent CHDs because it is simple and inexpensive, and it is 
supported by our current data. 
Hyperhomocysteinaemia is not only associated with CHD risk, but it is a strong risk factor for adult 
cardiovascular diseases as well.57 Since our experimental data suggest that prenatal exposure to 
hyperhomocysteinaemia induces the first features of atherosclerosis that are associated with 
cardiovascular diseases in later life,58 this may imply that the hyperhomocysteinaemic mothers and 
their children should be targeted for nutritional interventions. However, results of randomised 
controlled studies aimed at reducing the prevalence of hyperhomocysteinaemia and related morbidity 
must be available before strategies based on food interventions can be recommended. The vast 
majority of the evidence of lowering tHcy by folate intake is related to secondary prevention trials.59 It 
is still the question whether primary prevention is possible. 
The results of the studies described in this thesis can be implemented in the preconceptional care. 
Nowadays, women that are at risk for having a child with a CHD should be screened for 
hyperhomocysteinaemia. Moreover, the dietary intakes of these women should be evaluated, 
especially the intakes of folate and vitamin B12. In addition, special attention should be paid to low 
educated women, because they are a high risk group, partly due to malnutrition and a low use of folic 
acid supplements. This preconception screening is important for future risk assessment and 
preconceptional counselling of parents to be. In general, hyperhomocysteinaemia can easily be 
treated with a folic acid and/or vitamin B12 supplement and, therefore, this risk factor can be 
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eliminated before conception. Moreover, our findings can be implemented via the website 
www.zwangerwijzer.nl, which is a joint initiative of the Erasmus MC, University Medical Centre in 
Rotterdam and the Dutch ERFO-Centre. Using the website questionnaire, the parental risk factors can 
be identified and used in the preconceptional care, and thereby, the counselling can more effectively 
be pointed at the identified risk factors. Since August 2006, Rotterdam is the first city in the 
Netherlands with institutions that give preconception care to parents to be with a normal population 
risk for pregnancy complications. In future, this may reduce the prevalence of congenital 
malformations and other pregnancy related disorders. Therefore, if any preventive approach could 
decrease the number of children born with a CHD or the number of chronic diseases in later life, not 
only the anguish in many families could be avoided, it would mean an economical gain as well. 
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Introduction  
Congenital heart defects (CHDs) belong to the most common group of major congenital malformations 
in newborns. At present, birth defects are the leading cause of infant mortality, with CHDs accounting 
for one in every three birth defect-related infant deaths. A substantial part of the surviving children 
has to undergo surgery and complex medical treatments and they often suffer from serious physical 
and psychological problems. In addition, the estimated average lifetime cost of the most clinically 
important CHDs is over $300,000 in the United States of America. Therefore, prevention of CHDs can 
substantially reduce the paediatric morbidity and mortality and related health care costs as well.  
With regard to aetiology, only approximately 15% of the CHDs can be attributed to a known cause 
including genetic and chromosomal conditions with environmental exposures. Most CHDs, however, 
are considered complex diseases with a multifactorial aetiology, which are thought to result from 
interactions between both genetic and environmental factors. Several studies described that the 
maternal use of folic acid supplements in the periconceptional period reduces the risk of having a child 
with a CHD. Folic acid and its dietary form folate are important substrates of the homocysteine 
metabolism. Animal studies have indicated the involvement of homocysteine in heart development by 
stimulating the proliferation and migration of neural crest cells and inhibiting their differentiation. Mild 
to moderate hyperhomocysteinaemia results from inadequate intake of B-vitamins as well as from 
functional polymorphisms in key enzymes involved in the homocysteine metabolism or transport of B-
vitamins. The mother is the environment of the developing child in utero and, therefore, the maternal 
nutritional status will influence the homocysteine metabolism in the embryonic tissues as well. 
Moreover, besides functional polymorphisms in B-vitamin related genes derived from both parents, the 
interactions between the maternal nutritional status and polymorphisms in B-vitamin related genes in 
mothers and children might be important in heart development. 
In Chapter 2, a meta-analysis is presented of published studies investigating the association between 
maternal hyperhomocysteinenaemia, 5,10-methylenetetrahydrofolate reductase (MHTFR) polymor-
phisms in mothers and children, and the risk of a child with a CHD or cleft lip with or without cleft 
palate (CLP). This meta-analysis demonstrates that maternal hyperhomocysteinaemia is a risk factor 
for CHDs. The MTHFR C677T and A1298C polymorphisms in both mothers and children are not 
independently associated with CLP or CHDs. Future studies should be performed to investigate the 
interactions between maternal hyperhomocysteinaemia, B-vitamin intake, related polymorphisms and 
the risk of CLP and CHDs. 
Thereafter, this thesis presents the results of the ongoing HAVEN study, which is a Dutch acronym for 
the study of congenital heart anomalies and the role of genetic and nutritional factors. This case-
control study has been conducted from June 2003 onwards at the Department of Obstetrics and 
Gynaecology/Division of Obstetrics and Prenatal Medicine of Erasmus MC, University Medical Centre, 
Rotterdam, the Netherlands. Children with a CHD and both parents were recruited in collaboration 
with the Departments of Paediatric Cardiology of the same hospital and of Leiden University Medical 
Centre in Leiden, VU University Medical Centre and Academic Medical Centre in Amsterdam. Healthy 
control-children and both parents were enrolled in collaboration with the child health centres of 
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‘Thuiszorg Nieuwe Waterweg Noord’ in the surroundings of Rotterdam. 
 
Part I 
The first part of this thesis describes the maternal nutritional status of B-vitamins in association with 
the risk of having a child with a CHD. The nutritional status is partly determined by the metabolism 
and intake of nutrients. To study the B-vitamin status, we have measured the concentrations of serum 
vitamin B12, serum and red blood cell (RBC) folate, and plasma total homocysteine (tHcy) both in 
mothers and children, because these biomarkers partially reflect the effects of the nutritional intake 
on the homocysteine metabolism (Chapter 3). We demonstrate that maternal hyperhomocystei-
naemia, defined as a tHcy concentration above 14.3 μmol/L, nearly three-fold increases the risk of 
CHD in the offspring. This is substantiated by the establishment of higher risk estimates when tHcy 
concentrations rise. Moreover, the risk estimates are even higher if mothers do not use a folic acid 
supplement in the periconceptional period. Maternal hyperhomocysteinaemia shows to be partially 
caused by a low folate and low vitamin B12 status. Serum and RBC folate concentrations are 
significantly higher in case-children than in control-children, which is partially explained by formula 
feeding. The folate status of children warrants further investigation. 
We have performed a validation study for the estimation of the maternal dietary intake of folate and 
vitamin B12 with a food frequency questionnaire (FFQ) that is adapted by the Division of Human 
Nutrition of Wageningen University in Wageningen, the Netherlands (Chapter 4). The correlation and 
validity coefficients between the FFQ, the 24-hour recalls and the biomarkers are reasonably good. 
Furthermore, the estimated intakes of folate and vitamin B12 are comparable with the results of the 
most recent Dutch food consumption survey as well as the intake of energy and macronutrients. 
Therefore, the adapted FFQ is a reliable tool to estimate the dietary intake of energy, macronutrients, 
folate and vitamin B12 in women of reproductive age and it is suitable for the investigation of 
nutrient-disease associations in Dutch women. 
Using this FFQ, we have assessed the maternal intake of macronutrients and B-vitamins in case and 
control-mothers in relation to CHDs in their offspring (Chapter 5). The dietary intake of macronutrients 
and B-vitamins is comparable between 192 case-mothers and 216 control-mothers, but they all had a 
substantially lower median folate intake than the Dutch recommended dietary allowance of 300 μg. 
The intake of proteins and vitamin B6 and the concentrations of serum vitamin B12 and folate are 
significantly lower in hyperhomocysteinaemic case-mothers than in normohomocysteinaemic case-
mothers. A maternal dietary intake of vitamin B12 below 2.1 μg/day is associated with an 
approximately two-fold CHD risk, especially in low educated women. As hyperhomocysteinaemia is a 
strong risk factor for adult cardiovascular disease, these data may imply that the 
hyperhomocysteinaemic mothers and their children should be targeted for nutritional interventions. 
 
Part II 
In the second part of this thesis gene-nutrient interactions are described regarding folate and vitamins 
B2 and B12. In Chapter 6, we present the data of the interactions between nutritional and lifestyle 
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factors and two polymorphisms in the MTHFR gene. The MTHFR C677T polymorphisms are not 
significant associated with CHD risk. However, the MTHFR 1298 AA genotype in fathers and children 
show significantly increased CHD risks. Furthermore, a two-fold increased CHD risk is shown in 
children with the MTHFR 1298 AA genotype who are periconceptionally not exposed to folic acid 
supplements compared with MTHFR 1298 AC/CC carriers who are periconceptionally exposed. No 
significant interactions are detected between the MTHFR genotypes and dietary intake of folate and 
vitamin B2.  
Chapter 7 shows analyses of polymorphisms in the methionine synthase reductase (MTRR) and 
transcobalamin (TC) genes in combination with vitamin B12 related environmental factors. The MTRR 
A66G and TC C776G polymorphisms do not affect CHD risk. No significant interactions are observed 
between these polymorphisms in mothers or children, low vitamin B12 intake and CHD risk. The 
maternal TC genotype significantly influences serum vitamin B12 in case-mothers, which is not due to 
a confounding effect of the current use of B-vitamins. Moreover, the interactions between a low 
serum vitamin B12 and the TC 776 GG and maybe MTRR 66 GG genotypes are suggested to be 
associated with an increased CHD risk. However, these interactions are not statistically significant. 
This might be due to our sample size, but the ongoing recruitment for the HAVEN study will solve this 
problem in future.  
In the general discussion, the results of these case-control studies are discussed and our objectives 
are evaluated (Chapter 8). Furthermore, we recommend future research and discuss the implications 
regarding clinical practice and public health care. Maternal hyperhomocysteinaemia and a low dietary 
intake of vitamin B12 contribute to CHD risk as well as the interaction between the MTHFR A1298C 
polymorphism and folate status, and possibly the interaction between the TC C776G and MTRR C776G 
polymorphisms and vitamin B12 status. These findings indicate that the maternal nutritional status 
and gene-nutrient interactions are involved in the pathogenesis of CHDs. Therefore, it might be 
favourable to advise women in high risk groups to use a diet rich in vitamin B12 and maybe a vitamin 
B12 supplement in addition to the daily folic acid supplement intake in the periconceptional period. 
The use of B-vitamin supplements along with a healthy diet is a rational approach to prevent CHDs 
because it is simple and inexpensive, and it is supported by our current data. 
The results of the studies described in this thesis can be directly implemented in the preconception 
care. Nowadays, women who are at risk for having a child with a CHD should be screened for 
hyperhomocysteinaemia and their dietary intakes should be evaluated, especially the intake of folate 
and vitamin B12. In addition, special attention should be paid to low educated women, because they 
are a high risk group, partly due to malnutrition and a low use of folic acid supplements. 
Preconceptional screening is important for future risk assessment and counselling of parents to be and 
may cause a reduction in the prevalence of CHDs in future. 
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Introductie  
Aangeboren hartafwijkingen (CHD) behoren tot de meest voorkomende aangeboren afwijkingen bij 
pasgeborenen. Tegenwoordig zijn aangeboren afwijkingen de voornaamste oorzaak van sterfte onder 
zuigelingen en een derde van deze kindersterfte wordt veroorzaakt door CHD. Een groot aantal 
kinderen dat overleeft, moet chirurgie en complexe medische therapie ondergaan en heeft vaak 
ernstige fysieke en psychologische problemen. Daarnaast zijn de gemiddelde kosten voor de klinisch 
meest belangrijke CHD in de Verenigde Staten geschat op $ 300.000 per mensenleven. Daarom kan 
preventie van CHD zowel de morbiditeit en mortaliteit onder kinderen als gerelateerde kosten voor de 
gezondheidszorg reduceren.  
Slechts bij 15% van de CHD kan een bekende oorzaak worden aangetoond, zoals genetische of 
chromosomale afwijkingen en omgevingsinvloeden. Echter, de meeste CHD worden beschouwd als 
complexe ziekten met een multifactoriële ontstaanswijze, die de resultante zijn van interacties tussen 
genetische en omgevingsfactoren. Diverse studies hebben beschreven dat gebruik van 
foliumzuursupplementen door de moeder in de periconceptionele periode de kans op het krijgen van 
een kind met een CHD reduceert. Foliumzuur en het in voeding voorkomende folaat zijn belangrijke 
substraten van de homocysteine stofwisseling. Dierstudies wijzen op de betrokkenheid van 
homocysteine in de hartontwikkeling doordat homocysteine de proliferatie en migratie van neurale lijst 
cellen stimuleert en hun differentiatie remt. Milde tot matige hyperhomocysteinemie ontstaat door 
onvoldoende inname van B-vitamines en functionele variaties in sleutelenzymen die betrokken zijn in 
de homocysteine stofwisseling of in het transport van B-vitamines. Daar de moeder de omgeving is 
van het kind dat zich in haar baarmoeder ontwikkelt, zal de maternale voedingsstatus ook de 
homocysteine stofwisseling in de embryonale weefsels beïnvloeden. Naast de functionele variaties in 
de B-vitamine gerelateerde genen afkomstig van beide ouders, kunnen bovendien interacties tussen 
de maternale voedingsstatus en variaties in de B-vitamine gerelateerde genen in moeders en kinderen 
van belang zijn in de hartontwikkeling.  
In Hoofdstuk 2 wordt een meta-analyse behandeld van gepubliceerde studies betreffende de 
associatie tussen maternale hyperhomocysteinemie, 5,10-methyleentetrahydrofolaat reductase 
(MHTFR) genvariaties in moeders en kinderen en de kans op een kind met een CHD of met schisis. 
Deze meta-analyse toont aan dat maternale hyperhomocysteinemie een risicofactor is voor CHD. De 
MTHFR C677T en A1298C variaties in zowel moeders als kinderen zijn niet geassocieerd met CHD of 
schisis. Toekomstige onderzoeken zullen verricht moeten worden om de interacties te bestuderen 
tussen maternale hyperhomocysteinemie, inname van B-vitamines, gerelateerde genvariaties en de 
kans op het krijgen van een kind met een CHD of schisis. 
Vervolgens beschrijven wij in dit proefschrift de resultaten van de nog lopende HAVEN studie, wat een 
acroniem is voor het onderzoek naar CHD en de rol van genetische en voedingsfactoren. Deze case-
controle studie wordt sinds juni 2003 uitgevoerd door de afdeling Verloskunde en Vrouwenziekten, 
subafdeling Verloskunde en Prenatale Geneeskunde van het Erasmus MC te Rotterdam. Kinderen met 
een CHD en beide ouders worden gerecruteerd in samenwerking met de kindercardiologie afdelingen 
van hetzelfde ziekenhuis, het Leids Universitair Medisch Centrum, het VU Medisch Centrum en het 
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Academisch Medisch Centrum in Amsterdam. De werving van gezonde controle kinderen en beide 
ouders vindt plaats in samenwerking met de consultatiebureaus van ‘Thuiszorg Nieuwe Waterweg 
Noord’ in de omgeving van Rotterdam. 
 
Deel I 
Het eerste deel van dit proefschrift beschrijft de maternale voedingsstatus van B-vitamines en de 
associatie met de kans op een kind met een CHD. De voedingsstatus wordt deels bepaald door de 
stofwisseling en de inname van voedingsstoffen. Om de B-vitamine status in moeders en kinderen te 
bestuderen, zijn de concentraties gemeten van serum vitamine B12, folaat in het serum en in de rode 
bloed cel (RBC) en plasma totaal homocysteine (tHcy), omdat deze biomarkers gedeeltelijk de 
effecten van de voedingsinname op de homocysteine stofwisseling reflecteren (Hoofdstuk 3). Wij 
tonen aan dat maternale hyperhomocysteinemie, gedefinieerd als een tHcy concentratie hoger dan 
14,3 μmol/L, de kans op een kind met een CHD bijna driemaal verhoogt. Dit wordt bevestigd door de 
hogere risico’s bij een toenemende tHcy concentratie. Bovendien is het risico nog hoger als moeders 
geen foliumzuursupplement gebruiken in de periconceptionele periode. Maternale 
hyperhomocysteinemie wordt deels veroorzaakt door een lage folaat en vitamine B12 status. Serum 
en RBC folaat concentraties zijn significant hoger in patiënten dan in controle kinderen, wat 
gedeeltelijk verklaard wordt door flesvoeding. Deze folaat status van de kinderen rechtvaardigt dan 
ook verder onderzoek. 
Wij hebben een validatie studie uitgevoerd voor de schatting van de maternale voedingsinname van  
folaat en vitamine B12 met een voedsel frequentie vragenlijst (FFQ) die aangepast is door de Divisie 
Humane Voeding van de Wageningen Universiteit in Wageningen (Hoofdstuk 4). De correlatie en 
validatie coefficienten tussen de FFQ, de 24 uur recalls en de biomarkers zijn redelijk goed. Bovendien 
zijn de geschatte innames van folaat en vitamine B12, maar ook die van energie en macronutrienten, 
vergelijkbaar met de resultaten van het meest recente voedselconsumptieonderzoek. De aangepaste 
FFQ is dus een betrouwbaar instrument om de voedingsinname van folaat, vitamine B12, energie en 
macronutrienten te schatten voor vrouwen in de reproductieve leeftijdscategorie en het is geschikt om 
associaties tussen voeding en ziekte in Nederlandse vrouwen te onderzoeken. 
Met deze FFQ hebben we de voedingsinname van macronutrienten en B-vitamines vastgesteld bij 
moeders in relatie tot een CHD bij hun kind (Hoofdstuk 5). De voedingsinname van macronutrienten 
en B-vitamines is vergelijkbaar tussen 192 moeders van patienten en 216 moeders van een gezond 
kind, maar alle moeders hebben een aanzienlijk lagere mediane folaat inname dan de Nederlandse 
aanbevolen dagelijkse hoeveelheid van 300 μg. De inname van eiwitten en vitamine B6 en de 
concentraties van serum vitamine B12 en folaat zijn significant lager in hyperhomocysteinemische dan 
in normohomocysteinemische moeders van patiënten. Een maternale voedingsinname van vitamine 
B12 lager dan 2,1 μg/day is geassocieerd met een circa tweemaal verhoogde kans op een kind met 
een CHD, met name in laag opgeleide vrouwen. Aangezien hyperhomocysteinemie een sterke 
risicofactor is voor hart- en vaatziekten bij volwassenen, zouden deze gegevens kunnen impliceren dat 
de hyperhomocysteinemische moeders en hun kinderen een doelgroep zijn voor voedingsinterventies. 
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Deel II 
In het tweede deel van dit proefschrift worden gen-voeding interacties beschreven met betrekking tot 
folaat, vitamine B2 en B12. In Hoofdstuk 6 presenteren wij de resultaten van de interacties tussen 
voeding, leefstijlfactoren en twee variaties in het MTHFR gen. De MTHFR C677T variaties zijn niet 
significant geassocieerd met de kans op CHD. Echter, de MTHFR 1298 AA genotypes in vaders en 
kinderen zijn significant geassocieerd met een verhoogd risico. Bovendien wordt een tweemaal 
verhoogd risico van CHD gedemonstreerd in kinderen met het MTHFR 1298 AA genotype die 
periconceptioneel niet zijn blootgesteld aan foliumzuursupplementen vergeleken met MTHFR 1298 
AC/CC dragers die periconceptioneel wel zijn blootgesteld. Er worden geen significante interacties 
aangetoond tussen de MTHFR genotypes en de voedingsinname van folaat en vitamine B2.  
Hoofdstuk 7 geeft de analyses weer van de variaties in de methionine synthase reductase (MTRR) en 
transcobalamine (TC) genen in combinatie met vitamine B12 gerelateerde omgevingsfactoren. De 
MTRR A66G en TC C776G variaties beïnvloeden de kans op CHD niet. Er worden geen significante 
interacties aangetoond tussen deze variaties in moeders en kinderen, een lage inname van vitamine 
B12 en de kans op CHD. Het maternale TC genotype beïnvloedt de serum vitamine B12 concentratie 
significant in moeders van patiënten, wat overigens niet verstoord wordt door het huidige gebruik van 
B-vitamine supplementen. Bovendien suggereren de interacties tussen een lage serum vitamine B12 
concentratie en het TC 776 GG genotype en wellicht het MTRR 66 GG genotype, dat er mogelijk een 
associatie bestaat met een verhoogd risico van CHD. Echter, deze interacties zijn statistisch niet 
significant. Dit kan het gevolg zijn van de huidige groepsgrootte, maar de doorgaande werving voor 
de HAVEN studie zal dit probleem in de toekomst oplossen.  
In de algemene discussie worden de resultaten van de case-controle studies besproken en de 
doelstellingen geëvalueerd (Hoofdstuk 8). We bevelen toekomstig onderzoek aan en bediscussiëren 
de implicaties voor de kliniek en publieke gezondheidszorg. Maternale hyperhomocysteinemie en een 
lage voedingsinname van vitamine B12 dragen bij aan de kans op CHD, evenals de interactie tussen 
de MTHFR A1298C genvariaties en folaat status en mogelijk ook de interactie tussen de TC C776G en 
MTRR C776G genvariaties en vitamine B12 status. Deze resultaten geven aan dat de maternale 
voedingsstatus en gen-voeding interacties betrokken zijn in de ontstaanswijze van CHD. Daarom zou 
het gunstig kunnen zijn om vrouwen in hoog risico groepen een dieet rijk aan vitamine B12 te 
adviseren in de periconceptionele periode en wellicht ook een vitamine B12 supplement, naast het 
dagelijkse foliumzuursupplement. Het gebruik van B-vitamine supplementen naast een gezond dieet is 
een rationele aanpak om CHD te voorkomen, omdat het eenvoudig en goedkoop is en het 
ondersteund wordt door onze huidige data. De resultaten van dit proefschrift kunnen direct worden 
toegepast in de preconceptiezorg. Vrouwen met een verhoogd risico zouden gescreened moeten 
worden op hyperhomocysteinemie en hun voedingsinnames zouden geëvalueerd moeten worden, 
vooral voor folaat en vitamine B12. Laag opgeleide vrouwen verdienen extra aandacht, omdat zij tot 
een hoog risico groep behoren, ondermeer door slechte voeding en weinig gebruik van 
foliumzuursupplementen. Preconceptionele screening is belangrijk voor risicoschatting en advisering 
van aanstaande ouders en kan bijdragen aan een lagere prevalentie van CHD in de toekomst.
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jullie hartelijk danken voor jullie input. Margot, ‘jouw’ hartpreparaten hebben mij veel duidelijkheid 
verschaft over de anatomie van het menselijk hart. Ik heb veel bewondering voor jullie uitgebreide 
embryologische kennis! Prof. dr. R.E. Poelmann en dr. B. Hogers bedank ik voor het gebruik van de 
foto’s voor de figuur in het eerste hoofdstuk van dit proefschrift. Beste Marit, tijdens het SGI congres 
in Houston heb ik je beter leren kennen samen met de andere Houston-girls. Ik bewonder je 
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voortvarende manier van werken in Edinburgh en wens je veel succes met je zwangerschap! Lieve 
Ingrid, ook jou heb ik goed leren kennen in Houston. Dank voor je vriendschap, steun en hulp als ik 
eens vast liep met schrijven. Heel veel succes met je opleiding tot klinisch geneticus in Maastricht! 
 
De bijdrage van het Klinisch Chemisch Laboratorium is van onschatbare waarde voor de HAVEN 
studie. Reeds vanaf de start van de studie lopen de biochemische en genetische bepalingen erg goed 
en gaat er nauwelijks iets verkeerd in de logistiek. Prof. dr. J. Lindemans, dr. R. de Jonge, beste Jan 
en Robert, dank voor de mogelijkheden die jullie hebben geboden om diverse bepalingen te kunnen 
doen en ervoor te zorgen dat alles gestroomlijnd verloopt. Ik wil AnneMarie van Driel en Mariska Boot, 
hoofdanalisten, maar ook alle andere betrokken analisten, hartelijk danken voor de hulp van het 
adequaat verzamelen van de samples in het laboratorium in het Erasmus MC-Sophia. Daarnaast wil ik 
Bertrand van Zelst, Pieter Griffioen, Ina van Gorp, Kees van Leeuwen, Addie  Mooy, Roel de Nooijer 
en de andere analisten van het Klinisch Chemisch Laboratorium in de Centrumlocatie alle dank 
toezeggen voor het uitvoeren van de biochemische bepalingen, DNA-isolaties en genotyperingen. 
Bertrand, als DE contactpersoon voor de HAVEN studie wil ik je enorm bedanken voor de zeer prettige 
samenwerking. Problemen waren altijd snel en kordaat opgelost, je stond altijd voor me klaar, al werd 
je af en toe helemaal gek van de HAVEN studie. Toppie! Enkele genotyperingen zijn verricht op het 
laboratorium van de Inwendige Geneeskunde op de 5e etage van de faculteit. Ik wil daarom dr. André 
Uitterlinden danken voor de samenwerking en Rowena Nipius-Utberg bedanken voor haar hulp bij het 
uitplaten van de DNA-samples. 
 
De voedingsvragenlijst die in de HAVEN studie gebruikt wordt, is afkomstig van en aangepast door de 
afdeling Humane Voeding van Wageningen Universiteit. Ik wil dr. Jeanne de Vries en Saskia Meyboom 
hartelijk danken voor de samenwerking en voor het oplossen van alle problemen rondom de invoer 
van de voedingsvragenlijsten. Marleen Stegers, als onderdeel van je afstudeerscriptie voor de Master 
of Science Nutrition and Health heb je de recalls voor de validatiestudie verricht en heel veel 
voedingsvragenlijsten ingevoerd. Je hebt in korte tijd een hoop werk verzet wat van enorme waarde is 
geweest voor de HAVEN studie. Nogmaals hartelijk dank voor je hulp! Els Siebelink, research-dietiste 
en Jan Burema, statisticus, dank ik voor hun hulp bij respectievelijk het coderen van de 
voedingsinnames van de recalls en de analyses voor de validatiestudie.  
 
Marijana Vujkovic, jij hebt het invoerprogramma gemaakt voor de algemene vragenlijsten, hartelijk 
dank hiervoor! Dr. M.F. Wildhagen, beste Mark, vanuit de SPSS en Excel-bestanden heb je een 
prachtige database gebouwd, die aldoor nog verbeterd wordt. Dank voor je inzet en hulp! De 
statistische hulp van Wim Hop, René Eijkemans en Wim Lemmens wil ik ook zeker niet ongenoemd 
laten. Zonder jullie hulp en wijze raad was ik er niet uitgekomen! I gratefully acknowledge Fan Liu and 
Aaron Isaacs for their help and advices concerning the genetic analyses and Fakhredin Sayed-
Tabatabaei for his help in the meta-analysis. 
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Mijn collega’s van de afdeling Verloskunde en Vrouwenziekten zijn altijd een grote steun geweest. 
Piet, je bent de nestor van alle onderzoekers. Ik vind het bijzonder knap hoe jij in je carrière 
opgewerkt hebt. Sinds december 2006 mogen we je zelfs weledelzeergeleerde heer noemen. Ik mis 
ons gezamenlijk kopje koffie om 7.30 uur en de slinger aan de OK-lamp! Sandra, onze beide 
onderzoeken waren gericht op hartafwijkingen en ook nu werken we weer samen in de gynaecologie. 
Ik hoop dat dit nog lang zo blijft! Marianne, zo ongeveer om het jaar hebben we tegelijk onderzoek 
gedaan. Ik vind het heel knap hoe jij onderzoek, kliniek en je gezin kan combineren. Annelous, ook jij 
was mijn ‘room-mate’ gedurende een lange periode. We hebben veel lol gehad, maar ook elkaar 
kunnen steunen in het doen van onderzoek in de breedste zin des woords! Toen jij naar de 
Genetische Epidemiologie ging, nam Dineke jouw bureau en tegelijk ook de HAVEN studie over. 
Dineke, ik heb het heel fijn en leuk gevonden het stokje aan jou door te kunnen geven. Het is 
helemaal in de goede handen terecht gekomen! Hartstikke fijn dat jullie beiden mijn paranimfen willen 
zijn! Els, jij bekijkt het homocysteine metabolisme in het kippenembryomodel. Ik vind het fantastisch 
om te zien hoe nauwgezet jij met je onderzoek omgaat en je helemaal ingewerkt hebt in de 
proteomics-wereld. Succes ermee! Monica, tijdens je wetenschappelijke stage heb je de inclusie 
gedaan voor de HAVEN studie en daarnaast ook veel analyses. Ik wil je hartelijk bedanken voor je 
hulp en enthousiasme. Lydi, ook jij hebt voor je wetenschappelijke stage onderzoek gedaan binnen de 
HAVEN studie en samen met Dineke de inclusie voortgezet. Samen hebben we ons vastgebeten in de 
datainvoer, cleaning en vele genetische analyses. Ik vind het super dat ook jij doorgaat met 
promotieonderzoek binnen de HAVEN studie en wens je hiermee veel succes! Daarnaast wil ik ook 
Emilie, Olivier, Lindy, Sharon, Aagje, Manon, Ilse en Claudia danken voor de collegialiteit en 
gezelligheid en jullie alle voorspoed en succes toewensen met jullie onderzoek en klinisch werk. 
Bovendien wil ik alle stafleden, arts-assistenten, verpleegkundigen en secretaresses van de afdeling 
Verloskunde en Vrouwenziekten van het Erasmus MC danken voor de samenwerking. Ik wil in het 
bijzonder noemen Hans Duvekot, Christianne de Groot, Hajo Wildschut en Joop Laven. 
 
Mijn keuze-coschap heb ik in het Hofpoort ziekenhuis bij de afdeling Gynaecologie gedaan. Gert 
Hoogendoorn, Jette Kuit, Anneke van Egmond, Ied Goedhuis en Liesbeth Blokhuis wil ik graag 
nogmaals bedanken voor het leuke coschap, maar ook voor de steun en adviezen na die tijd. Jette, ik 
kon altijd bellen of mailen. Dank voor je steun betreffende het onderzoek en de sollicitatieronde!  
 
Ik wil ook alle gynaecologen, arts-assistenten, verloskundigen, verpleegkundigen, poli-assistentes en 
secretaresses van de afdeling gynaecologie / verloskunde van het Albert Schweitzer Ziekenhuis te 
Dordrecht hartelijk danken voor het warme welkom, de fijne werksfeer en het begrip voor de 
combinatie van afronden van het onderzoek en starten met de opleiding. Ik wil in het bijzonder Sjarlot 
Kooi bedanken voor de openheid en begeleiding. Henk Klapwijk wil ik alle lof en dank toezeggen voor 
het tekenen van de figuur op de omslag van dit proefschrift! 
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Harry & Riana, Henri & Lia, Marco & Marijtje, Martin & Wendy, Wilfred & Maria, Rick & Judith, Arjan & 
Corina, Ruud & Dineke, Wijnand & Jolanda, Ard & Corina, Ben & Anja, Reinier & Tineke, Lieuwe & 
Patricia, Hans & Annemarie, Tri, Esther, Khanh, Nienke, Teun & Nel, Ploon & Martin, Jan & Anita, 
Karin, Bert, jullie vriendschap is een grote steun in de rug. Dank jullie wel! Ik hoop jullie de komende 
tijd weer wat meer te gaan zien. 
 
Lieve papa en mama, dank voor jullie onvoorwaardelijke steun en liefde. Jullie hebben me alle 
mogelijkheden gegeven om te worden wie ik nu ben, maar er ook voor gezorgd dat ik met beide 
benen op de grond blijf staan. Lieve pa Verkleij, u zegt nooit zoveel, maar uw ogen zeggen genoeg. U 
bent een geweldige schoonpapa. Michael & Conny, José & Tjeerd, Wim-Jaap & Renate, Christian & 
Femke, Wietse, Katinka, Joke & Gerard, John & Angela, Miranda & John, lieve broers en zussen, dank 
voor jullie liefdevolle aandacht (?!?), relativerende woorden en de nodige afleiding.  
 
Lieve Alfred, jij bent alles voor mij en je bent mijn grote steun en toeverlaat. We gaan samen door. 
You’ll never walk alone!  
 
